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Purines are a class of nitrogenous bases and are essential small molecules to life. 
Purines are used within the cell as genetic information carriers, energy currency, 
signaling molecules, and cofactors for multiple processes. They are formed through de 
novo and salvage pathways found in cells across the phylogenetic tree. The substrates of 
enzymes within de novo purine synthesis are known to influence other processes within 
the cell, such as energy homeostasis. In humans, de novo purine synthesis disorders are 
rare, with around 100 people identified. These patients exhibit a range of phenotypes, 
with varying degrees of mental retardation, seizure activity, facial and body dysmorphic 
features, autistic features, respiratory failure, and congenital blindness. To date, the 
explanation of phenotypes associated with these disorders remains elusive and as such, 
no effective therapeutic has been identified. Rare disorders are often caused by a single 
genetic mutation and studying rare disorders can providing key insight into processes 
regulated by that specific enzyme. In this body of work, I use transcriptomic profiling 
techniques to provide cellular and organismal process characterization of a novel cellular 
model of de novo purine deficiency in three CRISPR generated HeLa cell lines. I 
examine the de novo purine synthesis enzymes ADSL, GART, and ATIC. Processes 
identified influenced by de novo purine dysregulation identified are focused around 
neural, embryonic, organ, and placental development, epithelial to mesenchymal 
transition, fatty acid and inflammatory response, muscle function, tumorigenesis, 
 iii 
oxidative stress responses, as well as TGFβ/SMAD signaling among others. Metabolomic 
profiling was employed to bolster transcriptomic findings, with aberrations of metabolic 
pathways involved in energy production, vitamin B6 and B5 metabolism, oxidative stress 
responses, lipids, amino acids, among others. My findings highlight areas in which de 
novo purine synthesis enzymes influence cellular processes responsible for cellular and 




I would like to express my appreciation to the following individuals for their 
assistance during these projects. Dr. David Patterson for his guidance and mentorship. 
My committee members, Drs. Gareth Eaton, Dinah Loerke, Joseph Angleson, Daniel 
Linseman, and Ali Azadani for their support and guidance during these years. Dr. Guido 
Vacano for his invaluable support. Terry Wilkinson for his assistance throughout the 
years. Dr. Nathan Duval for all the help along the way. To my collaborators, Drs. Marie 
Zikánová, Veronika Barešová of the Charles University in Prague, Czech Republic as 
well as Dr. Anthony Pedley of The Pennsylvania State University. I would like to express 
my gratitude to Drs. Ryan Sours and Colleen Winters of Towson University for fostering 




Table of Contents 
Chapter One: Introduction .................................................................................................. 1 
Overview ..................................................................................................................... 1 
Nitrogenous bases and their nucleoside and nucleotide conjugates ............................ 1 
Purine metabolism ....................................................................................................... 2 
De novo purine synthesis requires small molecule inputs from multiple connected 
pathways and processes ............................................................................................ 6 
DNPS evolution ........................................................................................................... 7 
Purines fulfill multiple roles in cellular and organismal functions ............................. 8 
DNPS pathway intermediates have roles outside of DNPS ...................................... 10 
Clinical relevance of DNPS dysregulation ................................................................ 15 
-omics ........................................................................................................................ 17 
Transcriptomic data generation and file conversion ................................................. 21 
Transcriptomic data interpretation through database probing ................................... 26 
Selection of specific KOs and cell line ..................................................................... 29 
Hypotheses and aims ................................................................................................. 32 
 
Chapter Two: Transcriptomic Characterization of crGART ............................................ 34 
Introduction ........................................................................................................... 34 
Materials and Methods .......................................................................................... 36 
Data processing ............................................................................................... 36 
ClueGO analysis ............................................................................................. 37 
Panther analysis .............................................................................................. 37 
Results ................................................................................................................... 37 
Adenine is required for proliferative growth of crGART ............................... 37 
GART substrate was not detected in adenine starved crGART cells ............. 38 
Transcriptome analysis of crGART versus HeLa identified differentially 
expressed genes ............................................................................................ 39 
ClueGO analysis: Functional enrichment analysis employing Gene Ontology 
and Reactome databases .............................................................................. 40 
Corroboration of Gene Ontology analysis via PANTHER analysis ............... 44 
Comparison of crATIC, crADSL and crGART DEGs ................................... 44 
Discussion ............................................................................................................. 45 
 
Chapter Three: Transcriptomic Characterization of crADSL ........................................... 67 
Introduction ........................................................................................................... 67 
Materials and methods .......................................................................................... 70 
Cell Culture ..................................................................................................... 70 
HPLC analysis of SAICAR metabolite accumulation .................................... 70 
RNA-seq ......................................................................................................... 72 
Processing ....................................................................................................... 72 
ClueGO analysis ............................................................................................. 73 
BiNGO analysis .............................................................................................. 74 
qPCR validation of DEGs ............................................................................... 74 
 vi 
Results ................................................................................................................... 74 
crADSL requires adenine for proliferative growth ......................................... 74 
SAICAR accumulates in crADSL but not WT HeLa cells. ............................ 75 
crADSL and WT show DEGs in both adenine rich and depleted conditions . 77 
crADSL and WT HeLa DEGs: enrichment in ontology terms and groupings in 
supplemented and starvation conditions ...................................................... 78 
crADSL and WT HeLa showed similar enrichment patterns using BiNGO 
analysis ......................................................................................................... 81 
Validation of gene expression patterns by qRT-PCR ..................................... 82 
Discussion ............................................................................................................. 82 
 
Chapter Four: Transcriptomic Characterization of crATIC ............................................ 104 
Introduction ......................................................................................................... 104 
Materials and Methods ........................................................................................ 107 
Cell Culture ................................................................................................... 107 
HPLC analysis of ZMP metabolite accumulation ........................................ 108 
RNA-seq ....................................................................................................... 108 
Data Processing ............................................................................................. 109 
Gene Ontology analysis ................................................................................ 109 
qPCR validation of DEGs ............................................................................. 110 
Results ................................................................................................................. 110 
crATIC requires adenine for proliferative growth ........................................ 110 
crATIC cells accumulate ZMP in adenine-depleted but not adenine- 
supplemented growth conditions ............................................................... 111 
crATIC shows differentially expressed genes compared to HeLa in adenine- 
depleted and adenine-supplemented conditions ......................................... 113 
DEGs showed enrichment in ClueGO Gene Ontology and Reactome database 
analysis ....................................................................................................... 114 
Corroboration of ClueGO results via BiNGO analysis ................................. 117 
Validation of RNA-seq by qPCR of candidate genes ................................... 117 
Discussion ........................................................................................................... 118 
 
Chapter Five: Metabolomic Characterization of crGART .............................................. 141 
Introduction ......................................................................................................... 141 
Methods............................................................................................................... 144 
Cell culture .................................................................................................... 144 
Cloning K1-GART CHO-K1 into pTarget ................................................... 144 
crGART transfections with K1-GART-pTarget plasmid ............................. 144 
Metabolomic profiling .................................................................................. 145 
Results ................................................................................................................. 145 
Transfection of crGART with pCMV-GART-K1 ........................................ 145 
MS analysis reveals differentially regulated metabolites ............................. 146 
Genotype analysis shows enrichment in subpathways ................................. 150 
Treatment analysis shows enrichment in DRM subpathways ...................... 151 
 vii 
Discussion ........................................................................................................... 152 
 
Chapter Six: Summary, Discussion, and Future Directions ........................................... 161 
Summary and Discussion ........................................................................................ 161 
Future Directions ..................................................................................................... 168 
Commonalities within DNPS HeLa-KOs: The CD36-PPARγ axis .................... 168 
crADSL may provide insight for epithelial to mesenchymal transition ............. 171 
crATIC and ZMP accumulation provides insight into energy production and 
inflammatory effects ........................................................................................ 173 
crGART reveals neural and placentation embryonic development defects ........ 175 
Metabolic effects for Vitamin B6 and DNPS dysregulation .............................. 177 
 




List of Figures 
Chapter One: Introduction .................................................................................................. 1 
Figure 1.1: Chemical structure of nitrogenous bases and their classes. .................. 2 
Figure 1.2: Purine synthesis pathways and catabolism ........................................... 4 
Figure 1.3: Inosine ring substrate contributions. .................................................... 6 
Figure 1.4: DNPS requires input derived from multiple pathways. ....................... 7 
Figure 1.5: DNPS intermediate effects. ................................................................ 10 
Figure 1.6: Schema of molecular biology dogma. ................................................ 18 
Figure 1.7: Schema of basic RNA-seq workflow for mRNA coding sequencing. 23 
Figure 1.8: Example Gene Ontology Term hierarchy. ......................................... 27 
Figure 1.9: Schema of CRISPR based NHEJ mutations. ...................................... 31 
 
Chapter Two: Transcriptomic Characterization of crGART ............................................ 34 
Figure 2.1. De novo purine synthesis pathway. .................................................... 35 
Figure 2.2: Adenine is required for proliferative growth of crGART cell line. .... 38 
Figure 2.3: log(2) fold change of DEGs in cell lines under experimental 
conditions. ............................................................................................................. 39 
Figure 2.4: Principle component analysis of crGART and HeLa replicates. ........ 39 
Figure 2.5: Prominent GO groups from ClueGO analysis .................................... 40 
Figure 2.6: Gene expression heat map of Gene Ontology Primary Germ Layer .. 42 
Figure 2.7: Gene expression heat map of Gene Ontology Placenta Development.
............................................................................................................................... 43 
Figure 2.8: ClueGO Biological process network map A. ..................................... 54 
Figure 2.9: ClueGO Biological process network map B. ..................................... 55 
Figure 2.10: ClueGO Biological process network map C. ................................... 56 
Figure 2.11: ClueGO Biological Process ontology terms. .................................... 57 
Figure 2.12: ClueGO Biological Process parent ontology groupings. .................. 58 
Figure 2.13: ClueGO Cellular Component network map. .................................... 59 
Figure 2.14: ClueGO Cellular Component terms and groupings. ........................ 60 
Figure 2.15: ClueGO Molecular Function network map. ..................................... 61 
Figure 2.16: ClueGO Molecular Function terms and groupings. ......................... 62 
Figure 2.17: ClueGO Reactome Pathways network map ..................................... 63 
Figure 2.18: ClueGO Reactome Pathways terms and groupings. ......................... 64 
Figure 2.19: ClueGO Reactome Reactions network map. .................................... 65 
Figure 2.20: ClueGO Reactome Reactions terms and groupings. ........................ 66 
 
Chapter Three: Transcriptomic Characterization of crADSL ........................................... 67 
Figure 3.1: de novo purine synthetic pathway (DNPS). ....................................... 68 
Figure 3.2: Adenine is required for proliferative growth of crADSL line. ........... 75 
Figure 3.3: SAICAR accumulates in crADSL cells in starvation conditions 
without adenine. .................................................................................................... 75 
Figure 3.4: HPLC-EC traces of crADSL cells. ..................................................... 76 
Figure 3.5: log(2) fold change of DEGs in cell lines under experimental 
conditions. ............................................................................................................. 77 
 ix 
Figure 3.6: Notable findings from RNA-seq/GO analysis. ................................... 79 
Figure 3.7: Candidate gene verification using qPCR. ........................................... 82 
Figure 3.8: ClueGO Biological Process network map. ......................................... 88 
Figure 3.9: ClueGO term and group outputs of GO Biological Process PP to MM 
comparison. ........................................................................................................... 89 
Figure 3.10: ClueGO Cellular Component network map. .................................... 90 
Figure 3.11: ClueGO term and group outputs of GO Cellular Component PP to 
MM comparison. ................................................................................................... 91 
Figure 3.12: ClueGO Molecular Function network map. ..................................... 92 
Figure 3.13: ClueGO term and group outputs of GO Molecular Function PP to 
MM comparison. ................................................................................................... 93 
Figure 3.14: ClueGO Reactome Pathways network map. .................................... 94 
Figure 3.15: ClueGO term and group outputs of Reactome Pathways PP to MM 
comparison. ........................................................................................................... 95 
Figure 3.16: ClueGO Reactome Reactions network map. .................................... 96 
Figure 3.17: ClueGO term and group outputs of Reactome Reactions PP to MM 
comparison. ........................................................................................................... 97 
Figure 3.18: BiNGO network map PP Biological Process. .................................. 98 
Figure 3.19: BiNGO network map PP Cellular Component. ................................ 99 
Figure 3.20: BiNGO network map PP Molecular Function. .............................. 100 
Figure 3.21: BiNGO network map MM Biological Process. .............................. 101 
Figure 3.22: BiNGO network map MM Cellular Component. ........................... 102 
Figure 3.23: BiNGO network map MM Molecular Function. ............................ 103 
 
Chapter Four: Transcriptomic Characterization of crATIC ............................................ 104 
Figure 4.1: De novo purine synthesis pathway. .................................................. 104 
Figure 4.2: crATIC requires adenine for proliferative growth. .......................... 110 
Figure 4.3: ZMP accumulates in crATIC. .......................................................... 111 
Figure 4.4: HPLC-EC traces of metabolites from crATIC cells. ........................ 112 
Figure 4.5: log(2) fold change of DEGs in cell lines under experimental 
conditions ............................................................................................................ 113 
Figure 4.6: Principle component analysis of crATIC and HeLa experimental 
groups. ................................................................................................................. 114 
Figure 4.7: Notable GO groups from ClueGO analysis. ..................................... 115 
Figure 4.8: Candidate gene verification by qPCR. ............................................. 118 
Figure 4.9: ClueGO Biological process network map. ....................................... 125 
Figure 4.10: ClueGO Biological process terms and groups. .............................. 126 
Figure 4.11: ClueGO Cellular component network map. ................................... 127 
Figure 4.12: ClueGO Cellular component terms and groups. ............................ 128 
Figure 4.13: ClueGO Molecular function network map. .................................... 129 
Figure 4.14: ClueGO Molecular function terms and groups. ............................. 130 
Figure 4.15: ClueGO Reactome pathways network map. ................................... 131 
Figure 4.16: ClueGO Reactome pathways terms and groups. ............................ 132 
Figure 4.17: ClueGO Reactome reactions network map. ................................... 133 
Figure 4.18: ClueGO Reactome reactions terms and groups. ............................. 134 
 x 
Figure 4.19: BiNGO network map of Biological process for PP comparison. ... 135 
Figure 4.20: BiNGO network map of Cellular component for PP comparison. . 136 
Figure 4.21: BiNGO network map of Molecular function for PP comparison. .. 137 
Figure 4.22: BiNGO network map of Biological process for MM comparison. 138 
Figure 4.23: BiNGO network map of Cellular component for MM comparison.
............................................................................................................................. 139 
Figure 4.24: BiNGO network map of Molecular function for MM comparison. 140 
 
Chapter Five: Metabolomic characterization of crGART .............................................. 141 
Figure 5.1: De novo purine synthesis pathway ................................................... 142 
Figure 5.2: Adenine is required for proliferative growth of KO but not pGART.
............................................................................................................................. 146 
Figure 5.3: Enrichment Value calculation. ......................................................... 147 
Figure 5.4: Heatmaps of select subpathway metabolites. ................................... 149 
Figure 5.5: Grand themes of transcriptomic and metabolomic data, proposed. . 154 
 
Chapter Six: Summary, Discussion, and Future Directions ........................................... 161 
Figure 6.1: DNPS pathway with salvage inputs. ................................................ 164 
Figure 6.2: CD36 gene count in HeLa and DNPS-KO mutant cell lines. .......... 168 
Figure 6.3: PPARγ gene count in HeLa and DNPS-KO mutant cell lines. ........ 169 







Chapter One: Introduction 
Overview 
 
Purines are a class of nitrogenous bases and are vital to cellular and organismal 
functions. Defects in purine synthesis have clinical implications in patients and are 
extremely rare; the processes by which they affect patients are not well understood. There 
is known relevance of DNPS in energy homeostasis, developmental, and tumor biology. 
The study of rare disorders often reveals vital information of biological significance. In 
this dissertation, I explore the potential processes that are affected by purine synthesis 
dysregulation and metabolite intermediate accumulation. 
Nitrogenous bases and their nucleoside and nucleotide conjugates 
Nitrogenous bases are essential small molecules to life. These nitrogenous bases 
can be conjugated with a pentose sugar to form a nucleoside, and further conjugated with 
one to three phosphate groups to form nucleotides (Figure 1.1A). Nucleotides can then be 
polymerized into nucleic acids, in the form of deoxy- and ribonucleic acid (DNA and 
RNA respectively). There are five common identities of nitrogenous bases, grouped into 
one of two classes. These two classes of nitrogenous bases are purines and pyrimidines. 
The pyrimidine class is comprised of cytosine, uracil, and thymine while purine class is 
comprised of adenine and guanine (Figure 1.1B) (Figure 1.1A, B adapted from (Watson 
et al. 2008)). Nitrogenous bases can be made via two types of pathways, de novo and 
salvage. Salvage pathways typically use degradation products of nucleic acid catabolism 
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as an input to generate nucleotides with 
minimal steps while the de novo synthesis 
pathways use small molecule precursors 
from other biochemical pathways over 
many steps to form purines and pyrimidines 




Purines are a class of nitrogenous 
bases containing a six-atom ring bound to a 
five-carbon ring with one of two side group 
identities dependent on it being adenine or 
guanine base (Figure 1.1A). The two types 
of pathways capable of generating purines are the salvage and de novo. De novo purine 
synthesis (DNPS) uses the small molecule phosphoribosyl pyrophosphate (PRPP) and 
generates inosine monophosphate (IMP) via ten or eleven steps (Jinnah, Sabina, and Van 
Den Berghe 2013; Kappock, Ealick, and Stubbe 2000) (Figure 1.2A). DNPS, the focus of 
this doctoral work, utilizes six enzymes in higher eukaryotes, a singular trifunctional 
enzyme, two bifunctional, and three monofunctional. Salvage synthesis (Figure 1.2B) 
commonly utilizes the small molecules adenine (Ade), guanine (Gua), or hypoxanthine 
(Hx) and within one step can be synthesized into AMP, GMP, or IMP, depending on the 
precursor molecule. IMP is converted into AMP or GMP, each requiring two more 
sequential steps. Typically, salvage synthesis relies on the small molecule input from 
Figure 1.1: Chemical structure of nitrogenous 
bases and their classes. Nitrogenous bases can 
be further conjugated into nucleosides and 
nucleotides. Adenosine triphosphate with 
nitrogenous base, nucleoside, and nucleotide 
(triphosphate) conjugation identified (A). 
Chemical structures of nitrogenous bases 
composing the two major classes, purines and 
pyrimidines. Dark red boxes on purine and 
pyrimidines indicate site of sugar conjugation 
making nucleosides from nitrogenous bases (B). 
Chemical structure accessed from Molecular 
Biology of the Gene 6th edition and skeletal 


































































purine catabolism of nucleic acids and diet. The commonly used salvage inputs are Gua, 
Ade, and Hx as previously mentioned. For DNPS dysregulation, Ade is a unique salvage 
input. Ade is able to be synthesized into AMP directly, and subsequently converted to 
IMP by AMP deaminase, which may then be further processed to generate GMP. Hx is 
converted directly into IMP and then able to be synthesized into either GMP or AMP, 
however in the conversion of IMP to AMP, the DNPS enzyme ADSL is bifunctional and 
required to convert SAMP to AMP. Gua is synthesized into GMP, but there is no 
mechanism in mammalian cells to convert GMP to IMP. Purine catabolism is essential 
for normal cellular function and breaks down purines to their eventual product of uric 
acid in humans, which may then be secreted by the body (Figure 1.2C) (Jinnah, Sabina, 
and Van Den Berghe 2013). Figure adapted from (Jinnah, Sabina, and Van Den Berghe 
2013). 






































































Figure 1.2: Purine synthesis pathways and catabolism. Purines can be synthesized via de novo and 
salvage pathways. DNPS uses the small molecule PRPP as input through ten sequential steps to IMP. 
Certain steps require other substrates as identified. IMP may then be synthesized into AMP or GMP and 
phosphorylated to ATP or GTP, these steps are not within DNPS (A). Salvage purine synthesis utilizes the 
small molecules (among others) adenine, guanine, and hypoxanthine to directly make AMP, IMP, or GMP 
in one single step. Adenine and hypoxanthine are the only salvage inputs capable of making AMP and 
GMP (A). Purine catabolism breaks AMP, IMP, and GMP into uric acid in humans for secretion (C). Small 
molecules/metabolites/intermediates are found as black text, enzymes are pink, functional domains of 
multifunctional proteins are purple with green lines indicating which steps the multifunctional enzymes 




Small molecule/Metabolite/Intermediate (Black): 
ZMP (AICAR): aminoimidazolecarboxamide ribotide 
ADP: adenosine diphosphate 
AMP: adenosine monophosphate 
ATP: adenosine triphosphate 
GDP: guanosine diphosphate 
GMP: guanosine monophosphate 
GTP: guanosine triphosphate 
IMP: inosine monophosphate 
PRPP: phosphoribosylpyrophosphate 
SAICAR: succinyl- aminoimidazolecarboxamide ribotide 
SAMP: succinyl-AMP or adenylosuccinate 
XMP: xanthine monophosphate 
PRPP: phosphoribosyl pyrophosphate 
5-PRA: phosphoribosylamine 
GAR: glycineamide ribonucleotide 
FGAR: phosphoribosyl-N-formylglycineamide 
FGAM: 5’-phosphoribosyl formylglycinamidine 
AIR: 5’-phosphoribosyl-5-aminoimidazole 
CAIR: 5’phosphoribosyl-4-carboxy-5-aminoimidazole 











PRAT: Phosphoribosyl amidotransferase 
GART: Phosphoribosylglycinamide Formyltransferase/Phosphoribosylglycinamide Synthetase/Phosphoribosylaminoimidazole 
Synthetase 
FGAMS: phosphoribosyl formylglycinamidine synthase  
PAICS: Phosphoribosylaminoimidazole Carboxylase/Phosphoribosylaminoimidazolesuccinocarboxamide Synthase 
ADSL: adenylosuccinate lyase  
ATIC: 5-Aminoimidazole-4-Carboxamide Ribonucleotide Formyltransferase/IMP Cyclohydrolase 
ADA: adenosine deaminase 
AK: adenosine kinase 
ADSL: adenylosuccinate lyase 
AMPD: adenylate deaminase 
PRAT: amidophosphoribosyltransferase 
APRT: adenine phosphoribosyltransferase 




HPRT: hypoxanthine-guanine phosphoribosyltransferase 
IDH: IMP-dehydrogenase 
NDK: nucleoside diphosphate kinase 
NMK: nucleoside mono-phosphate kinase 
XOR: xanthine oxidoreductase 
 
Enzyme domains (purple): 
GARS: phosphoribosylglycinamide synthetase  
GART: phosphoribosylglycinamide formyltransferase  
AIRS: phosphoribosylaminoimidazole synthetase  
CAIRS: phosphoribosylaminoimidazole carboxylase  
SAICARS: phosphoribosylaminoimidazolesuccinocarboxamide synthetase  
AICARFT: 5-aminoimidazole-4-carboxamide ribonucleotide formyltransferase  
IMPCH: IMP cyclohydrolase  
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De novo purine synthesis requires small molecule inputs from multiple connected 
pathways and processes 
In order to understand the implications of DNPS, we must first understand the 
interconnectedness of multiple biochemical pathways resulting in IMP generation. 
Glucose is transformed into pyruvate via ten steps. The glycolytic intermediates glucose-
6-phosphate (G6P), fructose-6-phosphate (F6P), and glyceraldehyde-3-phosphate (G3P), 
can be funneled into the pentose phosphate pathway, generating ribose-5-phosphate 
(R5P). R5P is converted into PRPP via phosphoribosyl pyrophosphate synthase (Dayton, 
Jacks, and Vander Heiden 2016). Once PRPP is synthesized, it may then be utilized for 
DNPS. The six enzymes necessary to complete the ten sequential steps in DNPS to 
convert PRPP to IMP in higher eukaryotes require other substrates to contribute atoms in 
the generation of the inosine moiety (Figure 1.3). DNPS utilizes atom donor substrates in 
various steps of the pathway to incorporate atoms and moieties into its final IMP 
structure. These substrates are glycine, glutamine, aspartate, and 10-
formyltetrahydrofolate (Figure 1.2A). 
Amino acid synthesis/transport 
processes, glutathione-gammaglutamyl 
amino acid cycle and the folate cycle 
are all therefore critical for the 
synthesis of IMP via DNPS (Figure 
1.4). Adenosine monophosphate 
(AMP) or guanosine monophosphate 















Figure 1.3: Inosine ring substrate 
contributions. Inosine is synthesized via 
contributions of substrates within DNPS, each 
contributing atom is highlighted in red boxes 
with their respective contributing substrate.  
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additional steps from IMP (Figure 1.2A). AMP and GMP can then be further processed 
into products based on cellular need, such as via phosphorylation to generate adenosine 




Evolution is classically thought as the gain of favorable adaptative features in a 
species population to the surrounding environment over time through the process of 
natural selection, and that all life shares an ancient common ancestor (Darwin 1859). This 
idea has been implemented in myriad subfields of biology, prompting the idea of enzyme 
evolution and metabolic pathway evolution (Caetano-Anolles, Kim, and Mittenthal 2007; 
Caetano-Anollés et al. 2009). Enzyme evolution occurs from processes such as gene 
duplication (Ohno 1970), rearrangement of gene fragments (Vogel et al. 2004), or 
horizontal gene transfer (Pál, Papp, and Lercher 2005). The DNPS pathway is highly 
conserved, found across all three cellular domains, Bacteria, Archaea, and Eukarya 
PRPP












Figure 1.4: DNPS requires input derived from multiple pathways. Glucose is funneled 
through the Glycolytic metabolic pathway. Certain glycolytic intermediates are then used 
within the Pentose phosphate shunt pathway which generates R-5-P. R-5-P is then 
converted into PRPP which is the initial small molecule input for DNPS. Molecules from 
amino acid synthesis and transport as well as the folate cycle are used as substrates within 
DNPS. 
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(Armenta-Medina, Segovia, and Perez-Rueda 2014). In microorganisms, such as bacteria, 
DNPS enzymes are monofunctional (Kappock, Ealick, and Stubbe 2000). Moving higher 
in cell and organism complexity, some DNPS enzymes adopt multifunctionality within 
the pathway, with higher eukaryotes (e.g. humans) utilizing six enzymes to complete the 
ten steps (Pedley and Benkovic 2017). Interestingly, the DNPS enzyme ADSL was found 
to have a conserved evolutionary characteristic as recent as the transition from 
Neanderthal to modern humans, with a single nucleotide point mutation that resulted in 
decreased ADSL stability in modern humans (Stepanova et al. 2020). The ubiquity of 
DNPS in living organisms across the phylogenetic tree highlights the importance of a 
functioning pathway necessary for the maintenance of life.  
Purines fulfill multiple roles in cellular and organismal functions 
Purines fulfill many roles within the cell. As previously stated, nucleotides can be 
polymerized into genetic information material in the form of RNA and DNA. The 
monomeric form of ATP is used as a major energy currency. Purines are also critical as 
primary and secondary signaling molecules. Purines are also used as cofactors for various 
cellular processes (Pedley and Benkovic 2017). 
Extracellular signaling activities have been identified for purines. Purinergic 
signaling has been implicated in cell proliferation, migration, cellular differentiation, 
embryonic death, wound healing, inflammation, and others (Burnstock 2009). Indeed, 
ATP has long since been proposed to act as a neurotransmitter (Burnstock, Dumsday, and 
Smythe 1972) and myriad functions in nervous system have been found, such as 
neuroprotection, control over autonomic function, neural-glial interaction, pain and 
mechanosensory transduction, and physiology of senses (Burnstock 2006). 
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Cyclic AMP (cAMP) is a classic example of a secondary messenger, employed as 
such in organisms ranging from amoebas, plants, to humans (Hofer and Lefkimmiatis 
2007) mediating processes such as memory, metabolism, gene regulation, and immune 
function (Beavo and Brunton 2002). Upon cellular signal, ATP will be converted to 
cAMP, which in turn mediates response (Serezani et al. 2008).  
Adenine base nucleotides are components of many coenzymes such as 
nicotinamide adenine dinucleotide, nicotinamide adenine dinucleotide phosphate, flavin 
adenine dinucleotide, and coenzyme A (Roy et al. 2016; Pedley and Benkovic 2017). The 
nicotinamide and flavin adenine dinucleotides are essential for the tricarboxylic acid 
cycle (TCA cycle, commonly known as Krebs or Citric acid cycle) and are used for redox 
reactions between oxidative phosphorylation and the TCA cycle, in the generation of 
energy in the form of ADP to ATP conversion (Martínez-Reyes and Chandel 2020). 
Coenzyme A and its derivatives have myriad cellular roles, such as use in synthesis and 
oxidation of fatty acids, synthesis of acetylcholine, acetylation of histones (Martinez, 
Tsuchiya, and Gout 2014), as well as oxidation of pyruvate for TCA cycle input 
(Martínez-Reyes and Chandel 2020).  
Guanine base nucleotides are most notable for their role in G protein-coupled 
receptors, expressed across most life forms, mediating a majority of cellular responses to 
external stimuli (Weis and Kobilka 2018). G protein couple receptors utilize guanosine 
nucleotides, binding and exchanging between GDP and GTP to recognize and incorporate 
extracellular signals (Weis and Kobilka 2018; Hanlon and Andrew 2015).  
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DNPS pathway intermediates have roles outside of DNPS 
 
DNPS intermediates are small molecule products and substrates of the enzymes 
found in the DNPS pathway. Some intermediates found in the pathway are relatively 
short-lived under cellular conditions. Notably, 5-PRA, the first substrate for the 
trifunctional enzyme GART, is broken down under cellular conditions within 5 seconds 
(Rudolph and Stubbe 1995). However, SAICAR and ZMP, the first substrates for the 
enzymes ADSL and ATIC respectively have been shown to regulate processes outside of 
DNPS. SAICAR has been recently shown as a binding partner of the glycolytic pathway 
enzyme PKM2 and is of keen interest for cancer research. ZMP is a known and well 
characterized activator AMPK, the master regulator of energy homeostasis and mTOR 
activity. (Figure 1.5) 
Glycolysis is a ten sequential step pathway taking glucose and forming pyruvate, 
directly forming two ATP and two reduced nicotinamide adenine dinucleotide molecules 
per glucose input. The last step catalyzes phosphoenol pyruvate into pyruvate through the 














Figure 1.5: DNPS intermediate effects. Multiple intermediates found within the DNPS pathway have 
off pathway effects. SAICAR was found to tetramerize PKM2 which increases glycolysis and may 
moonlight as a protein kinase. ZMP is a well characterized to phosphorylate AMPK, which inhibits the 
mTOR pathway, altering ATP metabolism, and remove nuclear translocation of NFkB. The 
intermediate 5-PRA is short lived under cellular conditions and has no known off pathway effect.  
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PKL, PKR, PKM1, and PKM2 (Dayton, Jacks, and Vander Heiden 2016), however we 
will only be discussing PKM2 as this isoform plays an important role in regulation of 
transcription and protein phosphorylation in addition to its role in metabolism. Normal 
aerobic cellular energy production relies slightly on glycolysis to produce pyruvate and 
form acetyl-CoA in the cytosol, which is then translocated into the mitochondria to 
produce high energy electrons in the form of nicotinamide and flavin adenine 
dinucleotide (NADH and FADH, the reduced forms) through the TCA cycle. These high 
energy electron carriers are then used in oxidative phosphorylation, using oxygen as the 
electron acceptor in the electron transport chain (ETC) which phosphorylates ADP to 
ATP creating vast amounts of usable energy per unit input. Anaerobic energy production 
is used during exposure to oxygen poor environments, unable to support proper ETC 
function and thus favoring glycolysis. Here pyruvate is shunted to lactic acid formation 
using the enzyme lactate dehydrogenase and nicotinamide adenine dinucleotide as an 
electron donor, generating small amounts of energy per unit input in the form of ATP.  
When cells become tumorigenic, a change in metabolism and energy production 
usually occurs. The Warburg Effect is based in an observation that most solid tumors 
produce lactic acid in an oxygen rich environment (Warburg and Minami 1923). This 
finding was rather curious, as lactic acid was typically thought solely as a byproduct of 
glycolytic metabolism in oxygen deficient environments. As these tumors were 
producing lactic acid in an oxygen rich environment, the Warburg effect became known 
as aerobic glycolysis. Tumor cells bypass checkpoints in the cell cycle designed to induce 
a vegetative state after division and as such, are uncontrollably dividing. The Warburg 
effect hypothesis speculates that due to tumor cells unchecked proliferation, an elevated 
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need exists for nucleotide bases; as the glycolytic intermediates can be funneled into the 
pentose phosphate pathway to make PRPP, necessary for the formation of purines and 
pyrimidines. The cell can therefore synthesize a large pool of necessary nitrogenous 
bases and therefore DNA and RNA for division events. PKM2 is the most easily 
manipulatable of the PK isoforms, with multiple regulators molecules and proteins 
commonly found in proliferating cells, permitting or halting its pyruvate kinase activity 
(Dayton, Jacks, and Vander Heiden 2016). This control allows selective signaling for 
glycolytic intermediates to build up for nucleotide synthesis or allowing pyruvate to form 
for lactate-based energy production. Tumor cells also utilize glutaminolysis pathway for 
energy production, providing an alternative input for TCA cycle (Zahra et al. 2020). It 
has been found that most tumors selectively express PKM2 over other isoforms of PKs 
giving credence to this hypothesis (Mazurek 2011).  
PKM2 exists as an active homotetramer (tPKM2), inactive homodimer (dPKM2), 
or and monomer (Dayton, Jacks, and Vander Heiden 2016) and is typically expressed in 
fat tissue, lung, pancreas, as well as highly proliferative cell types such as embryonic 
cells and tumors (Mazurek 2011). As previously stated, multiple avenues exist to 
modulate PKM2 activity, typically achieved through stabilizing or destabilizing its 
tetramer (Dayton, Jacks, and Vander Heiden 2016). The glycolytic intermediates 
phosphoenol pyruvate (PEP) and fructose-1,6-bisphosphate (FBP) as well as serine 
activates PKM2, while alanine, thyroid hormone T3, and ATP, deactivate PKM2 (Zhang 
et al. 2019). PKM2 activity is also influenced by protein-based regulators such as by 
ERK1/2 signaling, tyrosine kinases FGFR1, and 0-GlcNAcetylation (Zhang et al. 2019). 
SAICAR was recently found to bind PKM2, possibly stabilizing its tetramer (Figure 1.5, 
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tPKM2) (Keller, Tan, and Lee 2012), and possibly allowing an aberrant moonlighting 
function by adopting a protein kinase activity (Keller et al. 2014). Although the potential 
protein kinase activity of PKM2 has been questioned (Hosios et al. 2015), the 
preponderance of data suggests that the protein kinase moonlighting activity of PKM2 is 
real (Zhang et al. 2019). The findings that suggest SAICAR has a role in modulating 
PKM2 activity presents a novel research area in tumor biology, and therefore 
accumulation of SAICAR in within the cell may be used to study PKM2 activity.  
SAICAR however, cannot be fed to cells directly as mechanisms have not been found 
and it is difficult to synthesize, so more circuitous methods need to be applied. 
Researchers have employed glucose starvation methods (Keller et al. 2014) as well as 
siRNA against ADSL (Keller, Tan, and Lee 2012). Sugar starvation is less than ideal, 
owing to the potential total cellular metabolism effects of energy deprivation as well as 
pyruvate kinase activity directly being affected by the starvation. Stable transfection of 
anti-ADSL shRNA in HeLa cells have shown ~80% reduction of cellular ADSL protein 
and permitting SAICAR accumulation (Keller, Tan, and Lee 2012) but still allowing low 
levels of ADSL and DNPS activity.  
ZMP is also a small molecule of particular interest as it is a known AMP mimetic 
(Hardie 2011; Garcia and Shaw 2017; Douillet et al. 2019). AMP is a known allosteric 
effector of multiple enzymes, notably the cellular metabolism master regulator protein 
AMP-activated protein kinase (AMPK). AMPK is a heterotrimer, composed of an α, β, 
and γ subunit. AMPK senses the AMP/ATP ratio, upon increase in this ratio, AMP binds 
AMPK and promotes the phosphorylation of AMPK α subunit at Thr172 (pAMPK), 
activating AMPK activity (Hardie 2011). Activation of AMPK promotes ATP anabolism 
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and hamstrings ATP catabolism. ZMP is shown to be a potent AMPK activator using the 
same mechanisms of AMP, specifically it promotes AMPK phosphorylation (Hawley et 
al. 1995), inhibition of AMPK dephosphorylation (Davies et al. 1995), and allosteric 
activation of phosphorylated AMPK (Corton et al. 1995). pAMPK is a known effector of 
the mammalian target of rapamycin complex 1 and 2 (mTORC1 and mTORC2) (Saxton 
and Sabatini 2017; Huang et al. 2008). The mTOR pathways regulate vital cellular 
metabolic processes involved in lipid synthesis, glycolysis, mitochondrial and lysosomal 
biosynthesis, apoptosis, glucose metabolism, cytoskeletal rearrangement, and cell 
migration (Linke et al. 2017; Saxton and Sabatini 2017). pAMPK inhibits mTORC1 
pathway via phosphorylation of its regulatory protein component Raptor and indirectly 
via activation by phosphorylation of tuberous sclerosis complex 1/2, a GTPase complex 
that generates an inhibitor of mTORC1 (Inoki, Kim, and Guan 2012). pAMPK has been 
shown to affect processes seemingly outside of cellular metabolism. It can reverse the 
nuclear translocation of the proinflammatory transcription factor, NFκB, in response to 
inflammatory stimuli (Xiang et al. 2019), regulates inflammatory suppression (Jeon 
2016), and restriction of interferon-γ signaling (Meares et al. 2013). In addition to AMPK 
interactions, ZMP was shown to have 74 different enzyme interacting partners in yeast 
(Douillet et al. 2019), highlighting that ZMP effects within the cell are multiple and 
complex.  
Previous work used AICAriboside (the dephosphorylated form of ZMP) to 
promote phosphorylation of pAMPK. In these experiments, AICAriboside is 
administered in cell culture via media supplementation (Corton et al. 1995) or in animal 
models via injection (Xiang et al. 2019). Upon cellular import, AICAriboside becomes 
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phosphorylated via adenyl kinase (AK) into its active ZMP form and can then induce 
phosphorylation of AMPK (Hardie 2011). ATIC is a homodimer and is active only in its 
dimeric state (Spurr et al. 2012). The drug Compound 14 was recently discovered, 
blocking the dimerization of ATIC which allows the accumulation directly of the active 
form of ZMP without relying on cellular import and phosphorylation events (Spurr et al. 
2012).  
Clinical relevance of DNPS dysregulation 
 
DNPS is highly conserved and critical for cellular and organismal development. 
To date, only three enzymes are found to have mutations that result in decreased activity 
within the DNPS pathway in H. sapiens. These enzymes are ADSL, ATIC, and PAICS 
and deficiency is extremely rare. 
ADSL deficiency is the most common of DNPS defects. Currently, less than 100 
patients have been identified having this disorder (Jurecka et al. 2015). These patients are 
grouped into three classes depending on phenotype, neo-natal fatal, Type I severe, and 
Type II mild to moderate. The phenotype is a continuum, with degrees of psychomotor 
retardation, seizures, visual impairment, speech impairment, and craniofacial dysmorphic 
features (Jurecka et al. 2015). Multiple mutations have been identified leading to a 
mutation dependent decrease in ADSL enzymatic activity (Zikanova et al. 2010).  
PAICS deficiency is the second most common, with two patients (siblings from 
two separate pregnancies) identified in the Faroe Islands. The deficiency stems from an 
amino acid point mutation resulting in Lys53Arg leading to a 75% reduction in enzyme 
activity. These patients presented with multiple phenotypes such as small body, 
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brachycephaly, lung malformation, craniofacial dysmorphism, vertebral malformations, 
among others. Both infants died within three days of birth (Pelet et al. 2019). 
AICAribosiduria, also known as ATIC deficiency, has only been identified in a 
single patient. The patient was found to have one allele with a frameshift in exon two 
which resulted in unstable mRNA, and a point mutation of Lys426Arg. This mutation 
showed no detectable AICAR-TF activity and a 60% reduction in IMPCH activity of the 
ATIC enzyme (the first and second reaction mediated by ATIC respectively). This patient 
presented with profound mental retardation, epilepsy, brachycephaly, congenital 
blindness, and facial dysmorphic features, among others. Last available record of record 
patient check-up was performed at 4 years of age and no treatment was reported directly 
for AICAribosiduria (Marie et al. 2004). 
So far, all patients with defective DNPS have residual enzyme activity. It may be 
that complete lack of activity is lethal in embryos. Evidence for this includes the 
difficulty in generating mouse knockouts, to date, a singular mouse line has been made 
lacking a DNPS enzyme, FGAMS (“C57BL/6NJ-Pfasem1(IMPC)J/Mmjax” n.d.). Our 
laboratory in fact obtained mice with a heterozygous knockout of ADSL. Breeding and 
genotyping of several hundred matings of these mice never resulted in a homozygous 
ADSL knockout mouse. 
GART is implicated in Down syndrome (DS), however not due to a deficiency in 
enzymatic activity. DS is an aneuploidy caused by a triplication in Hsa21. The GART 
gene is located on 21q22 (Patterson 1987) and is therefore triplicated in DS. The DS 
phenotype is characterized by cognitive deficits in the form of intellectual and learning 
disabilities, hypotonia, craniofacial abnormalities, and cardiac malformations (Brodsky et 
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al. 1997). DS accounts for approximately 1 in 700 live births in the United States (Mai et 
al. 2019). DS shows unique spatiotemporal expression of the GART enzyme with one 
study showing cerebellar GART levels precipitously drop post-partum in control while in 
DS patients showed detectable levels as long as 49 days post-partum (Brodsky et al. 
1997). Two laboratories, ours and that of John Gearhart, produced mice transgenic for 
human GART and therefore triplicated for GART (two mouse copies and one human). 
These mice showed no detectable phenotype, with the possible exception of a slight 
hearing deficit (Knox 2006). 
It is therefore clear that any disorder affecting DNPS presents as developmental 
disorder. These clinical phenotypes show the importance for well controlled DNPS in 
embryogenesis. This is perhaps unsurprising as DNPS is critical for rapidly dividing 
cells, a feature of embryogenesis. Purinergic components have been of recent interest for 
pharmacological intervention for congenital neurological defects (Fumagalli et al. 2017). 
Taken together, full characterization of DNPS dysregulation is of particular importance to 
understanding embryogenesis as well as neurological defects.  
-omics 
 
The central dogma of molecular biology is that DNA is transcribed into RNA, 
which is then translated into protein. Proteins can then go on to perform countless cellular 
functions, from anchoring the cell to the extracellular matrix, importing or exporting 
cargo, trafficking, metabolizing small molecules, modifying the activity of other proteins, 
acting as a transcription factor, among myriad others. DNA is read and synthesized into 
RNA via transcription, while RNA is read and made into protein sequences through 
translation. Proteins may or may not directly alter metabolites, which are typically 
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thought of as small molecules under 1 kDa in size. The entire DNA sequence is known as 
the genome, while total RNA is known as the transcriptome, the entire protein content is 
known as the proteome, and all metabolites are known as the metabolome (Figure 1.6). 
Each of these “-omes” presents a novel set of data with their advantages and 
disadvantages. As such, integration of multiple -omics techniques may be required to 
gain a complete picture of response to stimuli or stress (Riekeberg and Powers 2017). 
  
The genome comprises information about the DNA sequences found within the 
cell, comprising of coding (gene) and non-coding stretches. Through probing genomics, 
information can be attained about the root or underlying cause in disease (International 
Human Genome Sequencing Consortium 2004). However, as cells multiply, errors in 
genomic replication can occur. Population based genetic drift and inheritance can also 
allow errors to occur and propagate. These errors manifest in various ways such as single 
nucleotide variations and can cause cells to function aberrantly. Single nucleotide 
variations in coding regions may alter protein sequence or in non-coding regions may 
influence gene expression or splicing (Metzker 2010). Genomics can inform a direct root 
cause of a disorder, however, gives scant information on how a cell is responding to that 





Figure 1.6: Schema of molecular biology dogma. DNA is transcribed to make RNA, which is 
translated to protein, some proteins can synthesize small molecules. The collective DNA, RNA, 
protein, or small molecules within a sample represent the genome, transcriptome, proteome, or 
metabolome respectively. 
 19 
understanding cellular responses. Nucleic acids present a major advantage in -omics 
research however, as minute amounts of DNA can be amplified and read/analyzed 
through polymerization reactions.  
The transcriptome represents all RNA in the cell, including any exon splice 
variations and coding single nucleotide polymorphism within the genome. 
Transcriptomics is a technique where cellular RNA is sequenced to gain information into 
what gene product is to be made as well as the RNA sequences quantified. This 
information taken together can explain differential expression of specific genes. When 
cells are exposed to a stimulus, a specific gene or groups of genes can be differentially 
expressed when compared to control conditions. Owing to the identity and concentration 
gathering component to transcriptomics, this technique can prove quite powerful. 
However, there are a few drawbacks. Transcriptomics, while representing what the cell is 
trying to accomplish in response to a stimulus, does not always track with its respective 
proteome (Schwanhäusser et al. 2011). This is to say that levels of transcript of a certain 
gene are not always in agreement with expression levels of that protein. This could be 
attributed to myriad reasons ranging from RNA and protein stability issues to post 
translational modifications. Transcriptomics has a similar benefit to genomics in that 
RNA sequences are able to be amplified using PCR based techniques. This allows trace 
amounts of RNA to be read and quantified giving an accurate snapshot of cellular 
response. Transcriptomic data can be generated through a process called RNA 
sequencing (RNA-seq). 
Proteomics is the study of the entire set of proteins within the sample and is rife 
with problems. The large barrier to entry is the excessively high level of complexity in 
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proteomics. While genomics and transcriptomics utilize a four nucleotide code with three 
nucleotide per codon system, proteomics utilize a code of 20 amino acids with over 200 
(Deribe, Pawson, and Dikic 2010) potential post translational modifications (e.g. 
phosphorylation, glycosylation, malonation, lipidation, acetylation, acylation, etc.) with 
each of these post translational modifications representing a potential change in function 
for each protein (Duan and Walther 2015). Examples of post translational modification 
altering protein activity are AMPK activates upon phosphorylation at the single residue 
Thr172 (Hardie 2011) while the protein CRMP2 is host to 4 nearly sequential 
phosphorylation sites with altered activity based on not only quantity of sites 
phosphorylated, but also order in which they are phosphorylated (J. Yu et al. 2019; 
Yamashita et al. 2012). In addition, cellular localization can confer protein activity. 
NFκB is a transcription factor typically sequestered in the cytoplasm, signaling induces 
release from sequestration and can translocated to the nucleus initiating transcriptional 
activity (Papa 2004). Alternative splicing as well as multimerization can alter protein 
function as well. There are scalability issues with proteomics owing to the fact that more 
protein cannot be made similar to that used in transcriptomics and genomics. A popular 
technique used for to proteomics is mass spectrometry (MS), which poses additional 
problems. MS data is biased towards peptide sequences with higher concentration, is 
susceptible to fragmentation differences, and contamination issues. Incomplete databases 
stemming from data complexity also pose an inherent issue when studying the proteome. 
As such, protein studies at the true -omics scale currently cannot be performed (Manzoni 
et al. 2018).   
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Metabolomics is the study of the entire set of small molecules produced by 
biological reactions within a sample. Metabolite changes represent the combination of 
genetics as well as environmental exposures (Manzoni et al. 2018), as such a 
metabolomic approach is an advantageous diagnostic tool as well as relevant to 
understanding molecular pathway aberrations related to specific disorders or stimuli. 
Metabolomic data can be generated, for example, via LC-MS techniques. MS fingerprints 
are then probed against databases assigning identity and concentration. Metabolomics is 
not without its drawbacks. Metabolome reference databases show no homogeny in their 
metabolite accession numbers and metabolites identified by their database, causing 
difficulty in probing multiple databases. Reference metabolomes are incomplete, in 
addition the biological role is not always clearly understood for all detectable 
metabolites. Metabolites also have a variety of functions, for example ATP is used as an 
energy currency as well as signaling molecule. Detection limitations also dictate total 
metabolites identified in metabolomic studies, which are often a fraction of the cellular 
metabolic profile. For these reasons, metabolomics is also currently incompatible with a 
true -omics scale (Riekeberg and Powers 2017; Manzoni et al. 2018; Min Yan and Xu 
2018). 
Transcriptomic data generation and file conversion 
 
For RNA applications TriReagent can be used to extract total cellular RNA from 
multiple types of samples. This approach yields high quality RNA for downstream 
applications such as RNA-seq. Considerations must be made for sample replicates. 
Current industry standards for cell culture applications, generally speaking, dictate a 
replicate of three with diminishing return above six replicates. 
 22 
RNA-seq allows comprehensive, broad discovery studies and provides 
information on how stimulus or genotype based gene expression patterns, gaining insight 
into the dynamics of cellular processes and its potential influence in health and disease 
(Manzoni et al. 2018). 
Dependent on the answer looking for, there are multiple RNA-seq methodologies. 
We will only be exploring one of these applications relevant to this dissertation. Coding 
gene RNA-seq requires total RNA to be enriched for messenger RNA (mRNA) and 
subsequent cDNA library preparation. For coding RNA-seq, total RNA is subjected to 
poly(A) tail enrichment, a typical feature found in mature mRNA and then fragmented. 
Modern sequencing instrumentation has sequence size limitation and therefore must be 
fragmented; due to simplicity, this step is typically applied to the enriched mRNA 
although the necessary cDNA libraries can be prepared using full length mRNA and then 
fragmented. cDNA is generated off of fragmented mRNA using random and oligo d(T) 
primers through first and second strand synthesis steps, ensuring total sequence coverage, 
generating the necessary cDNA required for sequencing. Blunt ends are created and then 
adapters are ligated. These adapters contain functional elements necessary for sequencing 
and can contain a barcode region, a specific sequence within the adapter that allows the 
cDNA library prepared to have a portion with the same sequence within each preparation, 
increasing RNA-seq workflow and efficiency by allowing multiplexing of various 
samples of prepared cDNA libraries within the same sequencing run. The adapted and 
barcoded cDNA is then amplified and is now ready for sequencing (Figure 1.7A, B) 
Figures from (“Universal Plus MRNA-Seq with NuQuant User Guide” 2019; Corney 
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2013). Sequencing conditions must be considered and includes end reads, sequence 
length, as well as sequencing depth. 
Sequencing of prepared cDNA can be done via single or paired end reads. For 
differential gene expression profiling, users can employ single end reads with appropriate 
read lengths of 50-75 base pairs; this minimizes reading across gene splice junctions 
while still allowing counting of all mRNAs from the sample. Identification of novel 
A B 
Figure 1.7: Schema of basic RNA-seq workflow for mRNA coding sequencing. mRNA is enriched 
from total RNA by polyA tail capturing. mRNA is fragmented and then cDNA is synthesized using 
primer and adapters and cDNA template is prepared for sequencing. representation of workflow, figure 
from NuQuant Illumina guide (A). Visual representation of workflow figure from Corney 2013 (B). 
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sequences/splice variants is facilitated by paired end reads with 75 base pairs, allowing 
more complete coverage of the transcripts with information from 5’ and 3’ ends. 
Sequencing depth is a necessary metric for RNA-seq applications, understood as the total 
number of reads within a sample typically from 5-200 million reads. These read depths 
are adjusted based upon abundance of transcript and type of RNA-seq desired (i.e. low 
abundance transcript requires more read depth as to ensure validity of results). These read 
quantities are targets and are rarely met exactly leading to considerations for downstream 
processing.  
Sequencer output files are converted from raw format into FASTQ format. The 
FASTQ is an inherently simple format, adapting the FASTA file format and assigning a 
numeric quality score to each nucleotide in a sequence; and thus has emerged as a 
standard file format for sequencing information (Cock et al. 2010). FASTQ files are used 
as direct input for downstream processing applications. Multiple routes exist to process 
these FASTQ files such as the TopHat-Cufflinks (Trapnell et al. 2012) or Salmon-
DeSeq2 (Love, Huber, and Anders 2014) workflows.  
Typically, for mRNA coding gene analysis, sequences from FASTQ files are 
processed to form gene counts for expression quantification and compared amongst all 
samples processed giving a normalized count. In large datasets, counts of individual 
identities are valuable to understand changes in abundance from between samples and 
conditions. These changes in abundance can be represented by a few terms. Fragments 
per kilobase of transcript per million mapped reads (FPKM) is a normalized estimation of 
gene expression. Since longer transcripts are expected to generate more reads than shorter 
ones (due to having more fragments) as well as differences in sequencing depth between 
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samples, the FPKM value accounts for these discrepancies and normalizes the counts. 
FPKM must be further processed to make it ideal for DEG analysis, which is accounted 
for in the CuffLinks processing suite (Trapnell et al. 2012). This total workflow makes 
FPKM a good metric for understanding differential gene expression indicating a relative 
concentration of specific gene transcript comparing control to experimental conditions. 
Normalization of counts through the DESeq2 processing suite utilizes a median-of-ratios 
methodology for generating DEGs. This is based upon modeling the read counts to a 
geometric mean value per gene scaled by a program calculated normalization factor and 
is unbiased by factors such as GC content and allowing DEG analysis (Love, Huber, and 
Anders 2014). 
Changes in abundance for RNA-seq applications are typically displayed as ratios 
or log(2) fold change. Log(2) values evenly represents the change between 
samples/conditions of each specific gene reflected over zero on a number line (i.e. if a 
gene transcript is twice as abundant in one condition, but another gene transcript is half as 
abundant, the log(2)fold change will be 1 and -1 for the first and second gene transcript 
respectively, rather than 2 and. 0.5). These are now known as a differentially expressed 
gene, or DEG. Significance is then calculated between the comparison groups. For 
software analysis, gene accession numbers offer ease of use, however for downstream 
application such as Gene Ontology analysis, accession numbers are translated into gene 
symbols. Applying cutoffs is common practice, used to remove low statistical count 
anomalies in genes associated with normalized gene count. The final list is now prepared 
for downstream applications. 
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Transcriptomic data interpretation through database probing 
 
Once lists of DEGs are generated, multiple databases exist to probe significance 
from them. In this study, Gene Ontology and Reactome were employed.  
Gene Ontology is a manually and digitally curated database sorting genes into 
three families, biological process, cellular component, and molecular function. Each of 
these families seeks to group genes into more specific terms upon specific criteria: 
biological process includes genes that contribute to completion of a biological objective, 
cellular component refers to gene product localization, while molecular function refers to 
the biochemical activity of the product. Not only are genes in GO grouped into three 
large families, GO families are also formed as functional hierarchies of terms, with 
increasing specificity of function/location/activity of term with each higher level (Figure 
1.8) Figure adapted from (Bindea and Mlecnik 2019). Terms at every level have 
associated genes (Ashburner et al. 2000).  
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Reactome Knowledgebase is a large list of manually curated genes falling into 
two main categories, Pathways and Reactions (Fabregat et al. 2018). Our system employs 
the use of enzyme knockouts (KO) of the DNPS therefore of genes involved in 
biochemical pathways, responsible for the reactions involved in purine synthesis, 
therefore Reactome provides a suitable complement to the GO families. 
Database probing programs exist, each one functioning slightly differently but 
overall concept remains constant. In essence, DEG lists are entered into the program, 
database choice is selected, then significant terms associated with the gene list are 
generated. Two versions of gene inputs typically exist, weighted and unweighted. In a 










Figure 1.8: Example Gene Ontology Term hierarchy. Gene Ontology terms are broken down by 
levels, with higher level values representing increased specificity. Higher levels are grouped into lower 
levels based upon relationships. Figure adapted from Bindea 2012. 
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utilizes the gene identity. Overrepresentation is a popular method for unweighted analysis 
that requires a preselected differentially expressed gene list (Rahmatallah, Emmert-
Streib, and Glazko 2014). In overrepresentation, hypergeometric analysis reveals how 
many genes are predicted to have their expression randomly changed per term. If there 
are more genes in the DEG list belonging to a specific term than what is predicted to have 
randomly changed, the term is therefore important for the analysis and p-values are 
calculated based on the difference between observed and predicted (Mlecnik, Galon, and 
Bindea 2018; Maere, Heymans, and Kuiper 2005). For exploratory analysis, the 
overrepresentation unweighted analysis system is ideal as large amounts of data can be 
generated with a relatively simple yet powerful analysis. The terms generated through 
overrepresentation analysis can be grouped into larger categories based on hierarchal 
overlap to be explored more in depth through targeted experimentation.  
ClueGO is an example of a database probing program (Mlecnik, Galon, and 
Bindea 2018). ClueGO can draw off multiple databases and is designed for smaller lists 
of DEGs. This is accomplished by applying cut offs based on log2(normalized fold 
change) between experimental and control conditions, using as input the most positive 
and negative changed genes. A large benefit of the ClueGO programing is the ability to 
probe different tiers of levels in the GO databases.  
ClueGO can probe GO levels 1-15 (least to most specific terms) based upon user 
defined parameters. Lower level probing yields terms due to the high amount of genes 
found within those terms, terms are essentially meaningless due to generality (e.g. 
Developmental Process GO:0032502), while high level terms presents a similar problem 
in reverse, that is to say terms are hyper-specific with very limited number of genes 
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comprising the term making it unlikely to show any enrichment in DEG lists. In order to 
obtain results, users must balance the rate of term return (as seen in low level probing) 
and term usefulness (as seen in high level probing). For initial assessment, mid-hierarchy 
assessment is incredibly useful as it allows for terms to be identified and for large 
groupings of terms to be assessed. That is to say if multiple terms are found within the 
lower level hierarchal group, it could be posited that this grand theme is affected by the 
experimental condition (Figure 1.8). 
Selection of specific KOs and cell line 
 
Owing to the points previously outlined, the effects related to the three enzymes 
(GART, ADSL, and ATIC) are a beneficial starting point to understanding generalized 
DNPS deficiency, congenital disorders of known enzyme deficiency, and metabolic 
intermediate accumulant effects. Murine models are not ideal for this type of study due to 
the difficulty of inducing mutations in DNPS enzymes for viable mouse models.  
This laboratory pioneered the study of the genetics of DNPS using Chinese 
hamster ovary (CHO) cells. This included isolation of mutants in each gene of the DNPS 
pathway including GART, ADSL, and ATIC. In particular, we collaborated with the 
laboratory of Dr. Stanislav Kmoch (Charles University, Prague, Czech Republic) to 
characterize the AdeI ADSL deficient mutant as a possible cell culture model of ADSL 
deficiency (Duval et al. 2013). However, this model has the obvious weakness that it is 
not a human model. 
The HeLa cell line was derived from cervical cancer in a patient in 1951 (Scherer, 
Syverton, and Gey 1953) and has been in culture since. It has been widely used 
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experimentally. There are over 107,000 manuscripts listed in PubMed using HeLa cells. 
Therefore, a great deal is known about essentially all aspects of HeLa cell biology.  
The immortalized HeLa cells have several key advantages. First, they are 
immortal and robust, being able to withstand and show proliferative growth in a wide 
range of conditions. The immortality of the cell line bypasses ethical issues with animal 
or patient tissue primary cell culture (Kaur and Dufour 2012) although the HeLa cell line 
specifically is rife with controversy (Beskow 2016). However, immortal lines suffer from 
not always replicating the behavior of their derived tissue (Kaur and Dufour 2012). In -
omics based experiments, this may perhaps be an advantage. Gross processes identified 
can be implemented and assessed for their veracity in tissue specific processes. Primary 
cell lines that reveal enrichment in processes in no way associated with the derived tissue 
would be received as suspect.  
The HeLa line has been used extensively in the search for the purinosome. Due to 
the fast catabolism of early pathway intermediates, the idea of a functional proteinaceous 
superstructure was therefore attractive (Smith et al. 1980). In 2009, the first images of 
cellular compartmentalization, wherein transfected HeLa cells expressing DNPS enzymes 
tagged to eGFP were shown to aggregate upon purine starvation and disassemble upon 
purine supplementation (An et al. 2008). Multiple reports have since been published by 
the Benkovic lab characterizing this cellular structure (Deng et al. 2012; Chan et al. 2015; 
Zhao et al. 2013; 2015).  
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CRISPR is a recently developed genomic editing technique that provides greater 
efficiency and specificity over previous techniques (Ran et al. 2013). One of the most 
basic forms of CRISPR techniques is knocking out a gene via non-homologous end 
joining (NHEJ). CRISPR utilizes a guide RNA sequence linked to a Cas9 endonuclease, 
the guide RNA targets the complex to specific sequences within the genome while the 
Cas9 is capable of breaking DNA. After the break in DNA is induced, native DNA repair 
mechanisms repair the break and can create 
insertions and deletions of nucleotides into the 
genome at the break site generating a frameshift 
mutation (Figure 1.9). Figure from (“CRISPR 
Guide” n.d.). When an early exon of the gene is 
targeted, the resultant frame shift mutations 
generated by insertion/deletion errors creates 
non-sense coding and likely introduces an early 
stop codon (Ran et al. 2013). Subcloning is 
performed to isolate cells of a specific 
break/repair lineage and screening is done to 
understand the mutation and efficacy of the 
knock-out. This process results in the genomic 
knock out and null expression of a targeted, 
specific gene.  
In 2016, our collaborators produced 
CRISPR-Cas9 generated knock outs of DNPS 
Figure 1.9: Schema of CRISPR based 
NHEJ mutations. Guide RNA and Cas9 
form a complex which targets sequence 
specific genomic DNA inducing a double 
strand break which may be repaired with 
insertions and deletions of nucleotides 
resulting in a frameshift mutation and 
subsequent silencing of the targeted gene. 
Image from addgene.org/guides/crispr/  
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enzymes in the HeLa cell line, they have termed crXXXX, where XXXX is the enzyme 
that is knocked out (Baresova et al. 2016). They have characterized the cell lines using 
immunoblotting, qPCR, as well as MS techniques (Mádrová et al. 2018). With exception 
of the crADSL line, all show no transcript or immunoreactivity for their knocked-out 
enzyme. crADSL, shows only 1.7% activity compared to WT (Baresova et al. 2016). The 
Kmoch laboratory has graciously provided our laboratory with the crGART, crADSL, 
and crATIC HeLa cell mutants. We continue to collaborate with this group to the present.  
I chose to explore the HeLa cell based DNPS KOs crGART, crADSL, and 
crATIC. As previously described, substrates of both ATIC and ADSL have off-target 
effects, and both proteins have clinical significance as enzyme deficiency were identified 
in patients (Marie et al. 2004; Jurecka et al. 2015). GART does not accumulate any 
substrate (Mádrová et al. 2018) and no GART deficient patients have been identified to 
date, therefore the crGART cell line likely represents effects of generalized DNPS 
deficiency. GART is also found on Hsa21 and is therefore triplicated in DS and could 
provide insight into GART involvement in the DS phenotype.  
Hypotheses and aims 
 
DNPS deficits have clinical implications, although are uncommonly rare. The 
phenotypes of DNPS deficiency are not well understood, highlighting the dearth in our 
current knowledgebase of the cellular and organismal ramifications of DNPS 
dysregulation. Rare disorders are oft overlooked, however their study many times leads to 
discoveries of important biological roles. The intermediates of DNPS were previously 
shown to have roles outside of DNPS in energy homeostasis as well as tumor biology.  
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Targeted therapeutics show little to no efficacy in DNPS dysregulated patients. 
These therapies have all been based on sound hypotheses however have shown no 
success. This implies that the phenotype for these disorders and therefore processes 
affected by DNPS dysregulation are largely unknown. In purine auxotroph cell lines, we 
are able to rescue the survival/proliferation phenotype by supplying an exogenous source 
of purine usually in the form of adenine. This intervention is similar to therapies tried for 
ADSL deficiency, in which some have been aimed at using salvage pathways or ramping 
up DNPS to overcome the decreased enzyme activity; these patients did not improve. 
Therefore, an untargeted approach must be employed to identify and characterize these 
disorders and processes influenced by DNPS.  
A broad scale, transcriptomic and metabolomic analysis of the DNPS-KO HeLa 
cell lines of crGART, crATIC, and crADSL represents a first step in understanding how 
DNPS affects cellular and organismal activity. DNPS has long been thought influential in 
embryonic and nervous system development, however the identification of processes and 
genes directly involved remained unclear. The processes elucidated will inform future 









Chapter Two: Transcriptomic Characterization of crGART 
Introduction 
 
De novo purine biosynthesis (DNPS) is one of the oldest and most fundamental 
biochemical pathways (Caetano-Anollés et al. 2009). In mammals, starting with 
phosphoribosyl pyrophosphate (PRPP), the six enzyme, ten step pathway produces 
inosine monophosphate (IMP), which is subsequently converted to guanosine 
monophosphate (GMP) or adenosine monophosphate (AMP) via two more enzymatic 
reactions. Purines are critical as building blocks and carriers of genetic information in the 
form of RNA and DNA, intra and intercellular signaling molecules, energy currency, and 
substrates and co-enzymes. While salvage pathways can produce purine nucleoside 
monophosphates from free purine bases and PRPP, ultimately, all purines are produced 
by DNPS. DNPS is upregulated at the G1/S phase (Zhao et al. 2015; Chan et al. 2015) 
and is critical during cellular division (Fridman et al. 2013), most likely to supply purines 
for DNA replication and elevated RNA transcription. Given its importance in cellular 
division, and that supply/transport of free purine bases across placental membranes is 
inefficient, DNPS is critical in mammalian development, including embryonic 
development. In mammals, the trifunctional GART enzyme catalyzes steps 2, 3, and 5 of 
DNPS (Figure 2.1). The human gene is located on Hsa21 and is therefore present in three 
copies in Down syndrome (DS, Trisomy 21), the most common genetic cause of 
intellectual disability in humans. Triplication of the GART gene has been hypothesized to 
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be related to the pathology associated with DS (Brodsky et al. 1997). Characterization of 
the crGART transcriptome should allow identification of pathways in which GART plays 
a regulatory role. These would then be logical candidates to investigate for relevance to 
DS. 
Functional mutations in DNPS genes are extremely rare in humans. To date, 
fewer than 100 patients have been identified with adenylosuccinate lyase (ADSL) 
deficiency, one patient has been identified with AICA-ribosiduria (ATIC deficiency), and 
two patients (siblings) have been identified with PAICS deficiency (Pelet et al. 2019). 
ADSL deficiency is a spectrum disorder with three generalized classes: neonatal fatal, 
severe, or mild to moderate. Features of ADSL deficiency include seizures, psychomotor 
retardation, respiratory failure, and craniofacial abnormalities (Jurecka et al. 2015). 
AICAribosiduria is characterized by mental retardation, blindness, epilepsy, and 
craniofacial and body dysmorphic features (Marie et al. 2004). The siblings identified 
with PAICS deficiency died within three days of birth and exhibited craniofacial 
abnormalities and body 
dysmorphic features (Pelet 
et al. 2019). The vast 
majority of these 
mutations are amino acid 
point mutations resulting 
in decreased enzymatic 
activity. Thus far, no 
functional mutations in 
Figure 2.1. De novo purine synthesis pathway. DNPS mediates 
the conversion of PRPP to IMP. IMP is subsequently converted 
to AMP or GMP. The HeLa GART KO, crGART, is indicated. 




























GART have been reported. Taken together, these data suggest that defects in DNPS are 
usually embryonic fatal.  
DNPS nulls for ADSL, ATIC, and GART were recently generated in HeLa cells 
via CRISPR-Cas9 induced mutagenesis (Baresova et al. 2016). The ADSL and ATIC 
mutants (crADSL and crATIC) accumulate DNPS pathway intermediates when cultured 
in purine free media. These intermediates, SAICAR and ZMP respectively, are regulators 
of transcription, and we have presented evidence for transcriptional regulation via DNPS 
deficiency and intermediate accumulation (Mazzarino et al. 2019; 2020). We were unable 
to detect intermediate accumulation in the GART mutant (crGART). This is expected 
since the initial substrate for GART is phosphoribosylamine (5-PRA), which is extremely 
unstable under physiological conditions. We hypothesize that changes in transcription 
due to GART knockout in this cell line are due to the deficit in DNPS, and not 
intermediate accumulation. To evaluate the crGART transcriptome, we employed RNA-
seq to compare the crGART and HeLa transcriptomes in adenine-supplemented and 
adenine-depleted conditions. Our results indicate that GART may have an important role 
in embryogenesis, neural development, and perhaps special relevance to Alzheimer’s 
disease and Down syndrome. 
Materials and Methods 
 
Methods were performed according to (Mazzarino et al. 2019), differences are 
outlined. 
Data processing 
RNA-seq sequence (FASTQ format by the Genomics and Microarray Core 
Facility at the University of Colorado, Denver) was aligned to the Ensembl 
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Homo_sapiens.GRCh38.98 transcriptome using salmon version 1.0.0, then differential 
gene expression analysis was performed using DESeq2 version 1.26.0 (and R version 
3.5.3). 
ClueGO analysis 
The Cytoscape (version 3.7.2) app ClueGO (version 2.5.5) was employed for 
ontology and pathway analysis of lists of differentially expressed genes (DEGs). A list of 
300 DEGs with the top 150 most positive log2 and 150 most negative log2 values was 
used to query gene ontology (GO) databases (UniProt-GOA_08.01.2020 for Biological 
process, Cellular component, and Molecular function) and Reactome databases 
(Pathway_08.01.2020 and Reactions_08.01.2020).  
Panther analysis 
Panther Overrepresentation Test analysis via the Gene Ontology Consortium 
portal (https://www.geneontology.com) was performed to confirm and augment the 
ClueGO results. Unlike ClueGO, Panther is capable of using large gene lists. The 
complete list of significant DEGs was used to query Gene Ontology biological process, 
cellular component, and molecular function. The “Test Type” option was set for “Fisher’s 
Exact” and “Correction” was set to “Calculate False Discovery Rate”. The GO ontology 
database release date was 2020-02-21.  
Results 
Adenine is required for proliferative growth of crGART 
Given that GART catalyzes three of the ten steps in the DNPS pathway, we 
hypothesized that crGART cells would exhibit proliferative arrest in adenine-deprived 
conditions. HeLa and crGART cells were cultured in complete-serum media overnight 
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and then subsequently cultured in media 
supplemented with dialyzed-serum (FCM) with 
or without supplemental adenine. HeLa cells 
showed proliferative growth in both media 
conditions while crGART showed proliferative 
growth in only adenine-supplemented 
conditions (Figure 2.2). 
GART substrate was not detected in adenine 
starved crGART cells 
Next, we assessed whether the GART 
substrate 5-PRA accumulates in the crGART 
cell line. We demonstrated previously that crADSL and crATIC cells accumulate 
substrate when cultured in adenine free media (Mazzarino et al. 2019; 2020). crGART 
cells were cultured as previously described and metabolites extracted. HPLC-EC analysis 
did not indicate accumulation of 5-PRA (data not shown). This is consistent with 
previous work (Mádrová et al. 2018) as 5-PRA is highly unstable and breaks down in 
approximately five seconds under cellular conditions (Rudolph and Stubbe 1995). Since 
it apparently does not accumulate substrate, this suggests that crGART is likely useful as 
a model of general DNPS deficiency.  
Figure 2.2: Adenine is required for 
proliferative growth of crGART cell 
line. WT HeLa cells (A, C) and crGART 
HeLa (B, D) were cultured in DMEM 
supplemented with 10% FCM with (A, B) 
or without (C, D) 100 μM adenine then 
fixed and stained with crystal violet. 
Entire cell growth area was imaged. 






Transcriptome analysis of crGART versus HeLa identified differentially expressed genes 
To investigate the effect of GART KO on the transcriptome, we compared the 
crGART and HeLa transcriptomes after culture in adenine-supplemented and adenine-
depleted conditions. 4218 genes were 
significantly differentially expressed by cell 
type. This represents a log(2)counts fold 
change range of 10.93 to -13.94 (Figure 
2.3A). In order to assess what processes or 
pathways are affected, we performed GO and 
Reactome functional analysis of DEGs. For 
ClueGO analysis the top 300 most DEG list 
used represents a log(2)counts fold change 
range of -13.74 to -7.67 and 5.83 to 10.93 
(Figure 2.3B). Positive values represent 
enrichment in crGART and negative log2 
values represent enrichment in 
HeLa. Principal component 
analysis shows clustering by cell 
type and supplementation 
(Figure 2.4). 
 
Figure 2.3: log(2) fold change of DEGs 
in cell lines under experimental 
conditions. All DEGs that satisfy cutoff 
constraints between crGART and HeLa 
(A). 150 most positively and 150 most 
negatively changed DEGs between 
crGART to HeLa (B). 
 


















Figure 2.4: Principle component analysis of 
crGART and HeLa replicates. PCA shows a robust 




ClueGO analysis: Functional enrichment analysis employing Gene Ontology and 
Reactome databases 
We queried the Gene Ontology database (Biological process, Cellular component, 
and Molecular function) as well as the Reactome knowledgebase (Pathways and 
Reactions) for this analysis. We obtained a large number of terms but will focus only on 
terms centered around special interest to our laboratory (Figure 2.5).  All ontology 
network maps, term, and grouping visualization figures are located after the text of this 
chapter.  
 
For the GO terms associated with Biological process, 70 GO groups were 
identified with 548 GO terms (Figures 2.8-2.12). Related GO groups were organized into 
neural function, development, muscle function, fatty acids, cardiac function, G-protein 
coupled activity, oxides, and lipids categories. Within neural function, associated terms 
include neuron migration, dendrites, axon, hippocampus, neuroblast proliferation, 
synapse, GABA, and catecholamines. DNPS is known to be important for neural function 
and diseases associated with DNPS exhibit strong neurological phenotypes. Interestingly, 
another category identified was development. Development includes disparate terms, 
ranging from organ morphogenesis related terms such as renal, pancreas, and prostate 
development, to mesenchyme morphogenesis, stem cell differentiation, alkaline 
Figure 2.5: Prominent GO groups from ClueGO 
analysis 
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phosphatase activity, blood vessel morphogenesis, epithelial cell differentiation, bone 
development, endoderm, etc. Placental development included labyrinthine development 
and female pregnancy. For muscle function terms, we obtained smooth muscle function, 
myotubes and sarcomere organization, vasoconstriction, actin filament movement, and 
striated and smooth muscle contraction. Cardiac function was also enriched, including 
sinoatrial and atrioventricular node function terms, as well as atria and ventricle 
development. Oxidation related terms such as nitric oxide and superoxide metabolism 
were found. Lipid terms included fatty acids, phospholipase activity, phosphatidyl 
metabolic process, PI3K, and inflammatory response centered around IL-1 and TNFα. 
Given the importance of purines in development and neurobiology, the observed 
enrichment in related terms was expected. However, enrichment in cardiac terms 
involving electrical conduction was unexpected and may suggest a novel line of inquiry. 
The gene enrichment for formation of primary germ layer (GO:0001704) and placental 
development terms (GO:0001890) (Figures 2.6, 2.7) was also unexpected and suggests a 
purine requirement early in development and that DNPS may play an important role in 
blastocyst formation. 
For the GO terms associated with Cellular component, 12 groups were identified 
with 26 terms (Figures 2.13, 2.14). Terms include voltage gated potassium channels, I-
band and intercalated disc, gap junction, GABA synapse and various other synaptic 
membrane terms.  
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For the GO terms associated with 
Molecular function, 25 groups were 
identified with 54 terms (Figures 2.15, 
2.16). Term categories included neuronal 
and ion transmembrane function, 
development, phospholipid activity, 
cytokine, etc. In the neuronal category, 
neuropeptide, acetylcholine receptor, 
potassium ion gate channels, 
neurotransmitter transmembrane transporter 
terms were prominent. For phospholipids, 
notable terms included lipase activity, 
phospholipase (A2, 1, and C) activity, 
phosphatidylcholine acylhydrolase activity, 
phosphatidylinositol 3 kinase, and nitric 
oxide synthase. Enrichment for Syndecan 
protein binding and G-protein coupled 
Figure 2.6: Gene expression heat map of Gene 
Ontology Primary Germ Layer. Genes identified 
differentially expressed in our data set that map to 
the Gene Ontology term Formation of Primary 
Germ Layer (GO:0001704) by log(2)fold change. 
Cell types are defined as “WT” for HeLa and 
“GART” for crGART, “1-4” for adenine 
supplemented and “A-D” for adenine deficient. 
Heat map dendrogram shows robust groupings 
along cell type. Adenine supplementation shows 
little effect. Genes not satisfying previously define 
threshold counts are removed. Figure generated by 





















































































































































































peptide receptor terms is consistent with the G-protein 
coupled activity category in the Biological process results 
above.  
Reactome Pathways knowledgebase showed 14 
groupings of 29 terms (Figures 2.17, 2.18). Categories 
include diseases associated with O-glycosylation of 
proteins, peptide hormone metabolism, rhodopsin-like 
receptors, TFAP-2, and GPCR and G-alpha signaling. 
Neuronal and development terms were identified, as well 
as TFAP-2 which is heavily involved in neural-crest 
development. Consistent with the GABA terms we 
obtained in Biological process, we identified GABA 
receptor and GABA B receptor terms. This suggests that 
neural deficits associated with DNPS or GART 
deficiency may be associated with alteration of 
GABAergic signaling.  
Reactome Reactions knowledgebase showed 10 
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Figure 2.7: Gene expression heat map of Gene Ontology Placenta 
Development. Genes identified differentially expressed in our data 
set that map to the Gene Ontology term Placenta Development (GO: 
0001890) by log(2)fold change. Cell types are defined as “WT” for 
HeLa and “GART” for crGART, “1-4” for adenine supplemented and 
“A-D” for adenine deficient. Heat map dendrogram shows robust 
groupings along cell type. Adenine supplementation shows little 
effect. Genes not satisfying previously define threshold counts are 
removed. Figure generated by Dr. Guido Vacano. 
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categories included proteoglycans and GPI anchors, GPCR, GEF, and Gi activated 
ligands. Keratin filaments was also noted.  
Corroboration of Gene Ontology analysis via PANTHER analysis 
PANTHER analysis with the complete list of significant DEGs was consistent 
with the ClueGO results and revealed new ontology terms such as DNA and RNA 
binding, polymerase, and transcription regulation.   
Comparison of crATIC, crADSL and crGART DEGs 
To get a better sense of which DEGs are due to DNPS deficiency rather than 
intermediate accumulation, we identified the significant DEGs unique to the crGART vs 
HeLa comparison. There were 1282 genes that changed significantly in the crGART vs 
HeLa comparison but did not change in the crADSL vs HeLa and crATIC vs HeLa 
comparisons (Mazzarino et al. 2019; 2020). The list of genes was used to query 
PANTHER via the Gene Ontology web portal (www.geneontology.org). We obtained 
Biological process ontologies related to RNA splicing and mitochondrion organization. It 
is unclear why these genes are significantly changed only in the crGART cell line. It is 
possible that the CRISPR Cas9 mutagenesis mediated an off-target change in the 
genome. Or, the absence of GART may have an effect unrelated, or peripherally related, 
to DNPS that affects the transcription of these genes. 
There are 7745 genes that change significantly in all the mutants vs HeLa. These 
are likely due to deficient DNPS rather than accumulation of metabolic intermediates. 
PANTHER functional enrichment analysis returned numerous Biological process 
ontologies, including regulation of protein localization to plasma membrane, regulation 
of osteoblast differentiation, positive regulation of I-kappaB kinase/NF-kappaB signaling, 
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heart morphogenesis, establishment of vesicle localization, Ras protein signal 
transduction, embryonic organ morphogenesis, and many others. This result illustrates 
the importance of DNPS in multiple aspects of cell development and function. 
Discussion 
 
In this study, we evaluated the purine dietary requirement for crGART and 
performed HPLC-EC to detect accumulation of metabolites during purine starvation. We 
compared the crGART and HeLa transcriptomes via RNA-seq analysis in adenine-
supplemented and adenine-depleted conditions.  
One of the purposes of adenine supplementation is to shut down DNPS. Adenine 
phosphoribosyltransferase (APRT) catalyzes the conversion of adenine and 
phosphoribosyl pyrophosphate (PRPP) to AMP and pyrophosphate (PPi). APRT is 
present in all mammalian tissues and is uniquely responsible for metabolic adenine 
salvage from dietary sources (Silva et al. 2008). Adenine supplementation effectively 
shuts down DNPS (Holmes et al. 1973; Tu and Patterson 1978). Finally, AMP can be 
converted to IMP by AMP deaminase, and then converted to GMP by IMP 
dehydrogenase (IMPDH, converts IMP into XMP) and GMP synthase (converts XMP 
into GMP) (Watts 1974). 
GART catalyzes three non-sequential reactions in DNPS, steps 2, 3, and 5. The 
conversion of 5-PRA to GAR is the first reaction catalyzed by GART [specifically the 
GARS domain of the trifunctional protein (Knox 2006). As discussed previously, 5-PRA 
is extremely unstable under physiological conditions, and is unlikely to accumulate. Our 
results show that crGART requires purine (adenine) supplementation for proliferative 
growth, but apparently does not accumulate pathway intermediates during purine 
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starvation. In the crADSL and crATIC DNPS-KO models, metabolic substrates 
(SAICAR and ZMP respectively) readily accumulate during purine starvation. There is 
strong evidence that both SAICAR and ZMP alter cellular processes (Keller, Tan, and 
Lee 2012; Corton et al. 1995; Meares et al. 2013). Since the crGART line does not 
accumulate detectable metabolic intermediates of DNPS during purine starvation, it is 
likely a useful model of DNPS deficiency in the absence of substrate accumulation. 
While the GART gene encodes a trifunctional protein, it also encodes a 
monofunctional GARS protein via alternative transcription. This alternative transcript 
includes an intronic polyadenylation signal located in the intron separating the last GARS 
exon from the first AIRS exon. In human, mouse and Drosophila, this transcript has an 
in-frame TAA stop codon which is part of the 5′ donor splice site. The transcript encodes 
a GARS protein with sequence identical to the GARS domain in the trifunctional protein. 
The biological significance of the monofunctional protein has not yet been elucidated. It 
is possible that GARS overexpression may play a role in elevated purine levels in DS. 
Monofunctional GARS protein may have a role in release of metabolites from the purine 
pathway (or purinosome) so they can be used in other metabolic pathways. Or, it may 
interact directly with PRAT, the first enzyme in the de novo pathway, to facilitate transfer 
and prevent degradation of (highly unstable) 5-PRA (Brodsky et al. 1997). The crGART 
cell line should be invaluable for investigating the role of the monofunctional GARS 
protein. 
We considered the possibility of using a PRAT KO cell line as an alternative 
model of DNPS deficiency. However, to our knowledge, a PRAT KO HeLa cell line is 
not currently available: the DNPS null HeLa cell lines include knocked-out GART, PFAS 
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(aka FGAMS), PAICS, ADSL and ATIC. Even if a PRAT KO cell line was available, 
there are other caveats that would render it an inappropriate model for DNPS deficiency. 
In humans, the PRAT gene is upstream of the PAICS gene and separated from it by less 
than 150 nucleotides [based on the coordinates of PPAT (ENSG00000128059) and 
PAICS (ENSG00000128050), Ensembl release GRCh38.p13]. This suggests that 
CRISPR-Cas9 mediated mutagenesis of PRAT would likely disrupt transcriptional 
regulation of the PAICS gene. The substrate for PRAT is PRPP, which participates in 
several enzymatic reactions, including phosphorylation of nucleosides in purine salvage, 
pyrimidine synthesis, histidine and tryptophan biosynthesis, NAD biosynthesis, and 
others (Hove-Jensen et al. 2017). PRAT KO would remove one pathway for catalysis of 
PRPP and would therefore likely disrupt substrate levels for the other enzymatic reactions 
involving PRPP. We had previously isolated and reported on a mutant that does not 
complement PRAT or FGARAT (aka FGAMS) mutants, and still produces 5-PRA using 
NH4Cl instead of glutamine as nitrogen donor (Oates, Vannais, and Patterson 1980). This 
suggests that PRAT KO might be rescued by a compensatory mutation or enzyme 
activity. Finally, PRAT enzyme activity is reduced by increased AMP concentration 
(Holmes et al. 1973). Increased AMP favors the (inactive) dimer form of the enzyme 
rather than the (active) tetramer form (Holmes, Wyngaarden, and Kelley 1973). 
Our RNA-seq analysis led to identification of numerous DEGs and gene 
ontologies from ClueGO functional enrichment analysis. Many of these were consistent 
with our previous analyses of the crADSL and crATIC mutants and are likely to be due to 
DNPS deficiency. These results support the hypothesis that DNPS is essential in 
development and that alterations in DNPS and intermediate metabolite accumulation both 
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regulate the transcriptome. This is consistent with previous work demonstrating that 
DNPS is upregulated in the G1/S phase cell cycle interface (Zhao et al. 2015; Chan et al. 
2015), is critical in embryogenesis which is marked by rapid cellular division, and that 
purines are essential in development (Fumagalli et al. 2017) especially in neural 
development (Rodrigues, Marques, and Cunha 2019). It is possible that inborn errors of 
metabolism due to mutation in ADSL, ATIC, and PAICS resulting in decreased 
enzymatic activity may cause in utero defects that lead to cognitive or body dysmorphic 
phenotypes. 
During the course of our analysis, we noted DEGs and gene ontologies potentially 
relevant to DS. This is perhaps unsurprising given that 1) the GART gene is located on 
Hsa21 and is triplicated in DS, 2) GART expression is dysregulated in DS and 3) purine 
levels are also dysregulated in DS. In addition, although GART is triplicated in DS and 
the current work involves a GART null model, it is likely that pathways affected by 
absence of GART greatly overlap those affected by increased GART. These ontologies 
include terms relevant to placental development, neural development and cognition, 
cardiac development, and Alzheimer disease. We further discuss prominent DEGs and 
gene ontologies below. 
People with DS are at elevated risk for developmental as well as aging related 
disorders. In addition to intellectual disability, common disorders include hypotonia (Lott 
2012a), congenital heart malformation, disease of pulmonary circulation, cardiac arrest, 
hypotension, infantile spasm, epilepsy, OSA (sleeping disorders), intellectual disabilities, 
dementia, hypothyroidism, and obesity (Alexander et al. 2016). Our transcriptomic 
analysis revealed multiple terms potentially relating GART and DNPS to these disorders. 
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Ontological groupings show enrichment in terms associated with organismal 
development, cardiac electrophysiology, neural function/transmission and GABA, 
placenta, alkaline phosphatase activity, phospholipase activity, Amyloid β, and muscle 
function.  
The placenta is the first and largest fetal organ (Turco and Moffett 2019), is 
derived from fetal and maternal components, and is essential for in utero development 
(Burton and Jauniaux 2015). It is responsible for hormone signaling and transfer of 
nutrients, gases, and waste between the embryo and the mother, supporting normal fetal 
growth and development (Gude et al. 2004).  Placental malformations are common in 
embryonic lethal mouse lines, which exhibit abnormalities in cardiac, neural, and 
vascular systems, indicating a strong link between placentation and cardiac and neural 
development (Perez-Garcia et al. 2018). 
In trisomy 21 placenta, villus abnormalities, hypovascularity and placental 
hypoplasia (Debieve 2001; Qureshi et al. 1997) have been observed. Labyrinth layers in 
trisomy 21 placenta were noted to weigh less and exhibit signs of delayed development 
(Adams, Guedj, and Bianchi 2020). About half of newborns with DS typically exhibit 
congenital heart defects (CHD). These CHDs typically manifest as impaired septum 
fusion, causing leakage between cardiac chambers (Freeman et al. 2008). This may be 
due to impaired placentation (Ramachandran et al. 2015; Radhakrishna et al. 2019). 
Owing to the term enrichment associated with placental formation and function, GART 
poses a potential lens to investigate an embryonic contribution to neurological and 
cardiac defects associated with DS. 
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DS is most commonly associated with intellectual disability (Alexander et al. 
2016). Previous work has demonstrated that defects in purine metabolism and/or purine 
concentration in the developing brain are related to intellectual disabilities (Brodsky et al. 
1997; Fumagalli et al. 2017). DS brains show decreased neuronal density by mass and 
volume in various brain regions (e.g. cortex, hippocampus, cerebellum), which occurs 
during development, possibly during gestation (Contestabile, Magara, and Cancedda 
2017). Purinergic signaling regulates axon guidance and growth as well as establishment 
of correct synaptic contacts (Fumagalli et al. 2017) and is crucial for CNS development 
(Jinnah, Sabina, and Van Den Berghe 2013). The GART enzyme exhibits altered 
spatiotemporal expression in the developing nervous system in DS. Typically, levels of 
GART are highly expressed in the developing cerebellum and decrease precipitously 
post-partum. However, in DS, GART levels persist and decrease later in development 
(Brodsky et al. 1997).  
Our ClueGO results include terms related to alkaline phosphatase function, 
specifically through differential expression of ALPP, ALPI, ALPG, and ALPL. ALPP, 
ALPI, and ALPG show elevated expression in crGART. ALPL, which encodes tissue 
non-specific alkaline phosphatase (TNAP), is elevated in HeLa. TNAP is a membrane 
bound, extracellular enzyme present in mineralizing bones, renal tissue, and the central 
nervous system (CNS) (Sebastián-Serrano et al. 2015). In studies of murine CNS 
development, TNAP was found to be associated with the neural tube (Narisawa et al. 
1994) and is highest in early embryonic development associating with neural precursor 
and progenitor cells (Langer et al. 2007). TNAP expression has also been observed 
during synaptic formation and maturation (Fonta et al. 2005), promoting axonal growth 
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(Díez-Zaera et al. 2011). A non-canonical role of TNAP is hydrolysis of extracellular 
nucleotides (Fumagalli et al. 2017; Zimmermann, Zebisch, and Sträter 2012). 
Extracellular ATP was found to induce migration of neural progenitor cells (Striedinger, 
Meda, and Scemes 2007), indicating that TNAP may play a role in regulating 
extracellular ATP pools for migratory events. Another TNAP function is found in the 
metabolism of the Vitamin B6, which is a cofactor for enzymes involved in 
neurotransmitter (e.g. GABA) synthesis (Calderón‐Ospina and Nava‐Mesa 2020). Not 
much is known about the direct role of TNAP in proliferation and differentiation. 
However, given the function and spatiotemporal expression of TNAP, it is likely that 
TNAP is directly involved in purinergic signaling or regulation of the extracellular purine 
pool. Hence, altered TNAP levels may potentially be deleterious during CNS 
development.  
Gamma-amino butyric acid (GABA) is the main inhibitory neurotransmitter in 
healthy adult brains and has been of particular interest in DS (Contestabile, Magara, and 
Cancedda 2017; Deidda, Bozarth, and Cancedda 2014). Analysis of fetal brain tissue has 
shown a smaller hippocampus and decreased GABA neurotransmitters in DS which 
suggests impaired neurogenesis or migration of GABAergic interneurons (Huo et al. 
2018). DS patients exhibit an increased incidence of epileptic seizures (Lott and Dierssen 
2010), children exhibit sleep disturbances (Carter et al. 2009) and hyperactivity 
(Pueschel, Bernier, and Pezzullo 1991): these conditions may be partially due to 
abnormal GABA signaling. Studies employing DS murine models have shown that 
altered GABA signaling results in synaptic excitatory/inhibitory signal imbalance, 
impaired synaptic plasticity (Contestabile, Magara, and Cancedda 2017; Deidda, Bozarth, 
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and Cancedda 2014; Begenisic et al. 2014), and learning and memory deficits (Costa and 
Grybko 2005; Kleschevnikov 2004). The enrichment for GABA-related terms within our 
analysis suggests that GART and DNPS may play a role in these processes.  
Alzheimer’s disease (AD) is a form of dementia characterized by accumulation of 
neural amyloid β plaques, Tau neurofibrillary tangles, and chronic neural inflammation. 
Recent work supports the hypothesis that inflammation plays a critical role in AD, and 
therapeutic intervention designed to reduce neural inflammation shows promise. 
Inflammation is typically mediated by cytokine and chemokine secretion as well as fatty 
acid metabolism (L. Chen et al. 2018). Chemokines and cytokines (such as IL-1β and 
TNFɑ) are secreted in response to injury and act as proinflammatory signals, resulting in 
clearance cell recruitment to the damaged tissue (L. Chen et al. 2018). Fatty acid 
derivatives, specifically lipoxins (derived from ω-6 via phospholipaseA2 and 
lipoxygenase catalysis of arachidonic acid) (Sugimoto et al. 2016) and ω-3 metabolites 
such as maresins, resolvins, and protectins (Serhan et al. 2015) are all potent anti-
inflammation mediators. ω-6 fatty acid is typically stored in the phospholipid bilayer as 
arachidonic acid, which is then cleaved by phospholipase activity and then metabolized 
via secondary enzymes to eicosanoids and lipoxins (Hanna and Hafez 2018). 
Coincidentally, extracellular ATP signaling plays a crucial role in inflammation through 
the purinergic P2 and P1 receptors (Kominsky, Campbell, and Colgan 2010). DNPS and 
GART levels may play important roles in these processes.  
In conclusion, our results indicate that DNPS deficiency affects the cellular 
transcriptome, significantly altering the expression of over 4000 genes. Our functional 
enrichment analysis identified ontologies and pathways related to placental development, 
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neural development, cardiac function and inflammation. Many of these ontologies are 
relevant to DS and AD. This is perhaps unsurprising, since the GART gene is trisomic in 
DS, and purine levels are significantly altered in DS. We believe that the crGART cell 
line is an attractive model for DNPS deficiency in the absence of substrate accumulation 
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crGART to HeLa cellular component %genes per term







Figure 2.14: ClueGO Cellular Component terms and groupings. Percent genes 
returned per total genes per term (A). Percent representation of total terms found within 
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1FSDFOUSFQSFTFOUBUJPO$PMPSTSFQSFTFOUPOUPMPHZHSPVQTFigure 2.16: ClueGO Molecular Function terms and groupings. Percent genes 
returned per total genes per term (A). Percent representation of total terms found within 
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1FSDFOUSFQSFTFOUBUJPO$PMPSTSFQSFTFOUQBUIXBZHSPVQTFigure 2.18: ClueGO Reactome Pathways terms and groupings. Percent genes returned per 
total genes per term (A). Percent representation of total terms found within representative parent 
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Figure 2.20: ClueGO Reactome Reactions terms and groupings. Percent genes returned 
per total genes per term(A). Percent representation of total terms found within representative 






Chapter Three: Transcriptomic Characterization of crADSL 
Introduction 
 
 Defects in de novo purine synthesis (DNPS) can cause inborn errors of 
metabolism. Of particular interest, adenylosuccinate lyase (ADSL) deficiency, an 
autosomal recessive inborn error of metabolism, has been observed in approximately 80 
individuals to date (Jurecka et al. 2015) and is typically diagnosed by SAICA-riboside 
accumulation in biofluids (Donti et al. 2016). With advances in genomic sequencing and 
reduction in cost, it is likely that the number of diagnosed ADSL deficient patients will 
increase in the future. The phenotype of ADSL deficiency is variable and affects multiple 
systems, presenting as fatal neonatal, severe, or mild to moderate forms including 
features such as seizures, autistic traits, psychomotor retardation, respiratory failure, and 
microcephaly. This implies that there are significant alterations in gene expression in 
ADSL deficiency. The ADSL enzyme is a homotetramer and mutations in ADSL can 
result in altered tetramer stability or active site disruption resulting in reduced levels of 
enzyme activity (Zikanova et al. 2010). In the most severe cases, enzyme activity may be 
reduced by as much as 75%. 
 DNPS is one of the most ancient biochemical pathways (Caetano-Anollés et al. 
2009). In mammalian DNPS, phosphoribosyl pyrophosphate (PRPP) is converted to 
inosine monophosphate (IMP) in ten enzymatic steps by six different enzymes. IMP is 
converted to either adenosine monophosphate (AMP) or guanosine monophosphate 
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(GMP) via two additional enzymatic steps (Figure 3.1). ADSL is a bifunctional 
homotetrameric enzyme that catalyzes the eighth step, forming aminoimidazole 
carboxamide ribonucleotide (AICAR) from 
phosphoribosylaminoimidazolesuccinocarboxamide (SAICAR). It is also responsible for 
the final step in the conversion of 
IMP to AMP, specifically cleaving 
succinyladenosine monophosphate 
(SAMP) into AMP (Figure 3.1). 
ADSL is thought to be an enzyme 
with straightforward and defined 
functions, however recent evidence 
suggests a more complicated cellular 
role.  
The DNPS intermediates and products have multiple functions within the cell 
including energy production/regulation via ATP, GTP, and cAMP, cellular signaling, 
growth, and regulation of other pathways. Recently, the intermediate SAICAR was found 
to allosterically bind pyruvate kinase M isoform 2 (PKM2) (Keller, Tan, and Lee 2012), 
the dominant isoform present in tumors. PKM2 catalyzes the last and only irreversible 
step of glycolysis, forming pyruvate from phosphoenol pyruvate. The dominance of this 
isoform in tumors is thought to be the root of the Warburg Effect: the production of lactic 
acid and consequent metabolic reprogramming via aerobic glycolysis in tumor cells 
(Yang and Lu 2013). PKM2 was also found to act as a co-regulator of transcription 
(Keller et al. 2014) by binding transcription factors. SAICAR binding to PKM2 is 
Figure 3.1: de novo purine synthetic pathway 
(DNPS). PRPP is the input small molecule and 
is converted by six enzymes in ten steps to IMP 
and is further processed to either AMP or GMP 
via two additional steps. ADSL is responsible 
for SAICAR to AICAR and SAMP to AMP. 
crADSL is the CRISPR generated HeLa cell line 
used in this study that lacks ADSL enzyme. 
Figure generated by Dr. Guido Vacano.  
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thought to activate a “moonlighting” PKM2 protein kinase activity that acts to directly 
alter transcription (Keller et al. 2014). However, this hypothesis is controversial (Hosios 
et al. 2015). SAICAR was also shown to bind both the dimeric and tetrameric forms of 
PKM2 (Ming Yan et al. 2016) although recent work suggests that the binding of 
SAICAR to the dimer promotes its pyruvate kinase activity (Ming Yan et al. 2016). 
PKM2 was found to induce the hypoxia inducible factor 1 subunit alpha (HIF1α) protein 
upon nuclear translocation of PKM2 (Luo et al. 2011) which initiates angiogenic and 
tumorigenic-related events in the cell. SAICAR also accumulates in glucose starved 
conditions (Keller et al. 2014) although the mechanism for this is not well understood. 
Recently, CRISPR-Cas9 was used to generate knock-outs of the enzymes 
involved in DNPS including ADSL (designated crADSL) (Baresova et al. 2016). The 
crADSL cells have approximately 1.7% ADSL activity compared to wild type cells 
(Baresova et al. 2016), accumulate SAICAR (Mádrová et al. 2018) and fail to grow in the 
absence of adenine (Baresova et al. 2016). To investigate the utility of crADSL as a 
model for ADSL deficiency, RNA-seq was employed to determine transcriptome 
differences between crADSL and wild type HeLa (WT) cells cultured for 10 hours in the 
presence/absence of adenine. RNA-seq is a tool that can provide a snapshot of global 
transcriptional activity and can aid in characterizing cellular response to mutations, 
nutrients, stressors, etc. Changes in gene transcription can be rapidly identified and 
parsed into various groupings, such as gene ontologies or characterized pathways and 
reactions. As an initial step in understanding alterations in gene expression in ADSL 
deficiency, we used RNA-seq to compare gene expression in wt HeLa and crADSL cells 
in the presence and absence of SAICAR accumulation. 
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Materials and methods 
 
Cell Culture 
crADSL was constructed as described previously (Baresova et al. 2016). HeLa 
cells (CCL-2) were purchased from ATCC (Manassass, Virginia, USA). Cells were 
grown on 60 mm TPP plates (Techno Plastic Products, AG, Switzerland) with regularly 
refreshed Dulbecco’s Modified Eagle Medium (DMEM, Gibco) supplemented with 10% 
fetal calf serum (FCS), 30 µM adenine, and normocin (Invivogen). For purine deprivation 
experiments (hereafter referred to as starvation), complete media with 30 µM adenine 
was exchanged two days and one day before starvation. Adenine is used as a nutritional 
supplement for DNPS experiments as it can be converted to AMP and GMP via enzymes 
not affected by DNPS knockouts (Kondo et al. 2000). Ten to twelve hours prior to 
starvation, media were exchanged to DMEM 10% FCS with 100 µM adenine, a 
concentration of adenine that completely inhibits DNPS (Tu and Patterson 1978). To 
induce starvation or control conditions, once plates reached ~50-70% confluence, 
medium was changed to DMEM supplemented with 10% FCM (fetal calf macroserum is 
FCS dialyzed against saline using a 3.5 kDa barrier), normocin, with or without 100 μM 
adenine. For cell colony staining experiments, cells were plated in complete growth 
media and then media were exchanged for DMEM 10% FCM, normocin, with or without 
30 μM adenine. Cells were fixed in 10% ethanol / 3.5% acetic acid solution then stained 
using 0.1% crystal violet solution.  
HPLC analysis of SAICAR metabolite accumulation 
At each time point, cell culture media was aspirated and cells were washed once 
with 1 ml cold (4 ºC) 1X PBS and then extracted with 500 µl cold (-20 ºC) 80% EtOH. 
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Plates were then thoroughly scraped and the cell material was transferred to microfuge 
tubes and centrifuged at 14,000 x g for 15 minutes at 4 ºC. The supernatant was collected 
and stored at -80 ºC. Samples were dried using a Speedvac, then resuspended in 300 µl 
freshly prepared mobile phase (50 mM lithium acetate, 5 mM tetra butyl ammonium 
phosphate, 2% acetonitrile, pH 4.1). Cellular debris was pelleted by two rounds of 
centrifugation at 14,000 x g for 20 minutes. Supernatant was frozen at -20 °C until 
analysis. Samples were transferred to HPLC vials and loaded in an autosampler kept at 
10 °C over the course of the runs. Separation of SAICAR was achieved by HPLC–EC 
analysis similar to our previously described method (Duval et al. 2013). Briefly, 
separation was obtained using reverse phase HPLC–EC with a TSKgel ODS-80Tm C-18 
column (250 mm × 4.6 mm ID, 5 μM) protected by Tosoh Bioscience TSKgel guard 
cartridge. A column temperature of 33 °C was maintained throughout the analysis. 
Mobile phase was delivered at a flow rate of 0.7 ml/min. Sample extracts and standards 
were kept at 10 °C and a 30 μl aliquot of each sample was injected using an ESA 
autosampler (model 542) using a 30 μl partial loop. After injection and separation, 
analytes were detected using a CoulArray HPLC system (model 5600A, ESA) with three 
electrochemical detector modules (four flow-through coulometric detectors in series per 
module for a total of twelve detectors). EC channels were set to a range of potentials 
from 0 to 900 mV in 100 mV increments, then 1200 mV and 0 mV to oxidize and detect 
SAICAR. Autosampler temperature was kept at 10 ºC over the course of runs. Sum of 
primary peaks area was used to measure analyte accumulation.  
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RNA-seq 
Cells were plated on the same day into 60 mm TPP dishes. Four biological 
replicates were cultured in purine rich or purine free (starvation) media conditions for 10 
hours as previously described in 2.1, and total RNA was extracted using TRIzol reagent 
(Sigma) according to the manufacturer’s protocol. Final purification was performed via 
spin columns following the manufacturer’s protocol (Machery Nagel), with 50 μl total 
volume DEPC treated water (Sigma). RNA was quantified by NanoDrop One (Thermo 
Scientific) and frozen at -80° C. RNA quality assessment and RNA-seq was performed 
by The Genomics and Microarray Core Facility at the University of Colorado, Denver. 
mRNA libraries were constructed using the Nugen Universal Plus mRNA-Seq + UDI kit 
(cat # 9144-96), and 50 bp single read sequencing was performed employing the Illumina 
HiSEQ4000. Conversion of .bcl to FASTQ files was done using CASAVA 2.0.  
Processing 
Computation was done on a Dell Precision T1700 computer with an Intel Core i7-
4790 3.60 GHz CPU and 32 GB RAM running Linux Mint. The RNA-seq sequences, 
provided in FASTQ format by the Genomics and Microarray Core Facility at the 
University of Colorado, Denver, were aligned using hisat2 version 2.1.0 to the 
“genome_snp_tran” indexed human genome [H. sapiens, GRCh38 
(ftp://ftp.ccb.jhu.edu/pub/infphilo/hisat2/data/grch38_snp_tran.tar.gz)]. Samtools 1.6 (Li 
et al. 2009) was used to sort entries in the sam file output from hisat2 and convert to bam 
format. The bam files were processed using the Cufflinks suite version 2.2.1 (Trapnell et 
al. 2013) with the “advanced” Cufflinks workflow: Cufflinks → Cuffmerge → Cuffquant 
→ Cuffdiff. The Cuffdiff output was processed using CummeRbund 2.24.0 and various R 
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and bash scripts. For each mutant vs. WT comparison, the gene_exp.diff file was filtered 
for significant entries where FPKM values were FPKM ≥ 1 and log2 fold change values 
were log2 ≥ 1 or log2 ≤ -1 (i.e., 2-fold or greater). The 100 DEGs with the highest 
absolute log2 values (positive and negative) were combined to generate lists of 200 genes 
for subsequent ClueGO analyses. Comparisons of crADSL to WT in conditions lacking 
adenine (MM, or “minus to minus” comparison) and in adenine supplemented conditions 
(PP, or “plus to plus” comparison) were performed. 
ClueGO analysis 
ClueGO is a Cytoscape app that extracts representative functional biological 
information for large lists of genes or proteins (Mlecnik, Galon, and Bindea 2018). 
ClueGO analyses were performed using Cytoscape version 3.7.0 and ClueGO 2.5.2. The 
GO and Reactome releases were Homo Sapiens_GO-EBI-UniProt-GOA_17.12.2018 and 
Homo Sapiens_REACTOME_17.12.2018. Data sets were run pairwise using the crADSL 
plus adenine vs. WT plus adenine comparison (PP) and the crADSL minus adenine vs. 
WT minus adenine comparison (MM) with the DEG lists described above. Analyses were 
performed using default settings: the evidence code was set to “all”, and network 
specificity was set to “representative” with a 3 gene/term cut off, approximating GO 
levels 3-11. Terms and groups were divided into three categories (MM, PP, or Shared) 
based on whether most genes defining a term or group were enriched in the MM or PP 
comparisons, or an equal number of significant genes was obtained from both groups 
(Shared). Further, “slightly enriched” denotes enrichment by one gene, while “heavily 
enriched” denotes enrichment by two or more genes.  
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BiNGO analysis 
BiNGO 3.0.3 is a Cytoscape app that analyzes a total gene list and performs GO 
term enrichment (Biological Process, Cellular Component, and Molecular Function) 
(Maere, Heymans, and Kuiper 2005). Gene lists were analyzed, and ontologies evaluated 
by False Discovery Rate (FDR). Nodes are colored according to their associated p-value.  
qPCR validation of DEGs 
qPCR was performed to validate the reliability of the RNA-seq analysis. Total 
RNA was prepared as described above and concentrations obtained by NanoDrop 
(ThermoFisher). cDNA was prepared using iScript cDNA synthesis kit (BioRad 
#1708890) using 500 ng total RNA per reaction according to the manufacturer’s protocol. 
Candidate genes were selected and primers ordered from IDT using PrimeTime service. 
The primers are TGFβI (Hs.PT.58.40018323), ALPP (Hs.PT.56a.38602874.g), Twist1 
(Hs.PT.58.18940950), IQGAP2 (Hs.PT.58.28018594), GATA3 (Hs.PT.58.19431110), β-
Actin (Hs.PT.39a.22214847), OASL (Hs.PT.58.50426392), TUSC3 (Hs.PT.58.3740957), 
and DPYSL3 (Hs.PT.58.39796068). qPCR was performed on IQ5 (BioRad) with 1 μl of 
cDNA using IQ Sybr Green Supermix (BioRad #170-8880) and the program: 95 °C for 5 
minutes followed by 45 cycles of 95 °C for 10 seconds and 60 °C elongation. Samples 




crADSL requires adenine for proliferative growth 
Cell growth and purine requirement were assessed for crADSL and WT HeLa 
cells. When starved long term for purines, crADSL cells showed detachment from the 
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plate and cell death in adenine depleted (purine 
free) media. In adenine supplemented media, we 
observed that crADSL takes more time to attach 
after re-plating and grows more slowly than WT 
HeLa. WT HeLa showed proliferative growth in 
both adenine-supplemented and non-supplemented 
media (Figure 3.2). These results confirm a 
requirement for purine supplementation for 
crADSL for proliferative growth.  
SAICAR accumulates in crADSL but not WT HeLa cells. 
HPLC-EC analysis of metabolites from starved crADSL and WT cells was 
performed to characterize SAICAR accumulation (Figure 3.3). In crADSL, the ADSL 
substrate SAICAR eluted at 50.1 minutes (Figure 3.4) with detectable accumulation at 6 
hours in starvation medium, but not in adenine supplemented medium, and continued 
until 10 hours, the last time point 
measured. The ADSL product 
AICAR, which elutes at 24 
minutes, was not observed and 
SAMP, the second substrate of 
ADSL, was not observed. This 
result is consistent with the DNPS 
pathway block due to ADSL 
inactivation.  
Figure 3.2: Adenine is required 
for proliferative growth of 
crADSL line. WT HeLa cells (A, 
B) and crADSL HeLa (C, D) were 
in DMEM supplemented with 10% 
FCM with (A, C) or without (B, D) 
100 μM adenine then fixed and 
stained with crystal violet. 
Figure 3.3: SAICAR accumulates in crADSL cells in 
starvation conditions without adenine. crADSL cells 
were cultured in 100 μM adenine supplemented (blue) or 
adenine-free (orange) DMEM with 10% FCM for 10 hours. 
Metabolites were analyzed on HPLC-EC. The plot indicates 
the sum of the primary peaks. 
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S. Figure 1: HPLC-EC traces of crADSL cells. Cells starved in FCM supplemented media with adenine (left traces) and without 
adenine (right traces) in two hour increments. Red square indicates elution time of SAICAR. Primary peak in channel 3 (300mV)
Figure 3.4: HPLC-EC traces of crADSL cells. Cells starved in FCM 
supplement d media with adeni e (l ft traces) and without adenine (right 
traces) in two-hour increments. Red square indicates elution time of SAICAR. 
Primary peak in channel 3 (300mV). 
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crADSL and WT show DEGs in both adenine rich and depleted conditions 
In the experiments described below, purine deprived cells are labeled M and cells 
in supplemented media are labeled P. RNA-seq analysis was performed to detect 
transcriptome changes by cell type and adenine supplementation. Entries with FPKM 
(fragments per kilobase of exon per million reads mapped) values less than 1 were 
dropped (which removes low count statistical anomalies), and only ≥ 2-fold FPKM 
changes (log2 ≥ 1 or log2 ≤ -1) were retained with a p-value cut off of 0.05 using 
Benjamini-Hochberg correction in Cufflinks (Trapnell et al. 2013). Comparison of 
crADSL to WT in conditions lacking adenine (MM, or “minus to minus” comparison) 
returns 1659 DEGs. A list of the 100 most positive and 100 most negative DEG log2 
values was prepared and encompasses log2 value ranges of 8.823 to 2.311 and -2.593 to -
8.788, respectively. Comparison of crADSL to WT in adenine supplemented conditions 
(PP, or “plus to plus” comparison) returns 1426 DEGs. A list of 100 most positive and 
100 most negative DEG log2 values was 
prepared and encompasses log2 value ranges 
of 8.577 to 2.266 and -2.526 to -8.289, 
respectively (Figure 3.5). For our generated 
full list of DEGs, there were 1144 shared 
genes and 282 (19.8%) and 515 (31.6%) 
unique identified genes respectively from the 
PP and MM comparisons. When the list was 
reduced to the top 200 DEGs used for further 
analysis, 153 genes were shared between the 
Figure 3.5: log(2) fold change of DEGs in 
cell lines under experimental conditions. A 
and B: all DEGs that satisfy cutoff constraints 
between PP comparison (A) and MM 
comparison (B). C and D: 100 most positively 
and 100 most negatively changed DEGs in PP 
comparison (C) and MM comparison (D). 
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two comparison groups and 47 unique genes for 
each PP and MM comparison (Table 3.1). Our 
analysis was limited to genes from the lists 
derived from each MM and PP comparison. 
crADSL and WT HeLa DEGs: enrichment in 
ontology terms and groupings in supplemented 
and starvation conditions 
Gene Ontologies (GO) are divided into three categories: biological process, 
cellular component, and molecular function. Each category has a specific aim: biological 
process includes genes that contribute to completion of a biological objective, cellular 
component refers to gene product localization, and molecular function refers to the 
biochemical activity of gene products (Ashburner et al. 2000). The Reactome 
knowledgebase systematically maps gene products into pathway and reaction networks 
(or metabolic maps) (Fabregat et al. 2018). In our discussion of ontology and Reactome 
enrichment in the gene sets, term will be used for a singular ontology or Reactome 
annotation that shows enrichment due to genes associated with that specific component, 
pathway, process, reaction, or function. It is important to note that terms may be enriched 
in a single comparison; that however does not indicate that the term was not significant in 
the other comparison. All ontology network maps, term, and grouping visualization 









Table 3.1: Shared and unique DEGs 
between comparison groups. Total 
gene counts that satisfied previously 
defined cutoffs in the total gene list in 
the top 200 genes that were used for 
ClueGO analysis parsed into the PP and 
MM comparison or shared between the 
two comparison groups.  
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In GO Biological Process, DEGs mapped to 95 shared terms in 27 groups 
(Figures 3.8, 3.9) The most notable among these are epithelial to mesenchymal transition 
with 29.65% of terms related to this group, amyloid fibril formation with 12.06% of 
terms associated, and actin nucleation at 7.04%. Other notable shared terms involve 
processes such as smooth muscle cell and heart structure development, neuron or brain 
associated function/development, bone mineralization, hormone processing, as well as 
interleukins, Wnt signaling, and tumor necrosis factor. In the PP comparisons, we see 
many overlaps within the shared groupings, however it should be noted that exit from 
mitosis, and transcription regulatory region DNA binding were heavily enriched terms. 
For the MM comparisons, we see mass overlap of terms associated with larger parent 
groups in the shared list, however Glycosaminoglycan catabolic process as well as some 
actin/myosin-based terms were heavily enriched while terms associated with TGFβ were 
mildly enriched. 
The Cellular Component ontology produced 6 shared terms in 4 groups (Figures 
3.10, 3.11). Extracellular matrix, platelet alpha granule, as well as peroxisomal 
Figure 3.6: Notable findings from RNA-seq/GO analysis. 
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membrane were shared. Mild enrichment was noted in the PP comparison lamellipodium 
membrane and filopodium, while for the MM comparison with 4 terms in 4 groups 
centered around plasma membrane, golgi, and photoreceptors. 
Molecular Function ontology showed 9 shared terms in 8 groups (Figures 3.12, 
3.13) in RNA binding at 22.22%, integrin binding at 11.11% Cell-cell adhesion, Laminin 
binding, and protein self-association type groupings. Mild enrichment in the PP showed 3 
terms in 3 groups in Histone acetyltransferase activity, HMG box domain binding, and R-
SMAD binding activity while MM has term enrichment in Aβ and TGFβ binding and 
lipoprotein particle receptor binding. 
The Reactome Pathway results showed 10 shared terms in 4 groups (Figures 3.14, 
3.15) involved with kinase activity as well as antiviral mechanism by IFN-stimulated 
genes at 7.41% gene term association term and complement cascades. Collagen type 
terms were also strongly enriched in shared pairings due to COL15A1, COL25A1, 
COL3A1, and COL4A4 being present in both lists analyzed. There were no strong 
preferential associations in the PP list with 5 terms in 4 groups, however slight 
enrichment in the PP terms were seen in scavenger receptor ligands, EPH-ephrin 
repulsion, and signaling by PDGF. Immune system terms OAS antiviral response and 
IFNG response (with 33.33% and 5.43% gene term association respectively) were seen in 
the PP comparison. The MM comparison showed more interesting enrichment with 19 
terms in 6 groups. Due to the TMOD1 and TNNT1 gene differential expression, striated 
muscle contraction was heavily enriched. HS-GAG metabolism and other terms 
associated with GAG were heavily enriched in the MM comparison due to differential 
expression of GPC5 and HSPG2. For genes slightly enriched in the MM comparison over 
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the PP comparison, collagen related terms such as integrin, ECM proteoglycans, and 
NCAM, CRMPs and semaphorin, as well as post-translational modification were also 
slightly enriched in the MM comparison. Various interferon and antiviral terms were 
slightly enriched in the MM comparison.  
The Reactome Reactions results showed similar patterns as Pathways, with strong 
enrichment in the MM comparison over the PP comparison. Twenty terms in three groups 
were shared (Figures 3.16, 3.17) and centered around collagen with 90.0% term 
enrichment, granule membrane proteins, and platelet alpha granule with 5.0% each. The 
singular enriched PP term associated with IFNG was only slightly enriched. MM 
comparison revealed 17 terms in 6 groups. Heavily enriched terms in the MM 
comparison were associated with muscle contraction due to the TMOD1 and TNNT1 
gene. GAG based tetrasaccharide linker terms were heavily enriched due to the presence 
of GPC5 and HSPG2. For terms that were slightly enriched in the MM comparison, we 
see once again interferon and immune-based terms as well as phosphorylation of CRMPs 
related terms due to the presence of DPYSL3 (CRMP4) in the MM gene list. 
crADSL and WT HeLa showed similar enrichment patterns using BiNGO analysis 
To validate our ClueGO findings, we chose to analyze gene sets using the BiNGO 
app in Cytoscape. Network maps, term and grouping visualizations are shown at end of 
text for this chapter (Figures 3.18-3.23). While there are new terms that appear in our 
data sets such as Response to Endoplasmic Reticulum Stress, on the whole this secondary 
analysis system complements our ClueGO findings.  
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Validation of gene expression patterns by qRT-PCR 
Candidate gene transcripts were selected that showed robust expression patterns 
and qPCR was performed to assess whether the expression pattern was maintained using 
a different analysis system. Primers for DPYSL3 (CRMP4), Twist1, TUSC3, TGFβI, 
IQGAP2, GATA3, ALPP, and OASL showed ΔCt values in similar expression patterns to 
the RNA-seq data log2 values (Figure 3.7), demonstrating the validity of our RNA-seq 




In this study, we evaluated the dietary requirements and metabolite accumulation 
during purine starvation for crADSL, and we performed RNA-seq to compare the 
crADSL and WT HeLa transcriptomes in purine supplemented and starved conditions. 
Further, we performed qPCR to verify our RNA-seq results. Our results demonstrate that 







































































Figure 3.7: Candidate gene verification using qPCR. Difference of crADSL against WT 
HeLa cells of biological quadruplicates in both PP and MM of RNA-seq (A) and qPCR (B) 
were normalized to β-Actin. Expression patterns show consistency. 
A B 
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accumulates over a time course of ten hours during purine starvation, and we obtain 
many DEGs both by cell type and adenine supplementation.  
Previous results (Keller et al. 2014) support the hypothesis that SAICAR 
accumulation should produce robust transcriptome changes via the “moonlighting” 
PKM2 protein kinase activity. It is important to note that their methods are limited to 
gene chip experiments and not evaluation of viable cells in culture. We observed changes 
in both PP and MM (SAICAR accumulating) conditions, which suggests that SAICAR 
accumulation and general ADSL deficiency both mediate transcriptome alteration. Our 
results show a greater number of DEGs in the MM versus PP comparison, which suggests 
that SAICAR may be regulating transcription activity, either by a PKM2-SAICAR co-
regulation activity or some other mechanism. If PKM2 does act as a co-regulator of 
transcription, the PKM2-SAICAR complex may potentially activate a select subset of 
targets for this activity. Our current experiments suggest a SAICAR derived effect on 
transcription.  
In GO Biological Process, we obtained a robust group of terms including and 
related to epithelial to mesenchymal transition (EMT) and transforming growth factor 
beta (TGFβ). EMT refers to the process by which polar epithelial cells undergo 
biochemical changes that convert them to mesenchymal cells, which exhibit increased 
resistance to apoptosis and enhanced migratory and invasiveness properties (Kalluri 
2009). EMT is important in embryogenesis, specifically during primitive streak formation 
as well as during neural crest formation. EMT in embryogenesis is orchestrated by the 
Wnt signaling pathway (Kalluri 2009). Consistent with the EMT related terms, we also 
observed Wnt signaling pathway in our shared comparison. Disruption in EMT might 
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play an important role in the developmental and neurological phenotypes associated with 
ADSL deficiency (discussed below). EMT is also important in inflammation and cell 
migration. Upon trauma to basement membranes, epithelial cells can undergo EMT in 
response to inflammation from injury (Kalluri and Weinberg 2009). Our results show 
changes in genes in inflammation/interferon pathways, such as interferon signaling, and 
IL-1β secretion. Terms associated with interferon, inflammation, and immunity were 
present in the MM comparison, which suggests that these transcriptional changes are the 
result of SAICAR accumulation and supports the tentative hypothesis that ADSL 
deficiency may be an immunological disorder. It also suggests that ADSL deficiency 
and/or DNPS deficiency may play an important role in immune dysfunction in cancer. 
In our GO and Reactome analyses, many shared terms mapped to development 
associated groups. Since ADSL deficiency is a developmental disorder with phenotypes 
including dysmorphic features, cognitive deficits, seizures, and psychomotor retardation, 
it is possible that these terms may be relevant to a plausible explanation of phenotype. In 
addition, we observed an interesting enrichment in many muscle and movement type 
terms and groups. This is consistent with the high level of expression of ADSL in muscle 
cells (Van Den Berghe and Jaeken 1986; Brand and Lowenstein 1978) and may be 
informative to the psychomotor retardation phenotype observed in ADSL deficiency. Our 
GO and Reactome results indicate that disruption to DNPS (and ADSL specifically) 
alters energy production and energy levels and sensing needs, which affect force 
generation in muscle cells. 
Cancer is characterized, among other features, by constitutive cellular division, 
alterations in cellular metabolism (Warburg Effect) (Liberti and Locasale 2016), collagen 
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network restructuring (Fang et al. 2014), metastasis and infiltration, and changes in 
immune function (Iommarini et al. 2017; Krzywinska and Stockmann 2018). Our results 
show enrichment for these and related terms, which suggests important roles for DNPS 
deficiency and/or SAICAR accumulation in these cancer-related processes. In addition to 
the collagen, integrin, EMT, actin, and ECM terms, our GO cellular component analysis 
showed enrichment for lamellipodia and filopodia. Filopodia employ integrins to produce 
finger-like protrusions preparatory to cellular migration. Filopodia formation is an 
important mechanism for cell migration and infiltration during tumor cell metastasis 
(Arjonen, Kaukonen, and Ivaska 2011). Recently, the role of ADSL in certain cancer 
types was probed suggesting a potential link in aggressive phenotypes (Park et al. 2018). 
While the scope of this manuscript is focused on the ontologies associated with 
DNPS and ADSL knockout, several individual genes were identified as of specific 
interest. Aberrations in ALPP, a placental alkaline phosphatase, have been implicated in 
spontaneous abortions (Vatin et al. 2014), and in some forms of cancers (Fishman et al. 
1968; Fishman 1987). Twist1 is a transcription factor important for craniofacial and 
organ development during embryogenesis, most likely from mesoderm derived tissues, 
and has been identified in multiple types of tumors and involved in cancer metastasis, 
resistance to chemotherapy, and it can over-ride oncogene induced apoptosis (Qin et al. 
2012). TUSC3 (tumor suppressor candidate 3) is associated with multiple functions 
including Mg2+ uptake, glycosylation and embryonic development, in addition to its 
tumor suppression function (X. Yu et al. 2017). IQGAP2 integrates Rho GTPase and 
Ca2+/calmodulin signals for cellular adhesion and cytoskeleton reorganization and was 
recently found to act as a tumor suppressor (Xie et al. 2012). DPYSL3 (CRMP4) is 
 86 
primarily a neuronal protein expressed during development and adult stages and is 
responsible for various tasks including cell migration, differentiation, neurite extension, 
and axonal regeneration (Alabed et al. 2007). It also has been found to play a role in 
some non-neuronal cancers in migration and metastasis, although the exact role is still 
being investigated (Matsunuma et al. 2018). GATA3 is a transcription factor and 
regulator of numerous developmental pathways and has been found heavily associated 
with breast cancer (Chou, Provot, and Werb 2010). OASL is a gene associated with viral 
response and immunity, with activation carried out by interferons (Choi et al. 2015). 
TGFβI is a ubiquitously secreted ECM protein with plausible participation in 
morphogenic, embryonic developmental, adhesive/migratory, tumorigenic, wound 
healing, and inflammatory processes (Thapa, Lee, and Kim 2007). It is apparent with 
ontologies and gene variability that DNPS and ADSL provide an important context for 
the study of developmental and cancer biology.  
Individuals with ADSL deficiency have a mutated form of ADSL with reduced 
enzymatic activity. This implies reduced (but not halted) conversion of SAICAR to 
AICAR and is consistent with results from patient studies (Jurecka et al. 2015; Zikanova 
et al. 2010). Due to a reduced rate of conversion of SAICAR to AICAR, we would expect 
transcriptome alteration due to persistent elevation in SAICAR and a reduction in the rate 
of DNPS. Here we present results detailing transcriptome changes in crADSL due to 
elimination of ADSL enzyme activity. Future studies will investigate differences between 
mutant forms of ADSL, and may employ specific cell lines to assess the effects of ADSL 
dysregulation in developmental, tumor, vascular and muscle biology. These cells and 
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cells transfected with mutant forms of ADSL should provide an invaluable cellular model 
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Chapter Four: Transcriptomic Characterization of crATIC 
Introduction  
De novo purine synthesis (DNPS) is essential for cellular function. Purines are 
critical as 1) components of DNA and RNA: the information carrying molecules of cells, 
2) intra and intercellular signaling molecules, for example G (guanine) protein coupled 
receptors, 3) as the major source of energy currency in the form of ATP and 4) substrates 
and co-enzymes for many cellular functions. In humans and other animals DNPS is 
accomplished via ten sequential enzymatic reactions resulting in conversion of 
phosphoribosyl pyrophosphate 
(PRPP) to inosine 
monophosphate (IMP) mediated 
by six enzymes (seven of the ten 
reactions are catalyzed by three 
multifunctional enzymes). IMP 
can then be converted through 
two reactions to either AMP or 
GMP (Figure 4.1).   
AMP-activated protein kinase (AMPK) is a major regulator of cellular 
metabolism. AMPK regulates the mammalian Target of Rapamycin (mTOR) pathway. 
AMPK activation shuts down mTOR signaling directly via phosphorylation of Raptor 
Figure 4.1: De novo purine synthesis pathway. DNPS is 
accomplished via the conversion of PRPP to IMP which is 
subsequently converted to AMP or GMP. The HeLa ATIC KO, 



























(Saxton and Sabatini 2017) and indirectly via activation and phosphorylation of Tuberous 
Sclerosis Complex 1 and 2 (TSC1 and TSC2). mTOR regulates vital cellular anabolic and 
catabolic processes involved in lipid synthesis, glycolysis, mitochondrial and lysosomal 
biosynthesis, apoptosis, glucose metabolism, cytoskeletal rearrangement, and cell 
migration (Saxton and Sabatini 2017). Recently, AMPK activation has been implicated in 
different cellular processes such as inflammation suppression (Jeon 2016), and 
suppression of several IFN-γ-induced cytokines and chemokines in primary astrocytes 
and microglia via its restriction of IFN-γ signaling (Meares et al. 2013).  
AMP is an allosteric effector of AMPK, and AMPK responds to increases in the 
AMP:ATP ratio by inhibiting ATP catabolism and promoting ATP anabolism (Garcia 
and Shaw 2017; Hardie 2011). AMPK can activate these processes in response to ATP 
depletion produced via fasting, exercise (Cantó et al. 2010) or other means. Generally 
speaking, AMP has three roles in AMPK control: promotion of AMPK phosphorylation 
(Hawley et al. 1995), inhibition of AMPK dephosphorylation (Davies et al. 1995), and 
allosteric activation of phosphorylated AMPK (Corton et al. 1995).  
ZMP is an AMP mimetic and a potent AMPK agonist. While AMPK has garnered 
the most attention as the best characterized effector of ZMP accumulation, several studies 
have shown that ZMP has multiple cellular targets (Hawley et al. 1995; Douillet et al. 
2019; Kirchner, Brüne, and Namgaladze 2018). This supports the hypothesis that ZMP 
can allosterically regulate enzymes ordinarily regulated by AMP. In multiple studies 
analyzing ZMP function, cells were fed AICA riboside (AICAr, the dephosphorylated 
form of ZMP) which is converted to ZMP within the cell. This approach involves 
adenosine transporters and adenosine kinases to ensure ZMP production and 
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accumulation in the cell (Garcia and Shaw 2017), however, once ZMP is formed, cells 
with active ATIC enzyme will catalyze it via DNPS. Recent work indicates that AICAr 
itself affects cell metabolism independently of its role as substrate for ZMP synthesis. For 
example, AICAr administration induces a potentially deleterious intracellular ATP 
depletion in hepatocytes (Guigas et al. 2006). Drug intervention inhibiting ATIC dimer 
formation has been shown to be efficacious in reducing tumor cell proliferation (Spurr et 
al. 2012), but can produce off target effects. Therefore, cell models that accumulate ZMP 
without exogenous AICAr should be advantageous for investigating optimal ZMP dosage 
levels in cells to produce beneficial effects.  
The bifunctional enzyme 5-aminoimidazole-4-carboxamide ribonucleotide 
formyltransferase (2.1.2.3) / inosine monophosphate cyclohydrolase (3.5.4.10) (ATIC) 
catalyzes the final two reactions of IMP synthesis, converting ZMP to FAICAR and then 
FAICAR to IMP (Figure 4.1). It is a homodimer, and dimerization is required for activity 
(Asby et al. 2015). Under some conditions ATIC may be a rate limiting step of the DNPS 
pathway (Marie et al. 2004; Baresova et al. 2016). So far, a single human with ATIC 
deficiency (AICA-ribosiduria) (Marie et al. 2004) has been identified and the mutations 
characterized: a mis-sense mutation in one allele resulting in K426R (transformylase 
region) and a frameshift in the other allele. This individual presented with profound 
developmental delay. It is likely that most mutations in ATIC are embryonic lethals, 
consistent with its critical role in DNPS and metabolism. Since ZMP is the substrate for 
ATIC, ATIC deficiency is likely to activate AMPK and have major consequences for 
cellular metabolism. DNPS nulls were recently generated in HeLa cells via CRISPR-
Cas9 (Baresova et al. 2016). The crATIC cell line (Baresova et al. 2016), which has no 
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ATIC activity and accumulates ZMP, will allow detailed study of the consequences of 
mutations in ATIC. For example, given that adenine supplementation effectively shuts 
down DNPS (Holmes et al. 1973; Tu and Patterson 1978), analysis of crATIC in adenine 
depleted growth media will allow detailed assessment of the effect of ZMP accumulation 
on transcription, translation, and metabolism. Transfection of crATIC with ATIC clones 
containing various mutations will allow cellular analysis of specific amino acid 
substitutions on ATIC structure and function. As an initial approach to these studies we 
present an analysis of the crATIC and HeLa cells in the presence or absence of adenine.  
Materials and Methods  
Cell Culture  
crATIC cells were described previously (Baresova et al. 2016). HeLa cells were 
purchased from ATCC (Manassas VA USA). Cells were grown on 60 mm TPP (Techno 
Plastic Products, AG, Switzerland) plates using DMEM with 10% fetal calf serum (FCS), 
30 μM adenine, and Normocin (InvivoGen). For purine depletion experiments (starvation 
conditions) cells were incubated in similar medium but using fetal calf macroserum 
(FCM: serum dialyzed against a 3.5 kDa barrier) with or without 100 μM adenine. 
Complete media was regularly refreshed, and ten to twelve hours before experiments, 
was replaced with adenine-depleted or 100 μM adenine-supplemented media. Cells were 
subjected to starvation conditions for ten hours. For histological staining, 10,000 cells 
were plated overnight in complete growth media (DMEM 10%FCS with 30 μM adenine 
and Normocin), media was replaced with starvation conditions (DMEM 10% FCM, 
Normocin, with or without 100 μM adenine) and after six days were fixed using 10% 
 108 
ethanol / 3.5% acetic acid solution and stained using 0.1% crystal violet. Entire culture 
areas were imaged.  
HPLC analysis of ZMP metabolite accumulation  
At two-hour intervals for ten hours, cells were washed once with cold 1x PBS and 
extracted with 500 μl ice cold 80% ethanol. Plates were scraped and the extract was 
centrifuged twice at 14,000 x g. Supernatant was collected and dried using a Speedvac 
then resuspended in 300 μl freshly prepared mobile phase. Samples were cleared twice by 
centrifugation at 14,000 x g and stored at -20 °C until analysis. HPLC-EC separation of 
ZMP was as previously described (Mazzarino et al. 2019). Analytes were detected using 
a CoulArray HPLC system (model 5600A, ESA) with EC channel potentials set from 0 to 
900 mV in 100 mV increments, then 1200 mV, and 0 mV to oxidize and detect ZMP. The 
autosampler was kept at 10 °C over the course of the runs. Sum of primary peak area was 
used to assess analyte accumulation.  
RNA-seq  
Cells were cultured as described above. RNA-seq was performed as previously 
described (Mazzarino et al. 2019). Four replicates (a single culture was split into four 
plates) of crATIC and HeLa were cultured in adenine-supplemented or adenine-depleted 
(starvation) media for 10 hours. Total RNA was extracted using Tri-reagent (Sigma) 
according to the manufacturer’s protocol, followed by spin columns (Machery Nagel) and 
elution with 50 μl DEPC treated water (Sigma). RNA purity and concentration were 
assessed using a NanoDrop One (Thermo Scientific). RNA was stored at -80 °C. RNA 
quality assessment and RNA-seq was performed by The Genomics and Microarray Core 
Facility at the University of Colorado, Denver. mRNA libraries were constructed using 
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the Nugen Universal Plus mRNA-Seq + UDI kit (cat # 9144–96), and 50 bp single read 
sequencing was performed employing the Illumina HiSEQ4000. The sequencing quality 
Q score was >38 for all reads. Conversion of .bcl to FASTQ files was done using 
CASAVA 2.0.  
Data Processing  
Computation was performed as previously described (Mazzarino et al. 2019). For 
each comparison group, the gene_exp.diff file (Cufflinks output) was filtered for 
significant entries where FPKM values ≥ 1 and log2 fold change values were log2 ≥ 1 or 
log2 ≤ -1. In each comparison group the 100 differentially expressed genes (DEGs) with 
the highest absolute log2 values (both 100 most positive and 100 most negative) were 
combined for ClueGO analysis. Total gene lists from our cutoffs were used for BiNGO 
analysis. Comparisons of crATIC to HeLa in adenine-depleted conditions are labeled as 
MM (minus to minus) or in adenine-supplemented conditions labeled as PP (plus to plus).  
Gene Ontology analysis  
Cytoscape (version 3.7.0) apps ClueGO (version 2.5.2) and BiNGO (version 
3.0.3) were used to provide representative biological information from the lists of 
differentially expressed genes (DEGs). ClueGO using the top 100 most positive and 100 
most negative DEGs was run using pairwise comparisons: HeLa plus adenine vs crATIC 
plus adenine (PP) and HeLa minus adenine vs crATIC minus adenine (MM). BiNGO is 
capable of utilizing our complete DEG lists but cannot run pairwise comparisons. The 
BiNGO analysis was limited to running one list of DEGs as a supplement to ClueGO 
results. The ClueGO analysis included biological process, cellular component, and 
molecular function gene ontologies as well as Reactome pathway and reactions, while 
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BiNGO was only run with biological process, cellular component, and molecular 
function gene ontologies.  
qPCR validation of DEGs  
qPCR was performed to validate the RNA-seq analysis. Total RNA was isolated 
as described above with cDNA prepared using the iScript cDNA synthesis kit (Bio-Rad 
#1708890) and qPCR conditions previously described (Mazzarino et al. 2019). Candidate 
gene primers were purchased from IDT PrimeTime service: TGFβI 
(Hs.PT.58.40018323), ALPP (Hs.PT.56a.38602874.g), Twist1 (Hs.PT.58.18940950), 
IQGAP2 (Hs.PT.58.28018594), GATA3 (Hs.PT.58.19431110), β-Actin 
(Hs.PT.39a.22214847), OASL (Hs.PT.58.50426392), TUSC3 (Hs.PT.58.3740957), and 
DPYSL3 (Hs.PT.58.39796068). Ct values were normalized to β-Actin.  
Results 
crATIC requires adenine for proliferative growth  
HeLa and crATIC cells were cultured in 
complete media then subsequently cultured in 
DMEM supplemented with dialyzed fetal calf 
macroserum with or without adenine. HeLa cells 
showed proliferative growth in both media conditions 
while crATIC cells only showed proliferative growth 
in adenine- supplemented conditions (Figure 4.2).  
Figure 4.2: crATIC requires 
adenine for proliferative 
growth. HeLa (A,B) and crATIC 
(C,D) cells were plated and 
cultured in adenine-supplemented 
(A,C) or adenine-depleted (B,D) 






crATIC cells accumulate ZMP in adenine-depleted but not adenine- supplemented 
growth conditions  
crATIC cells were cultured in adenine- depleted and adenine-supplemented 
media. Metabolites were ethanol extracted from cells in culture every two hours for ten 
hours. In samples from adenine-depleted (starved) cells, a ZMP peak was observed at the 
first time point in HPLC-EC traces (24.0 mins) and this peak increased linearly until the 
last time point measured (Figures 4.3, 4.4). A ZMP peak was not observed in samples 
from adenine- supplemented cells, which is consistent with previous results (Mazzarino 
et al. 2019).  
  
Figure 4.3: ZMP accumulates in crATIC. crATIC was grown in media with or without 
supplemental adenine. Accumulation of ZMP was measured by HPLC-EC and was 




























[ 0  m V ]
[ 1 2 0 0  m V ]
[ 9 0 0  m V ]
[ 8 0 0  m V ]
[ 7 0 0  m V ]
[ 6 0 0  m V ]
[ 5 0 0  m V ]
[ 4 0 0  m V ]
[ 3 0 0  m V ]
[ 2 0 0  m V ]
[ 1 0 0  m V ]

















[ 0  m V ]
[ 1 2 0 0  m V ]
[ 9 0 0  m V ]
[ 8 0 0  m V ]
[ 7 0 0  m V ]
[ 6 0 0  m V ]
[ 5 0 0  m V ]
[ 4 0 0  m V ]
[ 3 0 0  m V ]
[ 2 0 0  m V ]
[ 1 0 0  m V ]

















[ 0  m V ]
[ 1 2 0 0  m V ]
[ 9 0 0  m V ]
[ 8 0 0  m V ]
[ 7 0 0  m V ]
[ 6 0 0  m V ]
[ 5 0 0  m V ]
[ 4 0 0  m V ]
[ 3 0 0  m V ]
[ 2 0 0  m V ]
[ 1 0 0  m V ]

















[ 0  m V ]
[ 1 2 0 0  m V ]
[ 9 0 0  m V ]
[ 8 0 0  m V ]
[ 7 0 0  m V ]
[ 6 0 0  m V ]
[ 5 0 0  m V ]
[ 4 0 0  m V ]
[ 3 0 0  m V ]
[ 2 0 0  m V ]
[ 1 0 0  m V ]

















[ 0  m V ]
[ 1 2 0 0  m V ]
[ 9 0 0  m V ]
[ 8 0 0  m V ]
[ 7 0 0  m V ]
[ 6 0 0  m V ]
[ 5 0 0  m V ]
[ 4 0 0  m V ]
[ 3 0 0  m V ]
[ 2 0 0  m V ]
[ 1 0 0  m V ]
[ 0  m V ]

















[ 0  m V ]
[ 1 2 0 0  m V ]
[ 9 0 0  m V ]
[ 8 0 0  m V ]
[ 7 0 0  m V ]
[ 6 0 0  m V ]
[ 5 0 0  m V ]
[ 4 0 0  m V ]
[ 3 0 0  m V ]
[ 2 0 0  m V ]
[ 1 0 0  m V ]

























[ 0  m V ]
[ 1 2 0 0  m V ]
[ 9 0 0  m V ]
[ 8 0 0  m V ]
[ 7 0 0  m V ]
[ 6 0 0  m V ]
[ 5 0 0  m V ]
[ 4 0 0  m V ]
[ 3 0 0  m V ]
[ 2 0 0  m V ]
[ 1 0 0  m V ]

















[ 0  m V ]
[ 1 2 0 0  m V ]
[ 9 0 0  m V ]
[ 8 0 0  m V ]
[ 7 0 0  m V ]
[ 6 0 0  m V ]
[ 5 0 0  m V ]
[ 4 0 0  m V ]
[ 3 0 0  m V ]
[ 2 0 0  m V ]
[ 1 0 0  m V ]

















[ 0  m V ]
[ 1 2 0 0  m V ]
[ 9 0 0  m V ]
[ 8 0 0  m V ]
[ 7 0 0  m V ]
[ 6 0 0  m V ]
[ 5 0 0  m V ]
[ 4 0 0  m V ]
[ 3 0 0  m V ]
[ 2 0 0  m V ]
[ 1 0 0  m V ]

















[ 0  m V ]
[ 1 2 0 0  m V ]
[ 9 0 0  m V ]
[ 8 0 0  m V ]
[ 7 0 0  m V ]
[ 6 0 0  m V ]
[ 5 0 0  m V ]
[ 4 0 0  m V ]
[ 3 0 0  m V ]
[ 2 0 0  m V ]
[ 1 0 0  m V ]

















[ 0  m V ]
[ 1 2 0 0  m V ]
[ 9 0 0  m V ]
[ 8 0 0  m V ]
[ 7 0 0  m V ]
[ 6 0 0  m V ]
[ 5 0 0  m V ]
[ 4 0 0  m V ]
[ 3 0 0  m V ]
[ 2 0 0  m V ]
[ 1 0 0  m V ]
[ 0  m V ]

















[ 0  m V ]
[ 1 2 0 0  m V ]
[ 9 0 0  m V ]
[ 8 0 0  m V ]
[ 7 0 0  m V ]
[ 6 0 0  m V ]
[ 5 0 0  m V ]
[ 4 0 0  m V ]
[ 3 0 0  m V ]
[ 2 0 0  m V ]
[ 1 0 0  m V ]









2hr plus 2hr minus 2hr minus spike
Retention time (min)
6XSSOHPHQWDU\)LJXUH 1: HPLC-EC traces of metabolites from 
crATIC cells. Cells were cultured in FCM supplemented with 
adenine (A) and without adenine (B) for two-hour increments. The 
red rectangle indicates the elution time of ZMP with primary peak 
in channel 4 (300mV). C: Aligned and cropped t2 chromatogram: 
supplemented (plus), unsupplemented (minus) or unsupplemented 
and spiked (minus spike). The dashed line indicates the primary 
channel peak height (note starved sample and starved sample with 
ZMP spike).
Figure 4.4: HP C-EC traces of etabolites from crATIC 
cells. Cells were cultured in media supplemented FCM with (A) 
or without (B) adenine and metabolites extracted in two-hour 
increments. The red rectangl  indicates elutio  time of ZMP with 
primary peak in channel 4 (300mV). Aligned and cropped two-
hour chromatogram, purine supplemented (plus), purine deficient 
(minus), and purine deficient with ZMP spike. Dashed line 
indicates primary channel peak height in deficient and deficient 
with spike sample (C).   
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crATIC shows differentially expressed genes compared to HeLa in adenine- depleted and 
adenine-supplemented conditions  
The crATIC and HeLa cell transcriptomes were compared after culture in adenine 
supplemented (PP) and adenine-depleted (MM) conditions. In both comparison groups, 
DEGs were limited by cutoffs (see Materials and Methods). In the PP comparison, we 
obtained 1311 DEGs while in the MM comparison, we obtained 1662 DEGs. This 
suggests that adenine supplementation corrects for many of the differences in gene 
transcription in the two cell types. The DEGs with the top 100 (positive) and bottom 100 
(negative) log2 values were selected for further 
analysis. In the PP comparison, these represent 
log(2)fold ranges of -8.60573 to -2.31272 and 
2.26702 to 8.20331. In the MM comparison, the 
DEGs with the top 100 positive and bottom 100 
negative log2 values represent log(2)fold ranges 
of 8.39229 to 2.31793 and -8.87985 to -
2.41031. These 200 gene lists were used 
for ClueGO analysis (Figure 4.5). 
Comparing the MM and PP groups, 
228 genes were unique to the PP group 
while 579 genes were unique to the MM 
group. 1083 genes were common to both 
groups. When comparing DEGs with the 
Figure 4.5: log(2) fold change of DEGs in cell 
lines under experimental conditions. A and B: 
DEGs in PP (A) and MM (B) conditions. C and D: 
100 most positively and 100 most negatively 




























































Table 4.1: Shared and unique DEGs 
between comparison groups. Total 
gene counts that satisfied previously 
defined cutoffs in the total gene list in 
the top 200 genes that were used for 
ClueGO analysis parsed into the PP and 
MM comparison or shared between the 
two comparison groups.  
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100 most positive and 100 most negative log2 
values (200 total), 44 genes were found unique to 
each group, and 156 genes were shared between 
the two groups (Table 4.1). Principle component 
analysis showed tight clustering by cell type and 
media supplementation (Figure 4.6).  
DEGs showed enrichment in ClueGO Gene 
Ontology and Reactome database analysis  
RNA-seq experiments can provide 
important data bearing on global cellular changes in response to stressors and changes in 
environment.  
The lists of 200 DEGs described above were used as input for ClueGO, a 
Cytoscape application that extracts representative functional biological information for 
large lists of genes or proteins (Mlecnik, Galon, and Bindea 2018; Shannon et al. 2003).  
We queried Gene Ontology (GO, biological process, cellular component, and molecular 
function) (Ashburner et al. 2000) and the Reactome Knowledgebase (pathways and 
reactions) (Fabregat et al. 2018) to identify significant terms from comparison of the 
crADSL and HeLa transcriptomes. Although we identified many GO and Reactome 
terms, we focused on a subset of specific terms implicated in Alzheimer’s disease and 
Figure 4.6: Principle component 
analysis of crATIC and HeLa 
experimental groups. PCA shows robust 
differences by cell type. Figure generated 
by Dr. Guido Vacano. 
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cellular aging. All ontology network maps, term, and grouping visualization figures are 
located after the text of this chapter. Prominent findings are highlighted (Figure 4.7). 
 
For Biological Process GO ontologies, we obtained 55 groups: 34 associated with 
shared terms, 33 associated with the PP comparison, and 23 associated with the MM 
comparison. Notable shared terms included inflammation / immune response terms such 
as IL-1β secretion, t-cell activation involved in immune response, eicosanoid metabolic 
process, prostanoid metabolic process, prostaglandin metabolic process, negative 
regulation of TNF product, response to amyloid beta, glutamine family biosynthetic 
process, and long chain fatty acid biosynthetic process and transport. Regulation of 
pathway-restricted SMAD protein phosphorylation and transforming growth factor beta 
terms were also in the list. For the PP comparison group there was enrichment of fatty 
acid terms, including arachidonic acid metabolic process, and the cyclooxygenase 
pathway. Other terms included neuron cellular homeostasis and neuron migration, 
midbrain development, and neurotransmitter metabolic process. Regulation of cellular 
response to TGFβ stimulus, response to hyperoxia, negative regulation of embryonic 
Figure 4.7: Notable GO groups from ClueGO analysis. 
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development, and negative regulation of G1/S transition of mitotic cell cycle were also 
enriched terms. For the MM comparison, neuroinflammatory response, regulation of 
epithelial to mesenchymal transition, negative regulation of erk1/2 cascade, cellular 
response to fatty acid, and cellular response to prostaglandin stimulus were obtained in 
the analysis (Figures 4.9, 4.10).  
For Cellular Component ontologies, we obtained 10 groups. Five groups were 
from shared comparisons, 2 from PP and 5 from MM. Shared terms included golgi 
lumen, melanosome, and complex of collagen trimers. Terms enriched in the PP 
comparison included dystrophin-associated glycoprotein complex and brush border. 
Terms associated with the MM comparison included extracellular matrix component, cell 
division site, and actomyosin (Figures 4.11, 4.12).  
In the Molecular Function ontologies, 14 groups of terms were identified with 5 
groups from shared, 6 groups from the PP comparison, and 3 from the MM comparison. 
Terms found within the shared groupings were collagen binding, proteoglycan binding, 
neuropeptide receptor binding, and amino acid binding. In the PP comparison, terms of 
note include steroid hormone receptor activity, adenylyl transferase activity, cell-cell 
adhesion mediator activity, and lysophospholipase activity. In the MM comparison, terms 
such as Aβ binding and l-amino acid transmembrane transporter activity were found 
(Figures 4.13, 4.14).  
In the results from querying the Reactome Knowledgebase, we obtained 10 
groups in Pathways, 5 shared, 6 from the PP comparison, and 2 from the MM 
comparison. Within the shared groupings, we obtained terms such as signaling by retinoic 
acid, amyloid fiber formation, signaling by NOTCH1, arachidonic acid metabolism, and 
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collagen formation. In the PP comparison we obtained nuclear receptor transcription 
pathway, TP53 regulates transcription of cell cycle genes, transcriptional regulation of 
the AP-2 (TFAP2) family of transcription factors, IL-4 and IL-13 signaling, and synthesis 
of prostaglandins (PG) and thromboxanes (TX). In the MM comparison we obtained IL-
10 signaling, ECM proteoglycans, and diseases associated with glycosaminoglycan 
metabolism (Figures 4.15, 4.16).  
In Reactome Reactions, we obtained 7 groups of terms with 4 groups shared, 3 
groups from the PP comparison, and no groups from the MM comparison. Shared groups 
included expression of IFNγ-stimulated genes, exocytosis of specific granule membrane 
proteins, and terms associated with collagen. In the PP comparison we obtained 
formation of NR-MED1 coactivator complex, keratin filaments bind cell-cell adhesion 
complexes, and binding of AP1 transcriptional activator complexes to CCND1 promoter 
(Figures 4.17, 4.18).  
Corroboration of ClueGO results via BiNGO analysis  
To validate our ClueGO results, we performed enrichment analysis using the 
BiNGO application in Cytoscape (Maere, Heymans, and Kuiper 2005) and the complete 
significant DEG lists. While we obtained some new terms, on the whole this analysis 
produced term enrichment closely similar to that from our ClueGO analysis (Figures 
4.19-4.24).  
Validation of RNA-seq by qPCR of candidate genes  
To assess the validity of our RNA-seq results, we employed qPCR to confirm 
transcript levels for select genes. The results for these genes showed similar transcript 
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levels and trends based on Ct value comparison with the log(2)fold values from our 
RNA-seq results (Figure 4.8).  
 
Discussion  
In the present study, we evaluated dietary requirements for crATIC and 
metabolite accumulation during purine starvation.  
In addition to its role in rescuing the DNPS KO phenotype, adenine 
supplementation shuts down DNPS (Holmes et al. 1973; Tu and Patterson 1978) and 
prevents ZMP accumulation in crATIC. Adenine phosphoribosyltransferase (APRT) 
mediates conversion of adenine and phosphoribosyl pyrophosphate (PRPP) to AMP and 
pyrophosphate (PPi) and is present in all mammalian tissues. APRT is uniquely 
responsible for metabolic adenine salvage from dietary sources (Silva et al. 2008). 
Adenine supplementation also provides a source for synthesis of GMP. AMP can be 
converted to IMP by AMP deaminase, and then converted to GMP by IMP 
Figure 4.8: Candidate gene verification by qPCR. Gene transcription in PP and MM 
conditions measured by log(2)fold change of FPKM values from RNA-seq (A) and Ct 























































dehydrogenase [IMPDH, converts IMP into xanthine monophosphate (XMP)] and GMP 
synthase (converts XMP into GMP) (Watts 1974).  
We employed RNA-seq to compare the crATIC and HeLa transcriptomes in 
adenine supplemented and adenine-depleted conditions, and we performed qPCR to 
verify these results. We established a 10-hour starvation (cell culture in adenine-depleted 
media). At the end of this time course, ZMP levels were still increasing in crATIC cells, 
and we have not yet established a time point at which ZMP levels plateau. It is possible 
ZMP accumulation during this period may not have been adequate for full AMPK 
activation. As discussed above, ZMP is an AMP mimetic and likely has multiple 
enzymatic targets. The crATIC HeLa system can be employed to identify these targets.  
Our results demonstrate that crATIC requires purine (adenine) supplementation 
for proliferative growth, and that ZMP accumulates linearly over a time course of ten 
hours during purine starvation. After analysis of the RNA-seq data, we obtained many 
DEGs both by cell type and adenine supplementation.  
Although DEGs mapped to numerous gene ontologies, we focused our discussion 
on terms of specific interest. AMPK sensitivity is decreased in aged models (Reznick et 
al. 2007), however in Alzheimer’s disease (AD), an aging related disorder, pAMPK is 
abnormally elevated in tangle and pre-tangle bearing neurons (Vingtdeux et al. 2011). 
Data also suggest that insulin resistance seen in AD reduces the astrocytic energy supply 
via inhibition of AMPK, contributing significantly to the neurodegeneration observed in 
AD (Erol 2008). AMPK has a major role in Tau protein phosphorylation, as well as 
mTOR and autophagy pathways, which are dysfunctional in AD (Cai et al. 2012). Energy 
homeostasis in Alzheimer’s disease is also dysregulated possibly via an AMPK related 
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mechanism (Caberlotto et al. 2013), illustrating the need to understand energetic 
processes in dementia. Our results suggest a role for ZMP or ATIC in AD and possibly 
other amyloid or tau-based dementias. AD is a progressive, age related, dementia 
characterized by amyloid-β plaques, tau fibril formation, and extensive neuronal 
degradation in the brain. One feature of AD is chronic neural inflammation (Kinney et al. 
2018). Typically, inflammation is caused by a cellular response to stimuli and is normally 
terminated by a process called resolution. Arachidonic acid (AA) may play an important 
role in the inflammatory response in AD (Olivier 2016), especially in initiation of 
resolution (Wang et al. 2015; Whittington, Planel, and Terrando 2017; Serhan et al. 
2015). Chronic inflammation in AD is marked by a dysregulation of resolution in which 
the inflammatory response persists (Wang et al. 2015) .  
Normally, AA is a constituent of phospholipids. The circulating form is rare, as 
AA is rapidly scavenged and bound to albumin. Free AA can be cleaved from 
phospholipids by phospholipase (PLA) and is typically produced in response to injury or 
other stimuli. Free AA is metabolized rapidly through enzymatic pathways based on PLA 
protein- protein interactions with cyclooxygenase (COX), lipoxygenase (LOX), 
cytochrome P450 (CYP), fatty acid amide hydrolase (FAAH), or non-enzymatic lipid 
peroxidation and oxidative stress. FAAH is a concentration-dependent reversible 
reaction, producing anandamide (a neurotransmitter) from AA and ethanolamine, and AA 
release can be stimulated by anandamide (Scala et al. 2018; Ritter 2016). AA metabolic 
products have roles in processes such as platelet aggregation, vasoconstriction and 
dilation, toxic shock based organ dysfunction, inflammatory response, female fertility, 
fever mediation, Alzheimer’s and Parkinson’s disease neurodegeneration, mediation of 
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cAMP, suppression of excitatory neuronal signals via endocannabinoids, and smooth 
muscle response (Hanna and Hafez 2018).  
Cytosolic phospholipase A2 (cPLA2) is expressed in higher levels in brain tissue 
from AD patients (Stephenson et al. 1996) and eicosanoids, a product of AA COX and 
LOX based metabolism, act as mediators of neuroinflammation. In AD, COX2 is 
overexpressed, and this overexpression has been correlated with AD progression (Ho et 
al. 2001). In addition, the COX1 splice variant, COX3, has been found in AD brain (J.-G. 
Cui et al. 2004). The prostaglandin metabolite, PGD2, is overproduced in glial cells 
surrounding amyloid plaques (Mohri et al. 2007). However, NSAIDs which act as COX2 
inhibitors have so far been ineffective at mitigating the AD- associated inflammation 
(McGeer and McGeer 2007). Interestingly, LXA4, a metabolite produced via the LOX 
pathways from AA, has been implicated in reduction of reactive oxygen species (Y. Wu 
et al. 2012), inhibition of interleukin expression (Decker, McBean, and Godson 2009) 
and reduction of Aβ levels (Medeiros et al. 2013). LXA4 is also implicated in resolution 
of inflammation (Zhu et al. 2016). In cerebrospinal fluid and brain tissue from AD 
patients, LXA4 levels are lower than from control groups, while 15-LOX-2, the enzyme 
that catalyzes production of LXA4, was elevated in glial cells from AD patients (Wang et 
al. 2015). These results suggest that AA metabolism is differentially regulated in AD. 
Our results suggest that ZMP, ATIC, and DNPS may have important roles in AA 
metabolism and may be attractive targets for further investigation and development of 
new therapies.  
Microglial cells respond to diverse cues from injured neurons by becoming 
activated and inducing phagocytosis to initiate clearance of apoptotic cells or extruded 
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proteins (e.g., Aβ). Activation is accompanied by release of cytokines such as IL-1β and 
TNFα (Kettenmann et al. 2011) and regulatory cytokines (Carniglia et al. 2017). There 
are inherent differences between aged, chronically activated microglia compared to 
young microglia (Koellhoffer, McCullough, and Ritzel 2017). In young microglia, cells 
are sensitive to TGFβ signaling which leads to a reduction in cytokine release 
(Paglinawan et al. 2003), neuroprotection (Lieb 2003), and promotion of phagocytosis 
(Wyss-Coray et al. 2001). However, in chronically activated microglia, there is decreased 
phagocytosis (Ritzel et al. 2015), and a reduced response to TGFβ signaling, resulting in 
increased neurotoxicity and reduced uptake of Aβ (Ramírez, Rey, and von Bernhardi 
2008; von Bernhardi et al. 2007). This diminished response is largely attributed to 
reduced TGFβ-Smad coupling, the canonical pathway of TGFβ signaling, that occurs in 
AD (Colangelo et al. 2002) and aging (Tichauer et al. 2014). In non-canonical pathways, 
TGFβ activates MAPK, PI3K, and JNK: each are linked under certain situations to a pro-
inflammatory response (Derynck and Zhang 2003). In canonical TGFβ signaling, 
activation of the TGFβ-Smad pathway induces glial cells to transcribe MAPK 
phosphatase (MKP), a serine-threonine phosphatase responsible for negative regulation 
of inflammation that results in decreased TNFα production and reduced Aβ– mediated 
activation of MAPK and NFκB signaling (Flores and von Bernhardi 2012). However, in 
cases of chronic microglial inflammation observed in aging and AD, the TGFβ-Smad 
pathway is inhibited, resulting in reduced amelioration of inflammation. Our 
identification of ATIC and DNPS involvement in TGFβ signaling coupled with FA based 
inflammatory regulation provides a novel avenue for continued AD research.  
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During embryogenesis and fetal development, purines have an important role as 
signaling molecules (Massé and Dale 2012), particularly in neuronal development 
(Zimmermann 2011; Fumagalli et al. 2017; Rodrigues, Marques, and Cunha 2019). 
DNPS has been found upregulated at the G1/S cell cycle transition (Chan et al. 2015; 
Zhao et al. 2015). So far, mutations that cause reduction in PAICS, ADSL, or ATIC 
activity in humans all lead to significant developmental delay. These findings indicate the 
importance of the pathway for producing purines for DNA and RNA synthesis in 
embryogenesis and development. Consistent with these roles, in our comparison of the 
crATIC and HeLa transcriptomes, we identified many DEGs that mapped to ontology 
terms concerned with development and neuronal function as well as ontology terms 
associated with rapid cellular proliferation, such as tumorigenesis and cancer. Multiple 
terms also mapped to cell cycle checkpoints and terms associated with the G1/S phase 
interface.  
Previously, we characterized the crADSL cell line transcriptome (Mazzarino et al. 
2019). Common ontology terms from the crADSL and crATIC transcriptome analyses 
are likely related to general DNPS function rather than the specific mutated DNPS 
enzyme or accumulated intermediates. Common terms include transforming growth 
factor beta, collagen/ECM, glycosaminoglycan metabolism, interferons, and embryonic 
development. Terms specific to the crATIC analysis include G1/S checkpoint transition, 
dystrophin associated glycoprotein complex, retinoic acid response, arachidonic acid 
metabolism, and prostaglandin and thromboxane. Of note, phospholipase activity was 
common to both crADSL and crATIC while lysophospholipase was found only in the 
crATIC analysis.  
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As discussed above, the crATIC cell line is advantageous in that ZMP 
accumulation is achieved via cellular metabolism, not conversion of exogenous AICAr in 
the media. The crATIC cells and crATIC cells transfected with identified patient allele 
and other mutant forms of ATIC should provide important cellular models of DNPS, 
AICA-ribosiduria, and ZMP accumulation. The results reported here are an important 
first step in establishing this model, and for further investigation of ZMP’s role as an 
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MM biological process genes/term
sensory perception of taste
negative regulation of ERK1 and ERK2 cascade
neuroinflammatory response
cell-matrix adhesion
response to lithium ion
telomere capping
regulation of telomerase activity
fibroblast growth factor production
regulation of fibroblast growth factor production
glycosaminoglycan catabolic process




embryonic skeletal system morphogenesis
embryonic forelimb morphogenesis
regulation of epithelial to mesenchymal transition


















long-chain fatty acid metabolic process
negative regulation of ossification
transforming growth factor beta receptor signaling pathway




regulation of epithelial to mesenchymal transition_1
acid secretion_2
L-amino acid transport
L-alpha-amino acid transmembrane transport
smooth muscle cell proliferation
regulation of smooth muscle cell proliferation
positive regulation of smooth muscle cell proliferation
response to prostaglandin
positive regulation of reactive oxygen species metabol...
cellular response to prostaglandin stimulus
foam cell differentiation
macrophage derived foam cell differentiation
regulation of macrophage derived foam cell differentiation
cell adhesion mediated by integrin
circadian behavior_1
acid secretion_3
negative regulation of ossification_1
negative regulation of DNA binding





reactive oxygen species biosynthetic process
response to antineoplastic agent
response to fatty acid
response to prostaglandin_1
cellular response to ketone
positive regulation of reactive oxygen species metabol...
response to corticosteroid
cellular response to fatty acid
cellular response to prostaglandin stimulus_1
response to dexamethasone
response to glucocorticoid
cellular response to corticosteroid stimulus
cellular response to dexamethasone stimulus
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negative regulation of protein binding
negative regulation of developmental growth
regulation of action potential
cardiac muscle cell action potential involved in contraction
neuron migration
establishment or maintenance of bipolar cell polarity
establishment or maintenance of apical/basal cell polarity
establishment or maintenance of epithelial cell apical/bas...
positive regulation of reactive oxygen species metabol...
endothelial cell apoptotic process










vascular endothelial growth factor production
regulation of vascular endothelial growth factor production
anion homeostasis
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regulation of sodium ion transmembrane transport
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regulation of protein autophosphorylation_1
long-chain fatty acid metabolic process
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negative regulation of embryonic development
negative regulation of cellular response to growth fact...
regulation of cellular response to transforming grow...
negative regulation of cellular response to transformi...
transforming growth factor beta receptor signaling pathway
negative regulation of transmembrane receptor prote...
regulation of transforming growth factor beta recept...
negative regulation of transforming growth factor be...




negative regulation of cell cycle G1/S phase transition
negative regulation of G1/S transition of mitotic cell cycle
regulation of protein autophosphorylation_2
heart valve development_1
heart valve morphogenesis_1
regulation of endothelial cell apoptotic process_1
alpha-beta T cell differentiation
acid secretion_2
anion homeostasis_1
monovalent inorganic anion homeostasis_1
chloride transmembrane transport
response to increased oxygen levels
response to hyperoxia
negative regulation of smooth muscle cell proliferation
positive regulation of reactive oxygen species metabol...
negative regulation of vascular smooth muscle ce...
collagen biosynthetic process
regulation of collagen metabolic process
lipid storage
regulation of collagen biosynthetic process
positive regulation of phagocytosis
regulation of protein autophosphorylation_3
cell adhesion mediated by integrin
cell-cell adhesion mediated by integrin
positive regulation of muscle contraction
acid secretion_3
positive regulation of smooth muscle contraction
regulation of smooth muscle contraction
negative regulation of fat cell differentiation





lens development in camera-type eye
outflow tract septum morphogenesis
negative regulation of BMP signaling pathway_1
collagen biosynthetic process_1
regulation of collagen metabolic process_1
lipid storage_1
regulation of collagen biosynthetic process_1
anion homeostasis_2
signal transduction involved in mitotic cell cycle checkpoint
negative regulation of cell cycle G1/S phase transition_1
G1 DNA damage checkpoint
mitotic G1/S transition checkpoint
monovalent inorganic anion homeostasis_2
signal transduction involved in mitotic DNA integri...
negative regulation of G1/S transition of mitotic cell cycle_1
mitotic G1 DNA damage checkpoint
regulation of protein autophosphorylation_4
regulation of sodium ion transmembrane transport_1
intracellular signal transduction involved in G1 DNA dama...
signal transduction involved in mitotic DNA dama...
chloride transmembrane transport_1
regulation of sodium ion transmembrane transport...
DNA damage response, signal transduction by p53 cla...
signal transduction involved in mitotic G1 DNA dama...
neurotransmitter metabolic process
reactive oxygen species biosynthetic process
response to fatty acid
response to amine
positive regulation of reactive oxygen species metabol...
response to corticosteroid
cellular response to fatty acid
negative regulation of vascular smooth muscle ce...
response to glucocorticoid
positive regulation of protein import
positive regulation of protein import into nucleus

























































































































































response to fatty acid 18.48% **
negative regulation of ossification 9.95% **
cell adhesion mediated by integrin 7.58% **
regulation of macrophage derived foam cell differentiation
6.64%
regulation of smooth muscle cell proliferation 5.69% **
sensory perception of taste 0.47%
negative regulation of ERK1 and ERK2 cascade 0.47% **
neuroinflammatory response 0.47%
cell-matrix adhesion 0.47% **
response to lithium ion 0.47%
telomere capping 0.95%
fibroblast growth factor production 0.95% **
embryonic forelimb morphogenesis 1.42% *
glycosaminoglycan catabolic process 1.42%
positive regulation of reactive oxygen species metabolic
process 1.42% *
endothelial cell development 1.42%
regulation of epithelial to mesenchymal transition 1.9%
chondrocyte differentiation 1.9% *
circadian behavior 1.9% *
aorta development 1.9%
ventricular septum development 2.37% **
biomineral tissue development 2.84% *
ventricular septum morphogenesis 3.79% *
acid secretion 4.27%
long-chain fatty acid metabolic process 4.74% **
transforming growth factor beta receptor signaling
pathway 5.21% **
regulation of tissue remodeling 5.21% **
L-amino acid transport 5.69% *
MM biological process terms/group
PP biological process terms/group
response to fatty acid 15.29% **
negative regulation of cell cycle G1/S phase transition 8.24% **
positive regulation of osteoblast differentiation 8.24% **
cell adhesion mediated by integrin 6.27% **
collagen biosynthetic process 5.49%
negative regulation of smooth muscle cell proliferation 4.71% **
negative chemotaxis 0.39%
neuron cellular homeostasis 0.39%
cell-matrix adhesion 0.39% **
peptide hormone processing 0.39%
dentate gyrus development 0.39%
negative regulation of protein binding 0.39%
negative regulation of developmental growth 0.39% .
cardiac muscle cell action potential involved in contraction 0.78%
neuron migration 0.78% **
positive regulation of reactive oxygen species metabolic process
1.18% *
regulation of endothelial cell apoptotic process 1.18% .
establishment or maintenance of apical/basal cell polarity 1.18%
heart valve development 1.57%
bone mineralization 1.57% *
digestive tract development 1.57% *
chondrocyte differentiation 1.57% *
regulation of vascular endothelial growth factor production 1.96%
monovalent inorganic anion homeostasis 1.96%
biomineral tissue development 2.35% *
midbrain development 2.75%
outflow tract morphogenesis 3.14% *
regulation of protein autophosphorylation 3.53% *
long-chain fatty acid metabolic process 3.92% **
transforming growth factor beta receptor signaling pathway
4.31% **
negative regulation of G1/S transition of mitotic cell cycle 4.31% **
alpha-beta T cell differentiation 4.71% **
acid secretion 4.71%
Shared Biological Process terms/group
response to laminar fluid shear stress 17.11% *
cardiac septum development 9.21% **
positive regulation of nitric oxide biosynthetic process
7.02% *
long-chain fatty acid import 6.14%
regulation of vascular smooth muscle cell proliferation
5.26% **
glutamine family amino acid biosynthetic process 5.26% *
interleukin-1 beta secretion 0.44%
regulation of membrane depolarization 0.44%
sensory perception of sound 0.44% *
response to cold 0.44%
oligodendrocyte development 0.44%
regulation of protein oligomerization 0.44%
animal organ formation 0.44% .
positive regulation of synaptic vesicle recycling 0.88%
regulation of neuron migration 0.88% **
skeletal muscle fiber development 0.88%
response to retinoic acid 0.88%
calcineurin-mediated signaling 0.88%
sulfur compound catabolic process 1.32%
regulation of superoxide metabolic process 1.32% *
T cell activation involved in immune response 1.32% .
lung morphogenesis 1.32%
embryonic digestive tract development 1.75% *
actin filament depolymerization 1.75% *
positive regulation of transforming growth factor beta
production 2.19%
positive regulation of cell-matrix adhesion 2.19%
chondrocyte development 2.63% **
response to fluid shear stress 3.51% *
negative regulation of tumor necrosis factor superfamily
cytokine production 3.95%
prostanoid metabolic process 4.39% **
regulation of pathway-restricted SMAD protein
phosphorylation 4.82% **
long-chain fatty acid transport 4.82% **






6XSSOHPHQWDU\)LJXUH 3: ClueGO Biological process terms and groups. Pie charts show the proportion of the terms associated with the groups for Shared (A), PP (B), and 
MM (C).Histograms indicate number of genes found per term for PP (D) and MM (E) comparisons.Figure 4.10: ClueGO Biological process terms and groups. ie charts show the proportion of the 
terms associated with the groups for Shared (A), PP (B), and MM (C) comparison groups. 
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Shared cellular component terms/group
melanosome membrane 37.5% **
specific granule membrane 12.5% *
Golgi lumen 12.5% **
microvillus membrane 12.5% **
complex of collagen trimers 25.0% **
A
PP cellular component terms/group






extracellular matrix component 12.5%
**
B
MM cellular component terms/group
cluster of actin-based cell projections
70.59% **
basement membrane 5.88% **
collagen-containing extracellular
matrix 5.88% **






6XSSOHPHQWDU\)LJXUH 5: ClueGO Cellular component terms and groups. Pie charts show the proportion of the terms associated with the groups for Shared (A), PP (B), and 
MM (C).Histograms indicate number of genes found per term for PP (D) and MM (E) comparisons.Figure 4.12: ClueGO Cellular component terms and groups. Pie charts show the proportion of 
the terms associated with the groups for Shared (A), PP (B), and MM (C) comparison groups. 
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MM molecular function genes/term
amyloid-beta binding
integrin binding
extracellular matrix structural constituent conferri...
phospholipase activity











Shared molecular function terms/group
glutamate binding 37.5% .
collagen binding 12.5% *
hydrolase activity, acting on carbon-
nitrogen (but not peptide) bonds, in
cyclic amidines 12.5% *
laminin binding 12.5% .
proteoglycan binding 25.0% *
A
PP molecular function terms/group
phospholipase activity 22.22% *
cell-cell adhesion mediator activity
22.22% *
steroid hormone receptor activity
11.11% .
integrin binding 11.11% **
growth factor binding 11.11% .
protein self-association 11.11% *
adenylyltransferase activity 11.11% .
B
MM molecular function terms/group
L-amino acid transmembrane
transporter activity 37.5% .
amyloid-beta binding 12.5% .








6XSSOHPHQWDU\)LJXUH 7: ClueGO Molecular function terms and groups. Pie charts show the proportion of the terms associated with the groups for Shared (A), PP (B), and 
MM (C).Histograms indicate number of genes found per term for PP (D) and MM (E) comparisons.
Figure 4.14: lueGO Molecular function terms and groups. Pie charts show the proportion of 
the terms associated with the groups for Shared (A), PP (B), and MM (C) comparison groups. 
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PP reactome pathways genes/term
Nuclear Receptor transcription pathway
TP53 Regulates Transcription of Cell Cycle Genes
Transcriptional regulation by the AP-2 (TFAP2) family ...
Formation of the beta-catenin:TCF transactivating complex
Interleukin-4 and Interleukin-13 signaling
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MM reactome pathways genes/term
Interleukin-10 signaling
Integrin cell surface interactions
Non-integrin membrane-ECM interactions
ECM proteoglycans









Shared reactome pathways terms/group
Collagen degradation 61.54% *
Signaling by Retinoic Acid 7.69% .
Amyloid fiber formation 7.69% *
Signaling by NOTCH1 7.69% .
Arachidonic acid metabolism 15.38% .
A
PP reactome pathways terms/group
Synthesis of Prostaglandins (PG) and





TP53 Regulates Transcription of Cell
Cycle Genes 12.5%
Transcriptional regulation by the AP-2
(TFAP2) family of transcription factors
12.5% .
Formation of the beta-catenin:TCF
transactivating complex 12.5% .
B








6XSSOHPHQWDU\)LJXUH 9: ClueGO Reactome pathways terms and groups. Pie charts show the proportion of the terms associated with the groups for Shared (A), PP (B), and 
MM (C).Histograms indicate number of genes found per term for PP (D) and MM (E) comparisons.Figure 4.16: ClueGO Reacto e pathways terms and groups. Pie charts show the proportion of 
the terms associated with the groups for Shared (A), PP (B), and MM (C) comparison groups. 






































































































Shared reactome reactions terms/group
Prolyl 4-hydroxylase converts
collagen prolines to 4-
hydroxyprolines 80.95% *
Expression of IFNG-stimulated genes
4.76% .
GPLD1 hydrolyses GPI-anchors from
proteins 4.76%
Exocytosis of specific granule
membrane proteins 9.52% .
PP reactome reactions terms/group
Fillagrin and keratin intermediate
filaments polymerise forming a
network 50.0%
Formation of NR-MED1 Coactivator
Complex 8.33%
SET1 complex trimethylates H3K4 at
the MYC gene 41.67% .
A
B
0 1 2 3 4 5 6
PP reactome reactions genes/term
Formation of NR-MED1 Coactivator Complex
SET1 complex trimethylates H3K4 at the MYC gene
KAT5 HAT complex acetylates TCF4 gene at histone H4
FOXA1 and GATA3 bind to CCND1 promoter
Binding of AP1 transcriptional activator complexes ...
Estrogen-responsive CCND1 gene expression
Keratin filaments bind cell-cell adhesion complexes
Fillagrin and keratin intermediate filaments polymeri...
Lamellar bodies bind the early cornified envelope
Reinforcement of the Cornified Envelope
CDSN binds the cornified envelope















6XSSOHPHQWDU\)LJXUH 11: ClueGO Reactome reactions terms and groups. Pie charts show the proportion of the terms associated with the groups for Shared (A) and 
PP (B).Histograms indicate number of genes found per term for the PP (C) comparison. No terms were enriched in the MM comparison.
Figure 4.18: ClueGO Reactome reactions terms and groups. Pie charts show the proportion 
of the terms associated with the groups for Shared (A) and PP (B) comparison groups. Histogram 
indicated number of genes found per term unique to PP (C). No terms were found selectively 



















































































































































































































































































































































































































































































































































































































































Chapter Five: Metabolomic Characterization of crGART 
Introduction 
Purines are essential small molecules for cellular and organismal survival and 
function. Purines function as genomic bases in RNA and DNA, intra and intercellular 
signaling molecules, energy currency, substrates, and co-enzymes. De novo purine 
synthesis (DNPS) is among the first evolved and most fundamental biochemical 
pathways (Caetano-Anollés et al. 2009). In mammals, inosine monophosphate (IMP) is 
produced via a six-enzyme, ten-reaction pathway starting with phosphoribosyl 
pyrophosphate (PRPP) (Figure 5.1). The first step in the pathway, conversion of PRPP to 
5-PRA catalyzed by PRAT, is the first irreversible step in DNPS. In humans, the enzyme 
GART is trifunctional, catalyzing steps 2, 3, and 5 in DNPS and is encoded by the GART 
gene, located on Hsa21. 5-PRA is the first substrate for GART and is rapidly broken 
down to ribose-5-phosphate (Rudolph and Stubbe 1995). Adenine and PRPP are 
converted to AMP and PPi by adenine phosphoribosyl transferase (APRT), and AMP can 
then be converted to IMP + NH4 via AMP-deaminase (AMPD) (Jinnah, Sabina, and Van 
Den Berghe 2013). IMP can subsequently be used to produce GMP, hence, adenine 
supplementation successfully rescues deficits in DNPS (Figure 5.1).  
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Metabolomic profiles reflect a combination of genetic and environmental 
influences and can therefore be critical for diagnosis and for understanding biochemical 
pathway alterations associated with disease and environmental insults (Alonso, Marsal, 
and JuliÃ 2015). Deficiencies in DNPS have been identified and are rare. Most involve 
ADSL deficiency and fewer than 100 individuals exhibiting ADSL deficiency have been 
identified (Jurecka et al. 2015). Two individuals (siblings) have been identified with 
PAICS deficiency (Pelet et al. 2019), and only one patient has been identified with 
AICAribosiduria (ATIC deficiency) (Marie et al. 2004). The vast majority of these cases 
have genomic mutations which manifest as point mutations in the amino acid sequence, 
resulting in decreased enzymatic activity. AICAribosiduria and ADSL deficiency can be 
rapidly screened using the inexpensive Bratton-Marshall assay of body fluids to detect, 
respectively, AICAriboside (the dephosphorylated form of ATIC’s substrate, ZMP) or 
SAICAR. More recently, genomic sequencing has been used for definitive diagnosis. 
Figure 5.1: De novo purine synthesis pathway. DNPS mediates the conversion of PRPP to 
IMP. IMP is subsequently converted to AMP or GMP. The HeLa GART KO, crGART, is 




























PAICS deficiency was diagnosed via exome sequencing (Pelet et al. 2019). To date, no 
cases of GART deficiency have been identified.  
DNPS nulls for ADSL, ATIC, GART, PAICS and PFAS were recently produced 
in HeLa cells via CRISPR-Cas9 induced mutagenesis (Baresova et al. 2016) and 
characterized. The GART null, crGART, has no measurable GART protein or activity 
(Baresova et al. 2016; Mádrová et al. 2018). 
In purine free media, the crADSL (ADSL null) and crATIC (ATIC null) cell lines 
accumulate the intermediates ZMP and SAICAR, respectively (Baresova et al. 2016). 
Adenine supplementation inhibits DNPS (and therefore intermediate accumulation). 
However, RNA-seq analysis of crADSL, crATIC, and crGART versus HeLa revealed 
robust transcriptome differences by cell type, many of which were not affected by 
adenine supplementation [versus 10 hours of purine starvation (Mazzarino et al. 2019; 
2020). These results suggest that adenine supplementation, which is necessary for 
proliferative growth of the KO cell lines, does not completely correct the transcriptome 
phenotype of these cell lines.  
CRISPR based techniques are more specific than their previous iterations of 
genomic manipulation however off-target Cas9 activity has been noted (Newton et al. 
2019; X. Wu, Kriz, and Sharp 2014). To ensure that differences seen in metabolic 
profiles are solely due to the GART-KO instead of CRISPR artefacts, we compared 
crGART-KO (designated KO) with crGART stably transfected with pCMV-GART-K1 
(designated pGART). Our results show that pGART has a notably different metabolomic 




Cells were grown and starved for purines as previously described (Mazzarino et 
al. 2019). Cells were prepared for metabolite profiling as per Metabolon instructions. 
Briefly, cells were lifted using Detachin (Genlantis) and pelleted and washed in 1xPBS 
then aspirated and stored at -80°C. For purine auxotrophy assessment, 1,000 cells were 
seeded into 6-well plates (TechnoPlasticProducts AG Switzerland) and allowed to grow 
for 1-2 days. Media was exchanged for DMEM high glucose with l-glutamine, 10% 
FCM, 100 μg/mL normocin (Invivogen), with or without 30 μM adenine and allowed to 
grow for 7-10 days. FCM is fetal calf serum dialyzed against a 3.5kDa barrier to remove 
endogenous purines. 1,000 cells were plated, starved, fixed, and stained using crystal 
violet as previously described (Mazzarino et al. 2019).  
Cloning K1-GART CHO-K1 into pTarget 
The CHO-K1 GART cDNA (NCBI accession number EU622913.1) was cloned 
into the CMV promoted pTarget vector (Promega) (Knox et al. 2009). pTarget CHO-K1-
GART was amplified in Stellar Competent Cells (Clontech) E.coli then prepared using 
NucleoBond Maxi kit as per manufacturers protocol (Machery Nagel). Cloned inserts in 
pTarget vectors were sequenced using T7, pTarget-seq, or SP6 primers and gene-specific 
primers (GART_K1_711_F and GART_K1_957_F) by premixed DNA/primer samples 
(Eurofins Genomics).  
crGART transfections with K1-GART-pTarget plasmid 
crGART HeLa cells were transfected with K1-GART-pTarget. Cells were grown 
continuously in high glucose DMEM (Thermo Fisher Scientific), 10% FCS (Hyclone 
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FetalClone II Serum (US), Thermo Fisher Scientific), supplemented with Normocin 
(InvivoGen), Geneticin (Thermo Fisher Scientific), and Adenine (30 μM) (Millipore 
Sigma).  Transfections were performed using Lipofectamine 2000 as per manufacturer 
protocol (Invitrogen). Stable transfections were selected by Geneticin (Invivogen) and 
adenine starvation. 
Metabolomic profiling 
Cell pellets were sent to Metabolon for metabolic profiling using ultra high-
perfomance liquid chromatography/tandem accurate mass spectrometry 
(UHPLC/MS/MS). Peak detection, determination of relative concentrations, and database 
mapping was performed. Statistical analysis and interpretation were provided by 
Metabolon. DRM significance was determined by Welsh’s two-sample t-test for p values 
and False Discovery Rate for q-values (Storey and Tibshirani 2003), while effect 
groupings were determined by Two-Way ANOVA. 
Results 
Transfection of crGART with pCMV-GART-K1 
We will be referring to the pCMV-GART-K1 GART transfected cell line as 
pGART and the non-transfected cell line as KO.  
The pGART and KO cell lines were first assessed for purine auxotrophy. We 
previously demonstrated that pCMV-GART-K1 rescued the purine deficit the CHO 
GART-KO cell line AdeC (Knox et al. 2009). Given that human and CHO GART protein 
sequences exhibit 86% homology and 93% similarity (Knox et al. 2009), we expected 
that transfection of this plasmid into the crGART HeLa cell line would likely rescue the 
purine deficient phenotype. Crystal violet staining shows that pGART are capable of 
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proliferative growth in adenine 
supplemented and unsupplemented 
media while KO cells are purine 
auxotrophs and require supplemental 
adenine for proliferative growth 
(Figure 5.2).  
MS analysis reveals differentially 
regulated metabolites  
Fold change analysis use 
comparison groups to produce ratios 
of differentially regulated metabolites 
(DRMs), significance is then 
calculated between experimental conditions and DRMs are sorted into genotype and 
treatment effects. For our analysis, the term “genotype effect” refers to DRMs that 
change significantly by cell type (KO versus pGART) while “treatment effect” refers to 
DRMs that change significantly by adenine supplementation. Significance and 
assignment of each effect per individual metabolite are calculated by Metabolon. A total 
of 505 metabolites were identified. 377 metabolites were found attributed to genotype 
effect while 157 metabolites were found attributed with treatment effect. 
Pathway enrichment groups individual metabolites by functional association. 
Metabolon provides a calculated pathway enrichment value based upon their subpathway 
groupings each DRMs assigned to are (such as TCA cycle, Glutathione metabolism, etc.) 
and a subpathway enrichment value is calculated (Figure 5.3). Enrichment value is a 
Figure 5.2: Adenine is required for proliferative 
growth of KO but not pGART. Transfected pGART 
cells (A, B) and KO HeLa (C, D) were cultured in 
DMEM supplemented with 10% FCM with (A, C) or 
without (B, D) 100 μM adenine then fixed and stained 
with crystal violet. Entire cell growth area was 
imaged. Transfection, growth, and staining performed 
by Terry Wilkinson II.  
 






calculated number based solely on the number of DRMs found between experimental 
comparison groups and does not represent a directional change of metabolites or their 
respective pathways. This primary analysis aides in identification of subpathways that 
show large groupings of DRMs. Full output of subpathway enrichment analysis is given 










Figure 5.3: Enrichment Value calculation. m is 
number of metabolites in the subpathway identified, k 
is number of significant metabolites identified in the 
subpathway, n is the total number of significant 
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Table 5.1: Subpathway Enrichment Value. Metabolites are grouped into respective subpathway 
category and enrichment value is calculated based on significant changes metabolites in genotype or 
treatment effect groupings. Highlighted subpathways have a calculated enrichment value above 1 and 




Figure 5.4: Heatmaps of select subpathway metabolites. The γ-glutamyl amino acid (A), 
glutathione metabolism (B), and TCA cycle (C) subpathways showed enrichment by 
genotype comparison but not by treatment. This is visualized by upper dendrogram. KO and 
pGART showed groupings. Metabolites were preferentially enriched in pGART samples. 
Sample labels are coded “ade” for adenine supplemented conditions and “none” for adenine 








































































































































































































































































































Genotype analysis shows enrichment in subpathways 
Enrichment analysis of genotype effect reveals DRMs are clustered within 
multiple subpathways (Table 5.1). Of particular interest to our laboratory were gamma-
glutamyl amino acid, TCA cycle, glycolysis gluconeogenesis and pyruvate metabolism, 
glutathione, fatty acid metabolism, phosphatidylethanolamine and inositol, panothenate 
and CoA metabolism, and urea cycle; arginine and proline metabolism.  
Selective subpathways associated with purine and pyrimidine metabolism were 
enriched. Curiously, (hypo)xanthine/inosine containing was below the enrichment 
analysis equation threshold for highlighting a pathway of interest. These terms are 
directly related to purine catabolism where nucleotides are broken down through inosine, 
hypoxanthine, xanthine, and then to uric acid in humans. However, hypoxanthine is 
utilized as a salvage input, directly converted to IMP in a single step (Figure 5.1). It was 
expected that salvage synthesis is upregulated in DNPS-KOs and would result in 
decreased catabolic products, however these data may contradict this expectation. These 
data suggest that purine catabolism is unaffected by DNPS dysregulation. Subpathways 
are focused around energy, and energy production/maintenance type pathways. These 
involve glycolysis, gluconeogenesis, pyruvate, creatine, and the TCA cycle (Table 5.1). 
This is perhaps to be expected as adenine containing nucleobase production, the 
fundamental base of the major cellular energy currency ATP, is compromised in DNPS 
defects. Enrichment analysis unveiled urea cycle in genotype comparison. The urea cycle 
is closely tied to nucleotide synthesis and TCA cycle. Gamma-glutamyl amino acid terms 
were almost all selectively enriched in genotype analysis.  
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Treatment analysis shows enrichment in DRM subpathways 
Enrichment analysis of treatment effect reveals DRMs are clustered within 
multiple subpathways. Of interest, are aminosugar metabolism, dipeptide, fatty acid 
metabolism, gamma-glutamyl amino acid, glutamate metabolism, glutathione 
metabolism, pantothenate and CoA metabolism, and vitamin B6 metabolism (Table 5.1). 
Unsurprisingly, adenine supplementation showed robust enrichment in all terms 
identified associated with purine and pyrimidine metabolic subpathways such as purine 
metabolism, pyrimidine metabolism, nucleotide sugar, nicotinate and nicotinamide 
metabolism, and pentose metabolism. The (hypo)xanthine/inosine containing subpathway 
showed selective enrichment in the KO treatment effect group, with the large majority of 
metabolites elevated in purine supplemented cells. This is unsurprising as these 
metabolites are involved in salvage synthesis of purines. These data suggest that catabolic 
output of purine synthesis in DNPS dysregulation is reliant on salvage input products. 
Treatment effect also showed term enrichment in amino acid metabolism, specifically 
through lysine, glycine, serine, threonine, glutamate, and tyrosine metabolism. Amino 
acids are used as functional building blocks of proteins as well as cofactors in various 
metabolic processes. Amino acids are used as substrates in DNPS pathway, specifically, 
glutamine is used in the conversion of PRPP to 5-PRA and FGAR to FGAM, glycine is 
used in the conversion of 5-PRA to GAR, and aspartate is used in the conversion of 
CAIR to SAICAR. Amino acid metabolism may be differentially regulated to account for 
the reliance on DNPS synthesis or other metabolic processes influenced by DNPS 
dysregulation. 
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DNPS requires glycine, glutamine, and aspartate for synthesis of a singular IMP 
molecule. AMP is an inhibitor of PRAT, the first enzyme of the DNPS pathway. Adenine 
is directly converted into AMP and it stands to reason that adenine treatment will inhibit 
DNPS and therefore pathways associated with amino acid synthesis. 
Discussion 
In this study, we evaluated the purine dietary requirement for the crGART KO 
and generated pGART cell lines. We generated metabolic profiles of each cell line in 
adenine-supplemented and adenine depleted conditions and analyzed the metabolite 
profiles to functional pathways.  
Adenine supplementation inhibits DNPS via formation of AMP through salvage 
synthesis as AMP inhibits PRAT, the first enzyme of DNPS. AMP can be converted into 
IMP via AMP-deaminase and subsequently synthesized into GMP (Figure 5.1) (Jinnah, 
Sabina, and Van Den Berghe 2013). We have previously reported that adenine 
supplementation is effective at inhibiting DNPS (Mazzarino et al. 2019; 2020).  
GART catalyzes three non-sequential reactions in DNPS, the first of which is the 
conversion of 5-PRA to GAR. 5-PRA is highly unstable, breaking down with 
approximately 5 seconds under cellular conditions (Rudolph and Stubbe 1995). This 
makes GART attractive as a model of generalized DNPS deficiency, as other DNPS-KOs 
accumulate substrates that alter cellular processes outside of DNPS (Corton et al. 1995; 
Keller, Tan, and Lee 2012). Here, we report on metabolic alterations as a function of 
adenine starvation and supplementation as a function of the DNPS enzyme, GART. Our 
results have uncovered DRMs as a function of adenine treatment as well as cell type.   
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During our analysis, we noted many subpathways and connections to the Down’s 
syndrome (DS) phenotype. GART is located on Hsa21 and is therefore triplicated in DS. 
Expression of GART as well as purine levels in DS are dysregulated (Patterson 2009). 
Our system was only evaluated for purine auxotrophy and therefore no conclusions can 
be directly drawn about gene dosage effects. However, our analysis highlights pathways 
that GART or DNPS influence, and therefore is likely to inform the involvement of 
GART in the DS phenotype. I have compiled these notable findings together with 
transcriptomic data to highlight potential cellular processes and pathways of interest and 
how they relate (Figure 5.5). 
  












































































































































































































































































































































































































































































































































































































Increased oxidative damage and reactive oxygen species load is a well-
documented phenomenon in DS (Lott 2012b; Arbuzova, Hutchin, and Cuckle 2002), 
aging (H. Cui, Kong, and Zhang 2012), and Alzheimer’s disease (Lott 2012b). In DS, 
multiple gene families involved in regulating cellular oxidative stress are found altered, 
including SOD, APP, PPAR, among others (Izzo et al. 2017; 2018). Superoxide 
Dismutase 1 (SOD1) is a major protein antioxidant responsible for conversion of free 
radical oxygen to hydrogen peroxide (Perluigi and Butterfield 2012). Glutathione (γ-
glutamyl cysteinylglycine) is another primary redox buffer in mammalian cells, directly 
scavenge oxidizing species as well as through glutathione peroxidase activity and 
hydrogen peroxide generated by SOD (G. Wu et al. 2004). Glutathione levels are 
decreased in DS (Pogribna et al. 2001), as well as an increased in the activity ratio of 
SOD:Glutathione peroxidase (Pastore et al. 2003) all leading to increased hydrogen 
peroxide levels and oxidative stress. γ-glutamyl amino acids and glutathione are linked in 
mammalian cells by either the γ-glutamyl amino acid cycle or glutathione cycle(Orlowski 
and Meister 1970; Bachhawat and Yadav 2018). In either model, γ-glutamyl amino acids 
are used as a reservoir for γ-glutamyl groups for glutathione synthesis in mammals. In a 
recent metabolomic study, an abundance of γ-glutamyl amino acids are differentially 
regulated in the amniotic fluid of second trimester DS fetuses (X. Liu et al. 2020). DNPS 
and GART are directly involved in folate and one-carbon donor metabolism (Perluigi and 
Butterfield 2012). DS is characterized by hyperuricemia, or an excess uric acid build up 
which a product of purine catabolism. Hyperuricemia can be caused by an imbalance in 
the native antioxidant defense mechanisms (Perluigi and Butterfield 2012; Zana, Janka, 
and Kálmán 2007). An overwhelming majority of γ-glutamyl amino acids and glutathione 
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metabolites identified are selectively enriched in the genotype comparison, specifically 
enriched in the crGART-CDK line, with adenine treatment showing a minimal effect. 
This observation bolsters our position that correct dosage of the DNPS enzyme GART is 
necessary in antioxidant response. 
Hypotonia is displayed in nearly all children diagnosed with DS and is among the 
most common phenotypes (Dey et al. 2013). This phenotype is not well understood. 
Hypotonia is characterized by excessive joint flexibility and inadequate muscle tone and 
strength, resulting in hyper flexibility, poor motor ability, and control (Lauteslager, 
Vermeer, and Helders 1998) and can be improved with physical therapy intervention 
(Maïano et al. 2019). As hypotonia in DS can be rescued to a degree, a portion of the 
hypotonia phenotype may be overcome by increasing muscle mass. Children with DS 
exhibit hypotonic phenotypes at a young age, with inability to crawl and standing 
behavior delayed compared to disomic counterparts (Lauteslager, Vermeer, and Helders 
1998). These behaviors could be seen as strength training at a young age allowing muscle 
building for processive developmental milestones. Decreased muscle function could 
contribute to this delay in muscle development seen in DS. Mitochondrial dysfunction is 
a phenotype in DS (Arbuzova, Hutchin, and Cuckle 2002) including decreased ATP 
production (Izzo et al. 2017) and altered gene expression patterns, among other 
mitochondrial phenotypes (Izzo et al. 2018). There is evidence that links these altered 
mitochondrial states to the peroxisome proliferator activated receptor gamma (PPARγ) 
(Izzo et al. 2018). Mitochondrial function and proper ATP production are critical for 
muscle growth via strength training. Here, the enrichment of metabolic subpathway terms 
also associated with energy production, such as TCA cycle which generates high energy 
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electrons in the form of the adenine base FADH and NADH, creatine metabolism which 
acts as an ATP storage for muscle, as well as glycolysis and gluconeogenesis enriched 
purely along genotype comparison group lines suggests that GART is linked to these 
processes. The previously reported transcriptomic profiling of the crGART-KO cell line 
showed differences enriched in muscle structure and function terms as well as locomotor 
behavior (Chapter 2). This data, taken in tandem with our current metabolic profiling of 
the crGART-KO cell line, indicates a potential link between GART or DNPS and muscle 
structure and function relating to the hypotonia phenotype. 
B class vitamins are essential micronutrients with a variety of cellular functions 
and must be taken in via diet. Our data show an enrichment of DRMs assigned to B5 
(found in data as pantothenate) and B6 metabolism in genotype comparison. B5 
metabolites also showed DRM enrichment in adenine treated and untreated KO 
comparison. Vitamin B5 is used as a cofactor in the TCA cycle, the electron transport 
chain, as well as in the synthesis of coenzyme A, and is therefore critical for cellular 
energy homeostasis (Kennedy 2016). Vitamin B6 is involved as a cofactor in the 
synthesis of folates, has been found essential for nervous system (Kennedy 2016), 
mitochondrial function (Janssen et al. 2019), glutathione metabolism, and amino acid 
metabolism (Dalto and Matte 2017). B6 has been shown to activate PPARγ via weak 
agonism (Yanaka et al. 2011). The folate cycle produces one carbon donors, necessary 
small molecules for pathways such as purine (one of three GART reactions requires a 
folate derivative) and pyrimidine synthesis (Moffatt and Ashihara 2002). Transsulfuration 
of homocysteine to cysteine is B6 dependent and accounts for approximately half of the 
cysteine used in glutathione synthesis for intracellular pools (Mosharov, Cranford, and 
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Banerjee 2000). B6 in the nervous system acts as a cofactor for synthesis of multiple 
neurotransmitters such as γ-amino-butyric acid (GABA), serotonin, and dopamine 
(Calderón‐Ospina and Nava‐Mesa 2020). B6 administration has shown efficacious in 
mitigating chronic seizure activity (Spinneker et al. 2007; Tong 2014) as well as 
attenuating excitotoxic effects of neurotoxin exposure (Dakshinamurti, Sharma, and 
Geiger 2003), mediated possibly through its involvement in GABA synthesis. Regarding 
DS, differences in GABA (Contestabile, Magara, and Cancedda 2017) as well as an 
increased rate of seizures have been noted (Lott and Dierssen 2010). Studies have also 
found B6 metabolic abnormalities in DS children (McCoy, Colombini, and Ebadi 1969) 
and amniotic fluid (Baggot et al. 2008), although supplementation has shown ineffective 
(Kleijnen and Knipschild 1991). We have previously reported that the transcript levels of 
the ALPL gene is drastically reduced in GART-KO compared to WT HeLa (Chapter 2). 
ALPL encodes the tissue-non-specific alkaline phosphatase enzyme, an ectoenzyme 
capable of dephosphorylating circulatory, extracellular B6 (Whyte et al. 1985) thus 
allowing membrane permeability and its function to be exerted on the cell. 
Unsurprisingly, GABA ontological terms were enriched in our analysis (Chapter 2).  
Our analysis has uncovered only a small subset of differentially regulated lipid 
metabolites and owing to the difficulties associated with lipidomics we will be analyzing 
lipid metabolites with broad strokes. Lysophospholipids are single tailed lipid chains 
found typically as a byproduct of phospholipase activity. This lipid category is involved 
in PPARγ regulation (Tsukahara, Matsuda, and Haniu 2017) and has implications in 
immune response and inflammatory signaling mediated through GPCR coupling (Gräler 
2002), lipid droplet protein expression and formation (Guilherme et al. 2008), and 
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response to low-density lipoprotein (McIntyre et al. 2003). Our data presented here 
indicates that GART or DNPS deficiency decreases lysophospholipids and is not 
attenuated by adenine supplementation, suggesting a possible relation to PPARγ 
regulatory element or immune response. Diacylglycerols act as building blocks for 
glycerophospholipids and as lipid second messengers (Eichmann and Lass 2015). 
Ceramides, including lactosyl- and hexosylceramide, are involved in sphingolipid 
synthesis, and with regulation potential in cellular events including signal transduction, 
cell growth, differentiation, apoptosis, as well as protein kinase C activity, immune 
response, and insulin sensitivity (Young et al. 2012; Sofi et al. 2017; Alarcon-Barrera et 
al. 2020; Nakamura et al. 2013; Pralhada Rao et al. 2013). The data presented suggests 
that GART or DNPS deficiency increases lactosyl- and hexosylceramide metabolites and 
is not rescued by adenine supplementation. Sphingomyelins account for approximately 
10% of mammalian cellular lipids and is a part of the phosphosphingolipid family and is 
critical to myelination of neurons, insulin response, cholesterol association, cellular 
signaling (Slotte 2013), and but also are found as constituent in atherosclerotic plaques 
(Boini et al. 2018).  
Interestingly, PPARγ activity is found linked within myriad metabolic pathways 
examined in this study, and acts as a transcription factor, with myriad genes under its 
control (Kroker and Bruning 2015). PPARγ controls genes related to lipid metabolism, 
glucose and energy metabolism, inflammation, apoptosis, cell proliferation, and insulin 
sensitivity (Kroker and Bruning 2015; Janani and Ranjitha Kumari 2015). Additionally, 
PPARγ transcript levels are enriched in the crGART cell line over WT HeLa of log2(fold 
change) 4.48. The scavenger receptor CD36 is excessively expressed in the crGART line, 
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with a log2(fold change) 8.52. Both PPARγ and CD36 transcript levels are near zero for 
WT HeLa cells. A feedback loop exists between CD36 and PPARg, where activation of 
CD36 induces PPARγ transcription factor activity, where transcript identity synthesized 
is CD36-ligand specific (Maréchal et al. 2018). For example, oxidized low density 
lipoprotein will activate CD36 and in turn induces PPARγ transcription activity causing 
CD36 transcript synthesis, however the synthetic growth hormone releasing peptide 
hexarelin can activate CD36 and subsequently PPARγ transcription activity but the CD36 
gene is not transcribed (Maréchal et al. 2018). Indeed, PPARγ is sensitive to activation by 
phosphorylation or agonist outside of CD36, with different subsets of genes transcribed 
based upon activation signal type (Kroker and Bruning 2015). PPARγ in adipocytes was 
found activated by the B6 vitamer, pyroxidal-5’-phosphate, via a probable agonist 
mechanism, although partial or weak agonism is suspected (Yanaka et al. 2011). The 
neurotransmitter serotonin, in which B6 is directly involved in synthesis of as a cofactor, 
was also found to be a potent agonist of PPARγ (Waku et al. 2010). The involvement of 
PPARγ activity with influence in metabolic pathways uncovered here, as well as the 
heavily elevated CD36 and PPARγ transcript levels found with in DNPS-KOs, suggests 







Chapter Six: Summary, Discussion, and Future Directions 
Summary and Discussion 
The work presented here is not without the vital input from others. The Genomic 
sequencing core was responsible for the processing of RNA and RNA-seq FASTQ file 
generation. Dr. Guido Vacano performed the FASTQ to DEG lists and was instrumental 
in assisting me with the start-up of the ontological analysis. Dr. Vacano also generated 
heatmaps found in Chapter 2 as well as Chapter 5. Terry Wilkinson II performed the 
transfection and generation of the stable CMV promoted CHO-K1 GART crGART cell 
line as well as plating and staining the cells for purine auxotroph analysis. Metabolon 
processed and initially analyzed the metabolomic data for DRM significance.  
Purines are essential molecules for sustaining life in the form of cellular signaling 
events, genetic information, and energy production/regulation. DNPS is critical in 
embryonic development as DNPS is upregulated in replicating cells. Previous work 
robustly indicates the need for tight regulation of DNPS. DNPS deficits in patients, 
although rare, manifest as congenital defects, with phenotypes ranging from mild to 
severe mental retardation, physical dysmorphic features, seizures, and shortened life 
expectancy or embryonic death. DNPS metabolic intermediates have known effects 
outside of purine synthesis that include alteration of activity of PKM2, a kinase thought 
to be the root of the metabolic shift seen in tumors, as well as AMPK, a master regulator 
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of cellular metabolism. DNPS dysregulation is therefore critical to study for 
understanding widespread effects related to cellular and organismal function.  
The work described here is a characterization of the crADSL, crATIC, and 
crGART cell lines, probing the many cellular and organismal processes which are 
affected by DNPS dysregulation and outlining future research queries. I have shown that 
the cell lines used require exogenous purine supplementation in the form of adenine for 
proliferative growth, and that adenine supplementation inhibits DNPS, as there is no 
detectable SAICAR or ZMP found within the crADSL and crATIC cell lines 
respectively. I have generated a library of processes attributed to DNPS dysfunction. The 
novel CRISPR generated DNPS-KO cell lines represent a new cellular model to 
understand the wide-spread effects seen in patients as well as DNPS contribution into 
processes such as TGFβ/SMAD signaling, placentation, vitamin B6 metabolism, 
embryonic development, muscle function, tumorigenesis, and inflammation as uncovered 
in the work presented here.  
Replicate considerations for RNA-seq and other -omic experiments are critical. 
Two forms of replicates are used, biological and technical. Technical replicates have the 
biological material used from the same source where biological replicates consist of 
biological samples from different sources. The questions we sought to answer were 
between differences in the transcriptome seen between two distinct biological samples. 
Therefore, technical replicates of each biological sample were necessary to ensure 
accuracy of measurements between the distinct cell line populations. 
Purine starvation in DNPS-KOs cell lines investigated results in eventual cell 
death (Figures 2.2, 3.2, 4.2, 5.2), although the kinetics have not been explored 
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extensively. crATIC and HeLa cells were evenly plated in normal growth media then 
exchanged for adenine supplemented or deficient media and allowed to proliferate for 6 
days. In 24 hour time intervals, plates were fixed and stained using crystal violet, a 
general histological stain for adherent cells. HeLa cells showed proliferative growth for 
the full 6 days in both adenine supplemented and deficient conditions. As the HeLa cells 
have a functional DNPS pathway, this result is unsurprising. crATIC only showed 
proliferative growth in adenine supplemented conditions for the full 6 days. crATIC in 
adenine deficient conditions appear to arrest proliferation within 1-2 days, with a notable 
unhealthy morphology by day 3 progressively worsening through the sixth day (data not 
shown). It is unknown if these cells undergo a quiescent or senescent phase, nor the 
temporal scale for induction and the time a vegetative state would persist before eventual 
cell death. Ten hours was chosen as a time point for these experiments to balance the 
accumulation of intermediates and potential transcriptomic alterations for vegetative or 
death signaling cascades. Ten hours also represents approximately 40% of the average 
replicative cycle for WT HeLa cells of 24-25hours. Previous transcriptomic 
experimentation on Chinese Hamster Ovary cell based DNPS-KOs were purine starved 
for six hours, with an average WT-CHO replicative cycle of 14 hours, representing 40%. 
As DNPS is upregulated for cellular replication, this 40% of replicative cycle is likely 
ideal to minimize off target effects related to inability to replicate the genome during the 
S phase of the cell cycle. 
Purine supplementation supporting proliferative growth in these cell lines were 
achieved through the use of adenine and has been shown to be efficacious for all cell 
lines used for these studies (Figure 2.2, 3.2, 4.2, 5.2). Adenine is a salvage input and is 
 164 
converted by adenine phosphoribosyltransferase directly into AMP, which is capable of 
being metabolized into IMP via AMP deaminase and subsequently made into GMP. 
Hypoxanthine is a salvage input capable of making IMP directly through hypoxanthine 
phosphoribosyl transferase and into GMP or AMP (Figure 6.1). Therefore, crATIC and 
crGART should proliferate using hypoxanthine as a purine source but not crADSL, as the 
ADSL enzyme is required to in the conversion of IMP to AMP. 
Consistent with previously reported CHO cell line based DNPS-KOs, we have 
shown that Hela crADSL and crATIC accumulate their substrates, SAICAR and ZMP 
respectively, upon removal of an exogenous purine source. I used HPLC-electrochemical 
detection methods for substrate identification (Duval et al. 2013), which functions by the 
redox potential of the metabolites analyzed and is considered an extremely sensitive 
technique with detection limits in the 1-10 picogram range dependent on analyte (Kristal 
et al. 2007). SAICAR and ZMP are detected in this system by oxidation with 
Figure 6.1: DNPS pathway with salvage inputs. DNPS converts PRPP to IMP via ten 
sequential steps using six enzymes. Salvage synthesis utilizes adenine (ade), hypoxanthine (Hx), 
or Guanine (Gua) and through one step will synthesize AMP, IMP, or GMP respectively. AMP 
can be converted into IMP through AMP deaminase (AMPD) and subsequently synthesized into 
GMP. The enzyme ADSL catalyzes SAICAR to ZMP and SAMP to AMP. AMP inhibits the first 




























electrochemical channels set at 0, 100, 200, 300, 400, 500, 600, 700, 800, 900, and 
1200mV. Primary peaks were seen in the 300mV channel for SAICAR and ZMP (Figures 
3.4, 4.4). Cells were supplied exogenous adenine and can therefore synthesize purine 
nucleotides necessary for sustaining proliferative growth. It was expected that exogenous 
adenine supplementation would halt the DNPS pathway as AMP is an inhibitor of the 
enzyme PRAT, the first step in DNPS. This expectation was met, as SAICAR and ZMP 
were not detected in the crADSL and crATIC cell lines (respectively) when subjected to 
adenine supplementation (Figures 3.3, 3.4, 4.3, 4.4). It was hypothesized that upon 
removal of exogenous adenine and inducing a starvation state, DNPS would begin and 
metabolic intermediates would accumulate linearly. Indeed, this is the case with crATIC 
as the ZMP accumulation curve is relatively linear (Figure 4.3). However, crADSL 
exhibited a lag phase, with no detectable SAICAR from zero to four hours in purine 
starvation until measurable accumulation began (Figure 3.3). This result has been rather 
puzzling, although understanding this phenomenon was not within the scope of the 
experiments presented here. SAICAR can be dephosphorylated and exist as 
SAICAriboside which is excreted by the cell. It is not known if SAICAriboside is 
electrochemically active and therefore detectable in our HPLC-EC generated spectra. It is 
possible that the lag phase is due to an equilibrium that exists between SAICAR to 
SAICAriboside conversion or SAICAriboside excretion. SAICAriboside may also elute 
at retention times not covered in our methodologies.  Alternatively, metabolite extraction 
methodology was performed as previously published (Duval et al. 2013) and may explain 
the lag phase. In short, cells were washed with phosphate buffered saline and then 
metabolites were extracted with ice-cold 80% ethanol solution. Alcohol based solutions 
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promote entropic collapse of proteins and as PKM2 is a binding partner of SAICAR, it is 
possible that SAICAR remains bound to PKM2 upon alcohol exposure and therefore 
unmeasurable due to protein sequestration. Neither of these hypotheses are particularly 
attractive. ZMP also exists in equilibrium with its dephosphorylated form AICAriboside 
(Vincent, Bontemps, and den Berghe 1996) which can be similarly excreted. ZMP is also 
an allosteric effector of AMPK and has been shown to have myriad binding partners 
(Douillet et al. 2019), although not much has been explored for binding affinities and 
sites of these other protein partners. However, the AMPK-ZMP interaction has been 
characterized; ZMP induces phosphorylation of Thr172 as well as direct allosteric 
activation of phosphorylated AMPK (Hardie 2011). The mechanism of action for the 
SAICAR-PKM2 interaction is still being elucidated. However, evidence suggests that it 
binds dimeric PKM2 and may induce tetramerization (Dayton, Jacks, and Vander Heiden 
2016) or produce activity directly in the dimeric form (Ming Yan et al. 2016) and it is 
plausible that SAICAR only influences PKM2 activity when bound (i.e. binding does not 
induce a post translational modification). This would give credence to the protein-
metabolite sequestration hypothesis posited. Debris pellet after ethanol extraction could 
be solubilized with ammonium and metabolites released to assess this possibility. 
SAICAriboside excretion can be assessed via measuring media concentration of 
SAICAriboside by the cheap, sensitive, and simple Bratton Marshall assay (Jurecka et al. 
2015).  
ADSL was found to have a single nucleotide polymorphism that resulted in a 
single amino acid point mutation in Neanderthals compared to modern day humans. This 
amino acid change from Neanderthals to modern day humans is found across the species 
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and is not attributed to genetic variation within the species. The mutation in ADSL from 
Neanderthal to modern human manifests as decreased stability of the ADSL protein 
structure in humans, as monitored by circular dichroism spectra (Stepanova et al. 2020). 
This result is incorporated into a manuscript that is currently submitted to eLife. This 
work is an insight into DNPS evolution and refinement of protein sequences for optimal 
purine synthesis. 
Immortalized cell lines, especially the HeLa line, are known to drift and have 
variability over time and passage count. The cells used within this study are variable from 
the start. Within chapters 2, 3, and 4, the CRISPR DNPS-KO cells were gifts from our 
collaborators, Drs. Veronika Barešová and Marie Zikánová from The Charles University 
in Prague, Czech Republic. These cells were made from an ATCC sourced, CCL2 HeLa 
line. The WT HeLa cell line were purchased from ATCC by our own lab. The 
comparisons drawn, from a HeLa cell line in culture in the Czech Republic to our own 
HeLa cell line could likely produce artefacts in the analysis. In 2019, a manuscript was 
published comparing 14 HeLa strains in culture from 13 independent labs across the 
globe. They employed multi omics analysis to understand the differences seen across all 
of the lines. There are three common HeLa cell lines, CCL2 (original HeLa), S3 (third 
clone isolated from the CCL2 line), and Kyoto; the study mainly centered around the 
CCL2 and Kyoto lines. PCA analysis of copy number variation, mRNA, protein, and kloss 
(a measure of protein turn-over rate) reveals two distinct clusters, Kyoto and CCL2 lines. 
The plots show that while intra cell line variation was notable, there is indeed clustering 
(Y. Liu et al. 2019). These results indicate that our experimental design, while not ideal, 
is with merit. Indeed, CD36 gene transcript was found robustly expressed in all of our 
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DNPS-KO cell lines, was also highly expressed in an analogous experiment performed in 
the CHO cell lines. qPCR was also performed almost a year later with freshly harvested 
RNA. These results bolster my position of the validity of the experimental parameters. 
In the crADSL and crATIC analyses, transcriptomic terms were returned that are 
consistent with the phenotype, such as neural development and function, muscle function, 
embryonic development, and energy functions. The consistency of these terms to the 
phenotype indicates that we are indeed on the correct path to identify the underlying 
issues resulting from DNPS deficiency and processes likely influenced by DNPS. 
Future Directions 
Commonalities within DNPS HeLa-KOs: The CD36-PPARγ axis 
The data presented in this dissertation 
show similarities and differences in 
transcriptomic expression. These similarities 
are likely due to generalized DNPS 
deficiency and can provide key insight to 
processes likely affected by DNPS 
dysregulation. 
A common theme amongst the 
transcriptomics data set is the vast increase 
within the transcript count for the scavenger 
receptor gene Cluster of Differentiation 36 
(CD36), also known as fatty acid translocase 
seen in all genetic knockouts (Figure 6.2); 
Figure 6.2: CD36 gene count in HeLa and 
DNPS-KO mutant cell lines. Box plot of 
CD36 transcript counts of replicates by cell 
type and purine supplementation. WT HeLa 
cells, with fully functioning DNPS pathway, 
show negligible levels of CD36 transcript 
while all DNPS-KO mutants show elevated 
transcript levels, purine supplementation in 
the form of adenine shows negligible effect 

















CD36 was one of the most differentially regulated genes, transcript level does not appear 
to be augmented by adenine supplementation (Figure 6.2). CD36 has been found linked 
to a wide range of seemingly unrelated cellular processes and pathologies. CD36 is 
involved in fatty acid uptake and metabolism (Pepino et al. 2014), inflammation cascade 
(Kuda et al. 2011), angiogenesis, apoptosis, thrombosis, atherosclerosis, Alzheimer’s 
disease, and insulin resistance (Silverstein and Febbraio 2009). Unsaturated fatty acids 
such as ω3 and ω6 class were found to alter CD36 mRNA expression with increase or 
decrease dependent on cell type (Vallvé et al. 2002; Pietsch et al. 1995). 
Peroxisome proliferator activated receptor gamma (PPARγ) transcript was also 
found elevated within all DNPS-KO cell 
lines, however gene expression does appear 
to decrease slightly with adenine 
supplementation (Figure 6.3). PPARγ is an 
inducible transcription factor and is 
considered a master regulator in lipid 
metabolism, with roles in fat, carbohydrate, 
and general energy metabolism, insulin 
sensitivity, cell proliferation and 
differentiation, inflammation, and cancer 
(Kroker and Bruning 2015). PPARγ and 
CD36 are interrelated, where CD36 
incorporates a signal and activates PPARγ 














Figure 6.3: PPARγ gene count in HeLa 
and DNPS-KO mutant cell lines. Box plot 
of PPARγ transcript counts of replicates by 
cell type and purine supplementation. WT 
HeLa cells, with fully functioning DNPS 
pathway, show negligible levels of PPARγ 
transcript while all DNPS-KO mutants 
show elevated transcript levels, purine 
supplementation in the form of adenine 
slightly decreases mean transcript levels in 
DNPS-KOs negligible effect on transcript 




activity appears to be signal source specific, as agonist binding and ligand induced 
phosphorylation cause different subsets of PPARγ regulated genes to be expressed 
(Kroker and Bruning 2015). Curiously, CD36 is a target gene of agonist based PPARγ 
transcriptional activity (Kroker and Bruning 2015). The CD36- PPARγ axis has shown 
involvement in modulating fatty acid storage, triglyceride synthesis, glucose uptake, 
regulating fatty acid metabolism (Maréchal et al. 2018). It is unclear as to why DNPS-
KOs would be robustly expressing transcript for these genes.  
The ontologies elucidated suggest that inflammatory signaling and fatty acid 
processing are systems of interest, due to the control of CD36-PPARγ within these, we 
hypothesize that DNPS plays a role in mediating a chronic inflammatory cascade, as a 
complete rewiring of cells not native to expressing both PPARγ and CD36 are not likely 
to generate a new process for acute inflammation, and would instead rely on other means. 
Another plausible explanation is a defect in energy homeostasis. This idea is supported 
by the metabolomics data set, due to the large enrichment of differentially regulated 
metabolites as a function of GART enzyme KO suggesting an altered cellular energy 
landscape. DNPS-KOs may be more reliant on 
fatty acid hydrolysis, a process that can be 
regulated by CD36-PPARγ axis, for the 
generation of high energy elections for 
oxidative phosphorylation. Work has begun to 
i) identify if the increased transcript correlates 
to protein levels (Figure 6.4) and ii) to 






































Figure 6.4: Preliminary Western Blot of 
cellular lysate, CD36. HeLa, crATIC, CHO-
K1, and AdeF cells were grown and purine 
starved as previously described, lysed in 
RIPA buffer, and 30μg total protein was 
separated on 10% TG gel. Gel was transferred 
to a NC membrane and processed using 
1:1000 αCD36. crATIC shows elevated levels 
of CD36 protein over HeLa. A+/- denotes 
with or without supplemental adenine 
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phenomenon through probing fatty acid oxidation and glycolytic flux as well as altering 
pro- and anti-inflammatory fatty acid signaling. 
These transcript regulation findings are likely not an artefact of our methodology.  
Indeed, our laboratory performed RNA-seq on analogous DNPS-KO mutants to those 
presented here in the Chinese Hamster Ovary (CHO) cell line and showed increases of 
CD36 and PPARγ transcript over their WT CHO-K1 counterpart (Data not shown). 
These CHO mutants were made over three decades ago with vastly different techniques 
than CRISPR (Patterson 1975; 1976; Oates and Patterson 1977).  
crADSL may provide insight for epithelial to mesenchymal transition 
Transcriptomic analysis of the crADSL cell line uncovered potential research 
targets in epithelial to mesenchymal transition (EMT). EMT is a process by which polar, 
adherent epithelial cells undergo changes and become unattached and freely motile 
mesenchymal cells. EMT is strongly associated development, however the processes able 
to reactivate after development in certain instances like wound healing and cancer. 
Mesenchymal cells have increased resistance to apoptosis and are highly migratory and 
invasive (Kalluri 2009; Kalluri and Weinberg 2009). Loss of proper EMT control can 
result in deleterious processes such as tumor metastasis (Thiery 2002) and is therefore 
extensively studied in cancer biology. The ADSL substrate, SAICAR, is a known PKM2 
activator, an enzyme directly related to cancer metabolism as well as metastasis (Fan et 
al. 2014; Hamabe et al. 2014).  
The crADSL line presents a novel approach to understanding EMT. DNPS is 
critical for proper embryonic development and its substrate, SAICAR, is an effector of 
PKM2, an enzyme thought to be the center of the Warburg effect, altering most tumor’s 
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energy production pathways. EMT can be initially assessed via addition of TGFβ or with 
EMT Induction Supplement and screened for biomarker proteins such as e-cadherin and 
fibronectin (Tang et al. 2013).  Migration and infiltration experiments can also be 
assessed using similar methodology in a three-dimensional cell culture. The crADSL cell 
line can be used for understanding the role of DNPS as well as SAICAR in the EMT 
process, showing benefit for developmental and tumor biology. 
ADSL deficiency has clinical relevance, manifest as a developmental disorder. 
Deficiency is typically diagnosed via identification of the dephosphorylated substrates of 
ADSL, SAICAR and SAMP (Figure 6.1) (dephosphorylated forms known as 
SAICAriboside and SAdo) in biofluids, although with the recent advent of the affordable 
and rapid Next Gen whole genome sequencing (Metzker 2010; Dunn et al. 2018) we 
expect more patients to be identified by genomic means. Generally speaking, severity of 
phenotype is correlated to the SAdo:SAICAriboside ratio, with values above 2 are mild 
with values closer to 1 present as severe (Jurecka et al. 2015). The variability in the 
phenotype is striking, ranging from fatal neonatal encephalopathy with hypokinesia, to 
developmental delay compatible with life at least to the teenage years (Gitiaux et al. 
2009; Mouchegh et al. 2007). A heterozygous patient with two missense mutations in or 
near the catalytic active site, E80D and D87E, presented with a mild phenotype, although 
no reference data on substrate accumulation is known. It is not known if the patient is 
expressing both transcripts or if both mutant forms of ADSL proteins are present. Most 
studies of ADSL mutations have been performed using cell free extracts or purified 
proteins. The ADSL mutations, E80D and D87E, were identified in a single patient. Our 
lab were collaborators on the intital biochemical characterization of these mutants 
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(Sivendran et al. 2004). Previous work on the E80D and D87E ADSL mutants reveal 
increased stability and large amounts of aggregate formation of the D87E mutant while 
E80D show slightly decreased levels stability and slightly elevated aggregate formation 
over WT (Ray 2013). Currently, transfection of WT, E80D, and D87E mutant enzymes 
into the crADSL cell line show proliferative growth in adenine with WT and E80D 
ADSL, but not the D87E mutant. The aggregation characteristics of D87E may lead to 
sequestration or increased proteolytic clearance of this isoform in cells. We therefore 
hypothesize that only E80D ADSL protein is made in the cell, and will use this system to 
gain insight into isoform selection of this heterozygous patient. These two phenomena 
would likely explain the crADSL mutant isoform purine requirement differences.  
crATIC and ZMP accumulation provides insight into energy production and 
inflammatory effects 
The ZMP metabolite that accumulates in the crATIC cell line is a known AMP 
mimetic and activator of AMPK, a master regulator of cellular metabolism. AMPK 
sensitivity is diminished with age (Reznick et al. 2007) and shows aberrant 
hyperactivation in Alzheimer’s disease neurons (Vingtdeux et al. 2011). Alzheimer’s 
disease is characterized by neural extracellular amyloid β plaques and tau fibrils, as well 
as low grade chronic peripheral and neural inflammation (Kinney et al. 2018). Within the 
brain, mitochondrial function is diminished, tissue becomes insensitive to insulin 
signaling, and there are general aberrations in cellular energy homeostasis (Yin et al. 
2016). AMPK is not only an effector of cellular energy metabolism, but also has been 
implicated in regulating inflammation (X. Chen et al. 2018). In an animal model of 
induced rheumatoid arthritis (a known model of chronic inflammation), pro-inflammation 
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signaling induced by complete Freund’s adjuvant was mitigated by administration with 
AICAriboside (Xiang et al. 2019). The crATIC HeLa cell line represents an endogenous 
source of ZMP, non-reliant on drug interactions, gene silencing RNA, or exogenous 
AICAriboside. Therefore, the utilization of crATIC represents a novel means of 
understanding energy homeostasis and fatty acid processing in inflammatory disorders. 
Fatty acids in inflammatory cascades are processed via enzymatic activity, with the 
resultant molecule producing a pro- or anti-inflammatory effect. Arachidonic acid is an 
ω-6 fatty acid, with potential to be processed into the largely pro-inflammatory molecules 
prostaglandins and thromboxanes (Hanna and Hafez 2018). The ω-3 fatty acids 
eicosapentaenoic acid and docosahexaenoic acid are typically processed into potent anti-
inflammatory specialized proresolving mediators such as maresins and resolvins (Calder 
2012). Given the energetic dysregulation and chronic inflammation characterized by 
Alzheimer’s disease, a cellular model capable of accumulating ZMP to regulate AMPK 
activation and therefore temper inflammation as well as energy metabolic processes is 
attractive. In this model, I would achieve insight into energy signaling roles seen in 
chronic inflammatory disorders such as AD. Within these experiments, I propose to 
induce an inflammatory response with lipopolysaccharide or Amyloid β (Zhu et al. 2016) 
at various time points of ZMP accumulation. Mass spectrometry is a beneficial tool 
capable of identifying and, in certain cases, quantifying metabolite profiles. I would 
employ lipidomic MS techniques to identify free fatty acid composition and 
concentration ratios to understand pro- or anti-inflammatory signaling cascades as a 
function of AMPK activation and energy homeostasis derived fatty acid processing.  
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crGART reveals neural and placentation embryonic development defects 
A theory for the root cause of Down syndrome (DS) is the Gene Dosage 
hypothesis. This postulates that the phenotype of DS is the result of the cumulative effect 
related to the triplication and overexpression of the genes located on chromosome 21 
(Gardiner 2004). Here, I have outlined possible cellular processes influenced by the 
Hsa21 chromosome GART.  
Alkaline phosphates are a class of four membrane bound exoenzymes, in humans, 
responsible for the hydrolysis of phosphate esters (Štefková, Procházková, and Pacherník 
2015). Our results have shown that, in the crGART cell line, three alkaline phosphatase 
enzymes had elevated transcript levels whereas tissue non-specific alkaline phosphatase 
(TNAP) showed heavily decreased transcript levels compared to WT HeLa. Curiously, 
the three elevated genes are ALPP, ALPI, and ALPG are located together on 
chromosome 2, while the decreased gene, ALPL, is located on chromosome 1 (NCBI, 
GeneCards). TNAP is encoded by the alkaline phosphatase liver/bone/kidney (ALPL) 
gene and is abundant in these tissues although expression has been shown fairly 
ubiquitous (Sebastián-Serrano et al. 2015; Štefková, Procházková, and Pacherník 2015). 
TNAP activity is observed during neural developement (Langer et al. 2007), with 
expression promoting axonal growth (Díez-Zaera et al. 2011). The altered regulation of 
alkaline phosphatases, especially TNAP, may provide novel insight to mechanisms 
associated with DNPS dysfunction, axonal growth/synapse formation, and associated 
cognitive defects.  
Our transcriptomic analysis of crGART revealed perturbations in gene expression 
related to placental development, with emphasis related to the labyrinthine layer. As 
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DNPS is heavily relied upon for development, this finding is unsurprising. The placenta 
is the first and largest embryonic organ, responsible for hormone signaling as well as gas 
and nutrient exchange between the mother and embryo (Turco and Moffett 2019; Gude et 
al. 2004). The trophoectoderm forms in a pre-implantation embryo with interaction 
between the trophoectoderm and the uterine wall driving successful embryonic 
implantation (Pillai et al. 2019; Knöfler et al. 2019) and begins to gain complexity and 
structure upon implantation deriving the trophoblast lineage and proper placentation 
begins (Knöfler et al. 2019). Analysis of morphology of over 100 embryonic lethal 
mouse models have revealed that a majority of these lines exhibit placental 
malformations, with fetal phenotype commonalities of abnormalities in cardiac, neural, 
and vascular systems (Perez-Garcia et al. 2018). The labyrinthine layer is a heavily 
vascularized embryonic derived structure. Mouse embryonic stem cells lacking or 
triplicated GART would be beneficial for understanding the early phases of pre-
implantation trophoectoderm differentiation. While a true living mouse model lacking 
GART would be ideal for understanding placentation as a function of DNPS 
dysregulation, this is not feasible as DNPS is necessary for embryonic development and 
the embryo would likely not survive, in fact so far it has not been possible to isolate 
GART null mice. Transgenic mice expressing human GART under its own regulatory 
elements have been made in two laboratories, Dr. David Patterson’s laboratory and the 
laboratory of John Gearhardt at Johns Hopkins. In both cases there was minimal if any 
alteration in phenotype. Nonetheless, the crGART mutant could be used to make 
transfected cell lines expressing different levels of GART activity. Comparison of the 
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transcriptomes of these lines should allow precise definition of which transcript changes 
are actually due to alterations in GART levels. 
Metabolic effects for Vitamin B6 and DNPS dysregulation 
Clinical manifestation of DNPS dysregulation as well as DS are characterized by 
seizure activity (Marie et al. 2004; Jurecka et al. 2015; Lott and Dierssen 2010). Seizure 
activity was not identified in PAICS deficient patients, however the only two patients 
identified died within three days postpartum (Pelet et al. 2019) making observation 
unlikely. Metabolomic analysis of the crGART line showed differential regulation of 
small molecules related to myriad processes, among them was Vitamin B6 metabolism. 
B6 is a vitamer involved as a cofactor for folate synthesis (Kennedy 2016), 
neurotransmitter synthesis (Calderón‐Ospina and Nava‐Mesa 2020), mitochondrial 
function (Janssen et al. 2019), and amino acid and glutathione metabolism (Dalto and 
Matte 2017). In neurotransmitter synthesis, B6 acts as a cofactor in the formation of 
serotonin, dopamine, as well as GABA (Kennedy 2016; Calderón‐Ospina and Nava‐Mesa 
2020). GABA, largely known as the main inhibitor neurotransmitter (Contestabile, 
Magara, and Cancedda 2017) and is synthesized from the precursor glutamate, an 
excitatory neurotransmitter (Deidda, Bozarth, and Cancedda 2014). Dysregulation of B6 
can lead to GABA deficiency and excess glutamate, creating an imbalance between 
synaptic excitation and inhibition potential manifesting as seizures (Wilson et al. 2019). 
Indeed, B6 supplementation has been shown beneficial in mitigating chronic seizure 
activity (Spinneker et al. 2007; Ohtahara, Yamatogi, and Ohtsuka 2011) as well as 
efficacious in mitigating neurotoxin induced seizures (Dakshinamurti, Sharma, and 
Geiger 2003).  
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Seizure activity in individuals with DNPS deficiencies may stem from a B6 
metabolic deficits or improper dosage of TNAP, a regulator of B6. B6 exists as an active, 
but non-cell permeable phosphorylated form and a cell permeable dephosphorylated 
inactive form. B6 is ingested in its phosphorylated form and able to circulate freely. 
TNAP dephosphorylates B6, crossing cellular membranes or the blood brain barrier, and 
subsequently rephosphorylated, trapping it inside the cell (Calderón‐Ospina and Nava‐
Mesa 2020). To probe this, DNPS-KO or knock-down neuronal cells would be generated, 
targeting GART first, and assessed for TNAP transcript and protein activity in culture 
(Díez-Zaera et al. 2011) as well as modulating vitamin B6 media levels. Understanding 
excitatory and inhibitor neurotransmitter load as a function of DNPS will yield insights 
into neurotransmitter synthesis and processing. Quantification of neurotransmitter load 
will also be assessed under purine starved and rich conditions, as well as by GART 
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